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Resumo 
Cancro gástrico é uma doença agressiva com um elevado impacto na saúde 
mundial, devido ao diagnóstico tardio dos pacientes. Os eventos moleculares subjacentes 
ao processo de carcinogénese gástrica têm vindo a ser abordados de modo a identificar 
biomarcadores moleculares específicos para a deteção precoce do carcinoma gástrico. O 
cancro gástrico do tipo difuso, caracterizado por uma reduzida adesão intercelular, tem 
vindo a ser descrito como estando estritamente relacionado com a desregulação da 
proteína supressora de invasão, E-caderina. O comprometimento das funções biológicas 
da E-caderina resulta na perda da adesão celular e no aumento do potencial de invasão e 
metastização. E-caderina é uma glicoproteína que é modificada por glicosilação pós-
translacionalmente e cujas modificações têm forte efeito na doença neoplásica. De facto, 
a transformação maligna está fortemente associada com padrões alterados de glicosilação 
na superfície das células tumorais.  
A N-glicosilação da E-caderina mediada por GnT-III confere-lhe uma estabilidade 
na membrana celular o que conduz às suas funções adesivas adequadas. Esta glicoforma 
da E-caderina também regula a atividade da GnT-III por um mecanismo bidirecional o que 
contribui para a supressão de invasão e metastização. Neste estudo, demonstramos que 
este mecanismo é comprometido com a ativação da via de sinalização insulina / IGF-I no 
processo de invasão de células tumorais. Por outro lado, E-caderina pode também ser 
sujeita a N- glicosilação mediada por GnT-V o que compromete a adesão célula-célula. 
Pacientes com cancro gástrico exibem uma expressão aberrante da E-caderina 
especificamente modificada com estruturas β1,6 GlcNAc. Demonstramos que estes N-
glicanos deletérios estão presentes especificamente no local de N-glicosilação Asn-554 da 
E-caderina, sendo o local chave para a sua desregulação funcional nas células tumorais 
gástricas. Além disso, também verificamos que o perfil de O-manosilação da E-caderina, 
descrito recentemente como sendo crucial para a adesão célula-célula, encontra-se 
comprometido num contexto de cancro gástrico com implicações nas suas funções 
biológicas. O impedimento da ocupação do local Asn-554 da E-caderina com N-glicanos 
β1,6 GlcNAc potencializa o perfil de O-manosilação da E-caderina, estando assim 
associado com a recuperação das suas funções biológicas. Adicionalmente, verifica-se a 
existência de um mecanismo coordenado entre o perfil de O-manosilação proteico e a N-
glicosilação mediada por GnT-V em pacientes com cancro gástrico do tipo difuso. Assim 
sendo, a descrição do perfil de glicosilação da E-caderina em cancro gástrico pode 
contribuir para potenciais glico- biomarcadores de diagnóstico precoce do cancro gástrico 
do tipo difuso, e para o desenvolvimento de potenciais alvos terapêuticos. 
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Abstract 
Gastric cancer is an aggressive disease with a high impact on global health due to 
the late diagnosis of gastric cancer patients. The molecular events underlying gastric cancer 
process have been addressed in order to identify molecular biomarkers specifics for the 
early detection of gastric carcinoma. Diffuse gastric cancer, characterized by a reduced 
intercellular adhesiveness, has been strongly correlated with the dysregulation of the 
invasion suppressor protein, E-cadherin. The impairment of E-cadherin biological functions 
results in loss of cell adhesion and increased cell invasion and metastatic potential. E-
cadherin is a glycoprotein that is post-translationally modified by glycosylation which may 
exert a powerful effect on the outcome of neoplastic disease. In fact, malignant 
transformation is strongly associated with altered glycosylation patterns on the surface of 
cancer cells.  
E-cadherin N-glycosylation mediated by GnT-III confers a stability to the E-cadherin 
at the cell membrane leading to the proper adhesive functions. Moreover, this E-cadherin 
glycoform also regulates the GnT-III activity by a bidirectional crosstalk which contributes 
to the suppression of tumour invasion and metastasis. In this study, we have shown that 
this interplay is compromised with the activation of the insulin/IGF-I signalling pathway in 
the process of tumour cell invasion. E-cadherin may also undergo GnT-V-mediated N-
glycosylation that compromises the E-cadherin-mediated cell-cell adhesion. Human gastric 
cancer patients display an aberrant expression of E-cadherin specifically modified with the 
β1,6 GlcNAc branched N-glycans. Here, we have demonstrated that these deleterious N-
glycans are present specifically in the E-cadherin N-glycosylation site Asn-554, being the 
key site for the functional dysregulation of E-cadherin in gastric tumour cells. Furthermore, 
we have shown that the O-mannosylation profile of E-cadherin, recently described crucial 
in cell-cell adhesion, is impaired in a gastric cancer context with implications in its biological 
functions. Precluding the occupancy of E-cadherin Asn-554 with β1,6 GlcNAc branched N-
glycans potentiates the O-mannosylation profile of E-cadherin being associated with the 
recovery of the proper E-cadherin biological functions. In addition, we also have 
demonstrated the existence of a coordinated interplay between protein O-mannosylation 
and GnT-V-mediated N-glycosylation in human diffuse gastric cancer patients. Hence, the 
disclosure of the E-cadherin glycosignature in gastric cancer may contribute to potential 
glycobiomarkers for the early diagnosis of diffuse gastric cancer, and to the development of 
potential therapeutic targets.  
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General Introduction 
Gastric Cancer 
Epidemiology and Aetiology 
Gastric cancer is an aggressive disease with a daunting impact on global health. 
Gastric cancer remains the sixth most common type of cancer, and is the fourth leading 
cause of cancer-related death worldwide, after lung, breast and liver cancer [1]. Despite the 
decline in incidence over the past few decades, gastric cancer continues to present a major 
clinical challenge due to late diagnosis of most gastric cancers since survival is highly 
dependent on the stage at which the tumour is diagnosed [2].  
Large differences in gastric cancer incidence exists between continents, being 
highest incident rates found in Asia, followed by Europe, Central and South America, North 
America and Africa [3, 4]. Even within a given geographical area, certain ethnic groups have 
significantly higher risk of disease [5]. The risk of developing gastric cancer increases with 
age [6]. The male-to- female ratio in incidence and mortality is about 2:1 [7].  
Gastric cancer is a multifactorial disease: infectious, environmental, and host-related 
factors may interact favouring the development of tumour [8]. Chronic infection with 
Helicobacter pylori (H. pylori), classified as a class I carcinogen according the International 
Agency for Research on Cancer (IARC), has been implicated in gastric carcinogenesis [9-
11]. It is estimated that 50% of the world´s population is infected with H. pylori [12]. Another 
infectious agent associated with gastric cancer is the Epstein-Barr virus (EBV) [13]. 
Regarding environmental and lifestyle factors, tobacco smoking [14], low socioeconomic 
status, alcohol and meat consumption [15], diet rich in salt and poor in fruits and vegetables 
[16, 17], and high body mass index [18] are closely linked to increased risk of gastric cancer. 
At last, molecules involved in adhesion of the bacteria [19] as well as host genetic 
polymorphisms from diverse molecular pathways [20] are also associated with progression 
of the gastric carcinogenesis pathway. Genome-wide association studies have been largely 
used to evaluate single nucleotide polymorphisms simultaneously opening new avenues in 
cancer research [21]. 
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Histological classification  
Gastric cancer is a complex and heterogeneous disease with different morphologies, 
histogenesis and molecular backgrounds [22, 23]. The major histological type of gastric 
cancer is adenocarcinoma, which originates from the glandular epithelium and accounts for 
90% to 95% of all gastric malignancies [24]. Several gastric cancer classifications systems 
have been proposed over the past decades: World Health Organization (WHO) [25] and the 
Lauren´s classification [26]. The 2010 WHO system recognizes five major histologic 
patterns of gastric cancer: tubular, papillary, mucinous, poorly cohesive (including signet 
ring cell carcinoma), and mixed carcinomas [25, 27]. The Lauren´s criteria, which is the 
most commonly used classification, describes two main histological subtypes, the intestinal 
subtype and diffuse subtype gastric adenocarcinoma, which display distinct epidemiologic, 
morphological and molecular features [26, 28] (Figure 1). 
The intestinal subtype of gastric cancer represents nearly 70% of the cases, being 
more frequently diagnosed in older male patients [29]. It is more likely to be sporadic than 
inherited [30]. Histologically, it is characterized by glandular architecture with cells 
displaying cohesiveness and various degrees of differentiation [31]. The main carcinogenic 
event associated with intestinal subtype cancer is H. pylori infection which leads to a 
sequence of histological lesions (known as Correa´s cascade) that culminate in a malignant 
lesion [32]. The cascade of events corresponds to a gradual and multistep progression from 
chronic gastritis to chronic atrophy to intestinal metaplasia to dysplasia and carcinoma [33]. 
At the molecular level, intestinal gastric cancer is associated with overexpression of c-met 
oncogene [34], K-ras mutations [35], loss-of-function of tumour suppressive genes TP53 
[36] and APC [37], among others. 
In contrast to the intestinal subtype, diffuse gastric cancer is generally diagnosed in 
younger patients [5]. The diffuse subtype of gastric cancer develops without precancerous 
lesions; it is characterized by poorly cohesive cells with little or no gland formation displaying 
a worse prognosis than the intestinal type [38, 39]. Diffuse gastric tumours have an 
important mechanism of carcinogenesis that is through defective intercellular adhesions, 
mainly resulting from E-cadherin dysregulation [38]. Abnormal E-cadherin expression can 
occur through biallelic inactivation of its related gene CDH1 via germline or somatic 
mutations [40], loss of heterozygosity (LOH) [41, 42], epigenetic silencing of gene 
transcription through CDH1 promoter hypermethylation [43, 44], transcriptional silencing 
that target CDH1 promoter [45] or by alteration of E-cadherin glycosylation [46, 47]. CDH1 
inactivation occurs in early stages of diffuse type tumour development, whereas in intestinal 
type tumours it seem to take place in relatively late stages of carcinogenesis. Importantly, 
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CDH1 germline mutations characterizes the hereditary diffuse gastric carcinoma syndrome 
(HDGC) [48-50]. 
 
Figure 1 - Clinicopathological profiles and epidemiological settings of the two main histological 
subtypes of gastric cancer: intestinal subtype and diffuse subtype. Adapted from [47]. 
E-cadherin 
Cadherins constitute a large superfamily of transmembrane glycoproteins that 
mediate specific cell-cell adhesion in a calcium-dependent manner [51]. The family is 
widespread in normal tissues but the individual members display pronounced tissue 
specificity [52]. The cadherin superfamily is mainly composed by “classical” cadherins of 
type 1, closely related cadherins of type II, desmossomal cadherins, protocadherins, and a 
variety of cadherin-related molecules [53, 54].  
Classical cadherins were the first subtype of the cadherin superfamily identified in 
vertebrates [55-58]. Cadherins form primarily homophilic cell-cell interactions at the 
adherens junctions, and appear to modulate adhesion through dynamic interactions with 
the actin cytoskeleton [54, 59]. Epithelial cadherin (E-cadherin) is considered the 
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prototypical member of the cadherin superfamily, being identified in 1977 by Takeichi as a 
surface protein with Ca2+-dependent cell-cell adhesion properties [60]. E-cadherin is 
expressed primarily in epithelial cells, where it localizes at the basolateral surface of the 
epithelial junctional complex- the adherens junctions [59]. 
The human CDH1 gene, encoding E-cadherin, is situated in the long arm of 
chromosome 16, within the locus 16q22.1 [61, 62]. CDH1 gene is organized into 15 introns 
and 16 exons, which are translated into protein comprising 882 aminoacids (a.a). The signal 
peptide corresponds to the first 27 a.a (exons 1-2), and is followed by the precursor peptide 
(exon 2-4) (Figure 2A) [42, 63, 64]. 
 
Figure 2 - Schematic representation of (A) different levels at which E-cadherin expression is 
regulated in human tumours, [42] (B) classical cadherin-catenin complex [65], and (C) three-
dimensional structure of the extracellular domain (EC1–EC5) of E-cadherin combined with the 
representation of the four potential N-glycosylation sites [46]. 
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The immature form of E-cadherin (the precursor protein) is a polypeptide composed 
by a propeptide sequence of about 130 a.a and a mature polypeptide of about 728 a.a 
(Figure 2A) [42]. The propeptide corresponds to a short signal sequence for import into the 
endoplasmic reticulum (ER) where undergoes cytoplasmic trimming. Following this 
trimming process, the mature E-cadherin is routed towards the basolateral surface of 
epithelial cells [64]. E-cadherin mature protein is organized in three major structural 
domains: an N-terminal ectodomain of about 550 a.a comprising five tandemly repeated 
subdomains (EC1-EC5), a single transmembrane domain, and a short cytoplasmic domain 
(C-terminal) of about 150 a.a [46, 64]. 
Extracellular domain of E-cadherin 
The cell-cell adhesion mediated by E-cadherin is achieved through homophilic 
interactions of the extracellular domain of E-cadherin molecules. The N-terminal domain 
EC1 has been identified to correspond to the adhesive binding site [66]. EC1 contains a 
Histidine-Alanine-Valine (HAV) sequence which is thought to be essential for the process 
of cell-cell adhesion [67]. According to the literature, cadherins may form both lateral (cis) 
and adhesive (trans) dimers on the cell surface though distinct interactions involving EC1 
or EC1-EC2 domains [68-70]. The cadherin molecules on the cell surface establish lateral 
or cis- interaction and then among adjacent cells form trans adhesive bonds, forming zipper-
like structures [71]. Trans-interactions on opposing cell surfaces result in weak cell-cell 
adhesion, but strong cell-cell adhesion develops during lateral clustering of E-cadherin [72]. 
The five EC domains are rigidified by coordinating Ca2+ ions between any two consecutive 
EC domains [66, 73] and this binding of Ca2+ is essential to confer resistance of the 
extracellular region to proteolytic degradation [56, 74]. 
Intracellular domain of E-cadherin 
Further strengthening of cell-cell adhesion requires subsequent linkage to the 
cytoskeleton that is accomplished through the interaction of the E-cadherin cytoplasmic 
domain with cytoplasmic proteins called catenins (Figure 2B) [66]. The cytoplasmic domain 
is subdivided into the juxtamembrane domain (JMD) that provides a specific binding site for 
p120-catenin and p120-related proteins [75, 76], and the catenin binding domain (CBD) 
which specifically binds to β-catenin and plakoglobin [77]. 
Interaction of β-catenin to E-cadherin is required for transportation of the newly 
synthesized E-cadherin protein from the ER to the cell membrane [78]. β-catenin binds the 
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C–terminal cytoplasmic domain of E-cadherin in a phospho-regulated manner [79]. 
Phosphorylation of the three serine residues located in the cadherin cytoplasmic domain 
(S684, S686, S692) by casein kinase II (CKII) and glycogen synthase kinase-3β (GSK-3β) 
leads to increase in affinity of E-cadherin and β-catenin interaction. In contrast, tyrosine 
phosphorylation of β-catenin at Y489 and Y654 weakens interaction with cadherin [80]. In 
addition, β-catenin plays an important role in cell signalling pathways, such as in Wnt 
signalling [81, 82]. β-catenin functions as a transcriptional co-regulator, moving from the 
cytoplasm into the nucleus and cooperating with TCF/LEF transcription in order to activate 
the expression of numerous genes involved in migration and proliferation [83, 84]. 
Furthermore, β-catenin plays a key role in cadherin-adhesive function by acting as an 
adaptor for a range of cytoplasmic proteins which in turn interact with the actin cytoskeleton 
[72]. The best known is α-catenin which exists in either a monomeric or homo-dimeric state: 
monomeric α-catenin binds to the N-terminal portion of β-catenin while homo-dimeric α-
catenin binds to actin filaments [72, 85]. Phosphorylation of β-catenin at Y142 disrupts 
binding to α-catenin [80]. 
E-cadherin stabilization at the cell membrane also occurs through the association 
with p-120-catenin that interacts with the highly conserved juxtamembrane domain of E-
cadherin [75]. E-cadherin-p120-catenin interaction prevents the entrance of E-cadherin into 
degrading endocytic trafficking pathways or accelerates the recycling of internalized 
cadherin back to the plasma membrane [86]. The phosphorylation of p120-catenin 
increases binding affinity to E-cadherin [72, 87]. However, the loss of E-cadherin-p120 
catenin interaction destabilizes cadherin localization at the cell membrane, inhibiting its 
accumulation at cell borders [88]. Moreover, the weakness of E-cadherin-p120 catenin 
interaction promotes the ubiquitination-dependent endocytosis of E-cadherin by binding of 
E-cadherin to Hakai, an E3-ubiquitin ligase, in a Src-dependent manner [89, 90]. 
The E-cadherin trafficking may also be compromised by post-translational 
modifications of E-cadherin which have been reported to promote apoptosis [91]. O-GlcNAc 
glycosylation of E-cadherin cytoplasmic domain and incomplete processing arrest E-
cadherin transport late in the secretory pathway by interfering the binding of E-cadherin with 
type I gamma phosphatidylinositol phosphate kinase (PIPKIγ), a protein required for E-
cadherin recruitment to the adhesion sites [92]. 
 
General Introduction 
25 
 
Regulation of E-cadherin-mediated cell- cell adhesion 
Dynamic regulation of cadherin-mediated cell-cell adhesion is associated with 
diverse morphogenetic processes [93]. The crucial role of such dynamism is evident during 
embryonic development. In fact, E-cadherin is expressed from the very early stages of 
development, at the two-cell stage [94]. E-cadherin is the first adhesion molecule expressed 
in the mouse embryo, and is reported to be essential during morula compaction and 
blastocyst formation [95, 96]. E-cadherin null embryos failed to form a blastocyst cavity, 
which emphasizes the crucial role of this molecule in tissue morphogenesis and 
developments. Defects in cell junctional and cytoskeletal organization resulted in failure to 
maintain a polarized and compacted state and also failure to form a trophectoderm 
epithelium [97]. 
In adult tissues, epithelial cells also display dynamic behaviours, such as 
rearrangement, movement and shape changes implicated in developmental growth, cell 
renewal, cell migration, and wound healing [54, 59]. The remodelling of adherens junctions, 
which comprise cadherin adhesion molecules associated to cytoplasmic proteins, has major 
roles in controlling these behaviours. Endocytosis is one of the mechanisms that modulates 
the adherens junctions [98]. It has been shown that endocytic trafficking of E-cadherin 
controls assembly, disassembly and stabilization of adherens junctions [99]. In addition, E-
cadherin-mediated junction is also regulated by several signal transduction pathways, which 
transduce changes across the membrane to alter the state of the cadherin adhesive bond 
[54]. However, E-cadherin is not only a target for signalling pathways that regulate 
adhesion, but may itself send signals that regulate basic cellular processes, such as 
migration, proliferation, apoptosis and cell differentiation [100, 101]. 
E-cadherin dysregulation in cancer 
Disruption of cell-cell contacts and loss of cellular adhesion constitute a key step in 
tumour development and progression. In fact, E-cadherin is the main suppressor of 
epithelial tumour invasion, since E-cadherin impairment results in loss of cell adhesion and 
alterations of epithelial morphology, increased invasiveness and acquisition of metastatic 
potential, ultimately contributing to malignancy [102]. E-cadherin has also been implied in 
the process of epithelial-mesenchymal transition (EMT), a process described to be 
important in cancer metastasis [103].  
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The downregulation or inactivation of E-cadherin is particularly evident and 
significant in gastric cancer. The presence of non-cohesive cells with reduced intercellular 
adhesiveness is a defining feature of diffuse gastric carcinomas that exhibit an aberrant 
expression or complete loss of E-cadherin expression [104]. Several molecular 
mechanisms have been described to underlie E-cadherin dysfunction in cancer (Figure 2A), 
including: LOH of chromosome 16q21-22 [41, 42], mutations of the E-cadherin gene CDH1 
[40]; epigenetic silencing through promoter hypermethylation [43, 44]; transcriptional 
silencing that target CDH1 promoter [45]; microRNAs (miRNAs) [105], and endocytosis 
along with proteolytic processing of E-cadherin [64]. The absence or aberrant E-cadherin 
expression has been identified in sporadic diffuse/mixed gastric cancer cases due to the 
presence of CDH1 somatic mutations. Moreover, germline alterations of CDH1 gene 
characterize the HDGC. These germline mutations of the E-cadherin gene were first 
described in 1998 and since then, 68 families carrying germline CDH1 mutations have been 
identified worldwide including in Portugal [39, 106]. Furthermore, overexpression of E-
cadherin transcriptional repressors has also been associated with E-cadherin dysfunction 
in several types of cancer. These transcription repressors include Snail, Slug, Twist and 
SIP/ZEB2 [107]. Another mechanism that leads to CDH1 downregulation is the 
hypermethylation of its promoter that occurs in a large CpG island in the 5’ proximal 
promoter region of CDH1 [108]. In addition, miRNAs have also been reported as another 
level of E-cadherin regulation [109]. Moreover, alterations in the endocytic/recycling 
pathway of E-cadherin can also lead to its dysfunction in cancer [89, 110]. Loss or 
delocalization of p-120 catenin can lead to E-cadherin endocytosis affecting its stability at 
the cell membrane [111]. In addition the recycling of E-cadherin can be impaired by the 
ectodomain shedding of E-cadherin by metalloproteinases and other proteases [112]. 
Despite those above mentioned genetic/epigenetic mechanisms underlying E-
cadherin dysfunction in cancer, there is still a high percentage (around 70%) of human 
epithelial invasive cancers, including human sporadic gastric cancer cases (mainly diffuse-
type) displaying E-cadherin dysfunction that is not explained by any of the aforementioned 
mechanisms of E-cadherin genomic alterations [113]. This gap of knowledge constitutes a 
concern in the clinical practice and it is therefore of paramount important to address the 
mechanisms linking E-cadherin dysfunction to the tumorigenesis of gastric cancer. In this 
regard, we have been proposed the existence of another mechanism of E-cadherin (dys) 
regulation in cancer that operates at the posttranslational level of E-cadherin, the 
glycosylation (Figure 2C) [46]. 
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Protein Glycosylation 
The molecular mechanisms of neoplastic progression continue to be a fundamental 
focus of biomedical research. Although genetic and epigenetic changes have been reported 
to drive the progression of neoplasia [114, 115], posttranslational glycosylation may exert 
an equally powerful effect on the outcome of neoplastic disease [116, 117]. In fact, 
analogous to genomics and proteomics, glycomics aims to define the structure and 
functional roles of glycans in complex biological systems [118, 119]. The mammalian 
glycome repertoire- the spectrum of all glycans structures- is estimated to be 10-104 times 
larger than the proteome and far more complex than the genome and proteome [120-122]. 
Glycosylation consists in the covalent attachment of a carbohydrate to proteins and 
lipids producing different families of glycoconjugates [117] (Figure 3). Glycoprotein is a 
glycoconjugate in which a protein carries one or more glycans linked to a polypeptide 
backbone, usually via N- or O- linkage. N-linked glycans are attached to asparagine (Asn) 
residue of proteins in the consensus peptide sequence Asn- X- Ser/Thr, where X is any 
amino acid except proline [118]. O-glycans, particularly found on secreted or membrane-
bound mucins, consist of O-linked glycan attached to serine (Ser) or threonine (Thr) residue 
which can be further extended resulting in different types of O-glycans structures [118, 123].  
 
Figure 3 - Common classes of glycoconjugates in mammalian cells. Adapted from [117]. 
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Protein glycosylation is not a random process but rather a non-template driven 
process [118], and characterized by the microheterogeneity phenomenon in which any 
single specific site on a protein may be occupied by a relatively limited number of glycan 
structures. The extent of microheterogeneity can vary from one glycosylation site to another, 
from glycoprotein to glycoprotein, and from cell to cell type. Several factors may affect 
glycan heterogeneity dictating the type of cell surface glycans present on a given 
glycoprotein: expression and localization of glycosyltransferases in the ER /Golgi complex, 
the ratio of their activities, their accessibility to substrate, the nucleotide sugar metabolism, 
as well as the Golgi pH [116, 117]. Such structural variation of glycans precludes the precise 
prediction of glycans structures in a given cell type.  
Owing the complexity and dynamic nature of glycans, their biological roles span from 
nascent protein folding and intracellular trafficking to roles in molecular and cellular 
homeostasis [124], cell adhesion [125-127], cell-matrix [125] and host-pathogen 
interactions [47], immune modulation [128, 129], endocytosis, and signal transduction [124]. 
Therefore, minor alterations in glycan structure can significantly impact the structure and 
functions of glycoproteins by changing their conformation, stability, turnover, 
oligomerization, cell surface resident time, among other biological functions [117, 130].  
N-glycosylation 
The asparagine (N)-linked protein glycosylation occurs in all three domains of life: 
Bacteria, Archae and Eukarya [131]. In eukaryotic cells, about 90% of glycoproteins are 
likely to carry N-linked glycans with an average of 1,9 N-linked glycans per polypeptide 
chain [132]. The pathway initiates at the ER membrane where the glycan Glc3Man9GlcNAc2 
is synthesized and covalently coupled to the polypeptide backbone, and subjected to further 
trimming [133]. Here, the glycans have a common role in promoting protein folding, quality 
control and some sorting events [134]. Once the glycoproteins have folded and 
oligomerized correctly, they move to the Golgi complex, where N-glycans are extensively 
modified acquiring a diverse spectrum of structures and novel functions [118]. 
The assembly of the core oligosaccharide is performed by a series of 
glycosyltransferases that are encoded by asparagine linked glycosylation (ALG) genes 
(Figure 4). The three carbohydrate building blocks of the core oligosaccharide substrate (N-
acetylglucosamine- GlcNAc, mannose- Man, and glucose- Glc residues) emerge from the 
primary metabolism and enter the pathway as nucleotide activated sugars [118]. 
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Figure 4 - Schematic representation of the N-linked oligosaccharide assembly. Adapted from [118]. 
The process starts on the cytoplasmic surface of the ER membrane by the transfer 
of GlcNAc-1-phosphate from UDP-GlcNAc to the lipid-like precursor dolichol phosphate 
(Dol-P), forming GlcNAc-P-P-Dol. A second GlcNAc and five Man residues are 
subsequently transferred in a stepwise manner from UDP-GlcNAc and GDP-Man, 
respectively. The Man5GlcNAc2-P-P-Dol is then translocated to the ER luminal side by a bi-
directional flippase [133]. Further addition of four Man residues from Dol-P-Man and three 
Glc residues donated by Dol-P-Glc to the partially synthesized N-glycans is carried out in a 
stepwise manner. Dol-P-Man and Dol-P-Glc donors are formed on the cytoplasmic face of 
the ER from GDP-Man and UDP-Glc through transfer of the respective sugar to Dol-P and 
“flipped” across the ER bilayer to the luminal face. At this point, the specific 14-residue 
oligosaccharide consisting of Glc3Man9GlcNAc2 is completely synthesized to be further en-
bloc transferred to the side-chain amide of Asn residues specified by the consensus 
sequence Asn-X-Ser/Thr site (where X is any amino acid except proline). This en bloc 
transfer is catalysed by the oligosaccharyltransferase (OST), a multisubunit protein complex 
associated with the translocon complex. OST binds to the membrane-anchored Dol-P-P-
oligosaccharide and transfer the glycan to nascent protein by cleavage of GlcNAc-P bound, 
releasing Dol-P-P in the process [133]. The transfer of N-glycan to the innert side chain of 
Asn residues requires the formation of a loop so that the hydroxyl groups of Ser/Thr can 
contact the side-chain amide of Asn and render it more nucleophilic. The proline residue 
prevents the formation of such loop [135]. 
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The hydrophilic carbohydrates attached to the protein alter the biophysical properties 
of the newly synthesized polypeptide increasing stability, solubility, and resistance to 
proteases [136-138]. In addition, the defined structures of the N-glycans serve as sorting 
signals creating a series of checkpoints to reflect the folding status of the glycoprotein [139]. 
Inhibition of glycosylation causes improper and incomplete folding of polypeptides and 
consequently failure to reach the native conformation. In this situation, these polypeptides 
are retained in the ER and targeted for degradation [140].  
The N-glycan processing initiates immediately after the covalent attachment of the 
core glycan Glc3Man9GlcNAc2 to the protein in the lumen of the ER (Figure 5). Terminal 
glucose residue is trimmed by α-glucosidase I generating the Glc2Man9GlcNAc2 N-glycan 
which can associate with malectin. The possible functions of malectin include recruitment 
of α-glucosidase II for further processing and preventing aggregation of nascent 
polypeptides during the early synthesis [141]. 
 
Figure 5 - Schematic representation of quality control of glycoprotein folding. Adapted from [118]. 
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The next glucose residue is then removed by α-glucosidases II generating the 
monoglucosylated intermediate Glc1Man9GlcNAc2, the ligand of the ER-resident lectin 
chaperones calreticulin (CRT) and calnexin (CNX), members of the protein quality control. 
Both proteins, in conjugation with ERp57, an ER resident oxidoreductase, function as the 
major chaperone complex in the CNX/CRT complex. The binding of these non-stable 
glycoprotein intermediates with CNX/CRT/ERp57 complex assists the proper protein folding 
and also prevent the protein aggregation [140-142]. 
Removal of the last glucose residue by glucosidase II causes the glycoprotein 
release from CNX/CRT cycle. At this point, properly folded proteins are packaged in COPII-
coated vesicles and transferred to the Golgi. However, if the protein remained incompletely 
folded, the enzyme called UDP-Glc: glycoprotein glucosyltransferase (UGGT) catalyses the 
re-glucosylation generating a monoglucosylated N-glycan on the glycoprotein and 
consequently promoting the re-association with CNX/CRT complex. The cycle is repeated 
until the protein reached its native conformation. However, if proper folding of the protein 
still cannot be achieved, the unfolded glycoprotein further undergoes extensive mannose 
trimming which removes three to four mannose residues, generating Man5-6GlcNAc2.This 
intermediate will be then targeted to the ER- associated degradation (ERAD) pathway [139, 
142]. 
After processing and trimming in the ER, the folded glycoproteins which arrive in 
the cis-Golgi are of the high mannose type containing usually eight or nine Man residues 
[143]. These high mannose-type N-glycans may remain unchanged during passage through 
the Golgi and be present on cell surface or secreted glycoproteins. However, further 
mannose trimming may occur in the cis compartment of the Golgi until to generate 
Man5GlcNAc2Asn, a key intermediate in the pathway to hybrid and complex N-glycans [118] 
(Figure 6). 
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Figure 6 - Branching of complex N-glycans. Adapted from [118]. 
The Golgi membrane is covered with a spectrum of glycosyltransferases, 
glycosidases, and nucleotide sugar transporters that function together in a generally 
ordered manner from the cis-Golgi to the trans-Golgi network (TGN). Each Golgi 
glycosyltransferase transfers a sugar to a specific acceptor generated by preceding 
glycosyltransferases. Thus, Golgi glycosyltransferases must be appropriately localized in 
the cis-, medial-, trans- Golgi, or the TGN [143].  
A set of α-mannosidases I in the cis-Golgi compartment removes mannose residues 
to generate the Man5GlcNAc2-Asn intermediate. After mannose trimming, N-
acetylglucosaminyltransferase I (GlcNAcT-I or GnT-I), localized to the medial Golgi, 
catalyses the addition of the first GlcNAc residue to Man5GlcNAc2-Asn. This biosynthetic 
step is crucial for the conversion of high mannose to hybrid or complex-type N-glycans 
structures. Hybrid-type N-glycans keep the five mannose residues intact and extend the 
arm containing GlcNAc by addition of galactose (Gal), sialic acid (Neu5Ac) or other sugars. 
In complex-type N-glycans, the two outer mannose residues from GlcNAcMan5GlcNA2-Asn 
are removed by action of α-mannosidase II (another resident of the medial-Golgi) to form 
GlcNAcMan3GlcNAc2-Asn [118, 143].  
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Afterwards a second GlcNAc residue is added to mannose α1-6 in the core by the 
action of N-acetylglucosaminyltransferase II (GlcNAcT-II or GnT-II) to yield the precursor 
for all bi-antennary complex N-glycans. Further branching may occurs: N-
acetylglucosaminyltransferase IV (GlcNAcT-IV or GnT-IV) adds a GlcNAc residue to the 
Manα1-3 arm via β4 linkage initiating the synthesis of tri-antennary structures. Another 
enzyme N-acetylglucosaminyltransferase V (GlcNAcT-V or GnT-V) catalyses the transfer 
of GlcNAcβ1,6 branch to the Manα1-6 arms of bi-and tri- antennary substrates to form tri- 
and tetra-antennary N-glycans respectively. Then, N-acetylglucosaminyltransferase VI 
(GlcNAcT-VI or GnT-VI) may add the final branch to N-glycans to generate petra-antennary 
structures [118, 143].  
Hybrid and complex N-glycans may carry a “bisecting” GlcNAc residue linked to the 
internal β-Man residue of the core by N-acetylglucosaminyltransferase III (GlcNAcT-III or 
GnT-III). The presence of a bisecting GlcNAc inhibits many of the otherwise possible 
elongation and branching reactions [118].  
During subsequent terminal glycosylation, further sugar additions may occur in the 
trans-Golgi: 1) fucose (Fuc) residue addition to the GlcNAc residue adjacent to Asn (after 
GlcNAcT-I action); 2) elongation of branch GlcNAc residues of N-glycans (e.g. poly-N-
acetyllactosamine or polyLacNAc); 3) and “capping” and “decoration” of elongated branches 
(addition of Neu5Ac, Fuc, Gal, N-acetylgalactosamine- GalNAc) [118].  
O-Mannosylation 
Protein O-mannosylation is a posttranslational process that is initiated at the ER by 
the covalent attachment of mannose structures to Ser or Thr residues of secretory and/or 
membrane proteins catalysed by the homologous protein O-mannosyltransferase 1 
(POMT1) and 2 (POMT2). These O-mannose core structures may be further extended via 
different linkages originating distinct extended O-mannosylated structures [144]. The O-
mannosylation in mammalian proteins has been demonstrated to play crucial roles in 
several biological mechanisms such as infections, cell adhesion, neuronal development 
[145, 146], and in cellular interactions-based pathologies, including congenital muscular 
dystrophies (CMD) [147-150] and cancer metastasis [151-153]. 
In mammals, O-linked glycans initiated by mannose attachment were first detected 
in a proteoglycan-enriched fraction of rat brain lysate, and were considered to be present 
on a limited number of glycoproteins from brain, nerve, and skeletal muscles [154]. In 
mammalian brain tissues, O-mannose glycans account for up to 30% of all O-linked glycans 
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to proteins [150, 155, 156] . Moreover, O-mannosyl glycans are the major modifications of 
secreted and cell wall proteins in yeast which makes the eukaryotic model yeast 
Saccharomyces cerevisiae as the best model to characterize O-mannosylation pathway 
and function of O-mannosyl glycans [144]. 
The most well characterized O-mannosylated mammalian protein is α- dystroglycan 
(α-DG), an integral glycoprotein of the dystrophin-glycoprotein complex [157, 158]. The α-
DG links the extracellular matrix (ECM) to the actin cytoskeleton by interacting with ECM 
proteins in a glycosylation-dependent manner. Disruption of the O-mannosylation pathway 
causing the hypoglycosylation of α-DG results in the impairment of α-DG-mediated 
epithelial cell-basement membrane interaction, and underlies various forms of CMDs [159], 
as well as cancer metastasis [160]. Recent glycomics and glycoproteomic studies using 
mass spectrometry technology demonstrated a wide spectrum of known O-mannosylated 
proteins and their implications in cell biological functions and pathologies [161]. Several 
additional proteins were thus identified to be modified with O-mannosyl glycans, including 
CD24 [162], receptor tyrosine phosphatase β (RPTPβ) [163], neurofascin 186 [164], 
lecticans [165], cadherin’s and plexins [161]. However, the specific structures and the 
biological roles of O-mannosyl glycans in each proteins remain to be elucidated. 
Beyond a structural role, O-mannosylation has been reported to be essential in ER 
protein quality control [166-170]. ER- stress situations trigger increased levels of protein O-
mannosyltransferases (PMTs) by the unfolded protein response (UPR) [171]. Proteins 
which normally are not carriers of O-mannosyl glycans but failed to acquire the proper 
folding, undergo O-mannosylation in order to be targeted for degradation via proteasome-
dependent ERAD pathway [168-170]. 
Evidences suggest that a single polypeptide translocating into the ER can undergo 
O- and/or N-glycosylation processes, and therefore competition between PMTs and OST 
enzyme complexes for acceptor proteins substrates was reported [144, 172].  Ecker et al 
demonstrated that N-glycosylation of cell wall protein Ccw5 only occurs in pmt4 mutant 
suggesting that O-mannosylation precedes and can prevents N-glycosylation [173]. Indeed, 
PMTs have the potential to alter N-glycosylation site occupancy: 24% of the identified 
glycopeptides specific N-glycans acceptor sequon were only used in pmt mutants. 
Nevertheless, Harty et al reported an opposite situation:  N-glycans may introduce 
conformational changes which prevent O-mannosylation of N-glycosylated precursor [170]. 
Taken together, the potential crosstalk between O-mannosylation and N-glycosylation and 
its relevance in cell biology remain to be clarified, being a subject addressed on this PhD 
thesis. 
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The biosynthesis of O-mannosyl glycans is initiated at the cytosolic side of ER, 
where membrane dolichol is phosphorylated by the dolichol kinase Sec59, originating Dol-
P [174]. The enzyme GDP-Man: Dol-P mannosyltransferase (Dpm1) is then responsible for 
the transfer of mannose residue from GDP-Man to Dol-P, resulting Dol-P-Man, the only 
mannosyl donor in all eukaryotes [175, 176]. Dol-P-Man is then flipped from the cytosol to 
the luminal side of the ER [177]. In the ER lumen, protein O-mannosylation is initiated by 
the covalent attachment of mannose to Ser or Thr residues of secretory and membrane 
proteins [176] (Figure 7). The O-mannose core structures can be further extended via 
GlcNAcβ1-2Man, GlcNAcβ1-4Man, or GlcNAcβ1-6Man linkage [178-181]. Twenty-three 
different O-mannosylated structures have been characterized so far [182]. 
 
Figure 7 – Simplified O-mannosylation pathway. Adapted from [183]. 
The genes encoding PMTs, which initiates protein O-mannosylation, have been well 
characterized in the yeast Saccharomyces cerevisiae [144]. Saccharomyces cerevisiae 
comprises six PMTs grouped into three subfamilies, PMT1, PMT2, and PMT4 [184]. Two 
homologues, POMT1 and POMT2, have been identified in mammals [185] and classified 
as PMT4 and PMT2, respectively [186]. POMT1 and POMT2 are widely expressed in all 
mammalian tissues. These ER-resident proteins catalyse the initial step of O-mannosylation 
pathway- the transfer of mannose residue from Dol-P-Man to Ser and Thr residues of 
proteins in the secretory pathway via an α linkage [176, 187]. Formation of a POMT1 and 
POMT2 heterocomplex constitute a prerequisite for the proper O-mannosyltransferase 
activity in mammalian cells [187]. Knockout of POMT1 or POMT2 result in embryonic 
lethality and complete loss-of-function causing severe neuronal migration disorder, known 
as Walker-Warburg syndrome (WWD), the most severe phenotype of CMD [188, 189].  
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Concerning the O-Mannose elongation, one of the possible mannose-linkage 
structures existing in O-mannosyl glycans is GlcNAcβ1-2Man via protein O-Mannose β-1,2-
N-acetylglucosaminyltransferase 1 (POMGnT1) activity [190]. This glycosyltransferase is 
expressed in a variety of mammalian tissues and is localized in the cis-Golgi [191]. After 
POMT1 and POMT2 actions, POMGnT1 catalyses the transfer of GlcNAc residue from 
UDP-GlcNAc into O-mannosyl-modified glycoprotein in a β2 linkage [192] (Figure 7). The 
muscle-eye-brain (MEB) disease is predominantly associated with POMGnT1 gene 
expression alterations [148, 193, 194]. 
An alternative elongation pathway implicates human protein O-mannose β-1,4-N-
acetylglucosaminyltransferase 2 (POMGnT2) which is responsible for the transfer of 
GlcNAc from UDP-GlcNAc to O-mannose residue through β4-linkage [181]. POMGNT2 
knockout mice exhibited abnormal neuronal migration and die in the first day of birth [195]. 
This pathways involves further extension by β3GalNAc-T2 and subsequent phosphorylation 
of the mannose residue at addition C6 position by protein O-mannose kinase (POMK) 
enzyme, generating GalNAcβ1-3GlcNAcβ1-4(P-6)Man structure [181]. POMGnT2, 
β3GalNAc-T2 and POMK are ER-resident enzymes and POMK-mediated phosphorylation 
requires the GalNAcβ1-3GlcNAcβ1-4Man structure generated by prior action of POMGnT2 
and β3GalNAc-T2 [181] (Figure 7). 
Finally, the last alternative extension pathway involves the action of β1,6-N-
acetylglucosaminyltransferase-IX/Vb (GnT-IX/ GnT-Vb). The O-mannose glycan 
GlcNAcβ1-2(GlcNAcβ1-6)Man structure has been identified in α-DG glycoprotein from 
mammalian brain [179, 180]. The GnT-Vb activity requires the previous action of POMGnT1 
to generate the GlcNAcβ1-2Man structure [196] (Figure 7). Other enzymes have been 
identified to be involved in further extension of the three types of O-mannosyl glycans core 
structures [182]. Mutations in known and putative glycosyltransferases involved in the 
biosynthesis of O-mannosyl glycans have been associated with defects in proper 
glycosylation of α-DG giving rise to human diseases. 
Glycosylation alterations associated with cancer 
Malignant transformation is strongly associated with altered glycosylation patterns 
on the surface of cancer cells, being a key event in the process of tumour development and 
progression [197]. In fact, expression of aberrant glycans have been implicated during the 
various steps of tumour progression, including proliferation, invasion, metastasis and 
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angiogenesis [130]. Altered expression and activity of glycosyltransferases and chaperones 
and mislocalization of glycosyltransferases are the major factors that affect the protein 
glycosylation in tumour cells [117]. Owing to the wide range of glycans with different 
structures and levels of expression present on tumour cells, compared with their non-
transformed counterparts, cancer-associated aberrant glycosylation has been considered 
a hallmark of neoplastic cells [117]. Cancer-specific glycan epitopes have been presented 
themselves as potential cancer biomarkers for diagnostic, prognostic purposes and also as 
appealing therapeutic targets [117].  
The major changes in glycan structures during malignancy encompass alterations 
both in O- and N-glycans structures which may occur both at early and late stages of cancer 
progression and metastasis. The most-widely occurring cancer-associated changes in 
glycosylation are: increased sialylation, truncated O-glycan, fucosylation, and branching N-
glycans [116, 117, 198]. During neoplastic progression, many tumours exhibited high levels 
of the sialylated antigens SLea, SLex [199, 200] and STn [201, 202]. Furthermore, core 
fucosylation have been reported to be related with cancer [203]. Upregulation of core 
fucosylation has been found in liver, ovarian and colon tumours tissues [203-205] and in 
the serum levels of hepatocellular carcinoma (HCC) and ovarian patients [205, 206]. 
N-linked glycans in cancer 
The expression of complex β1,6-branched Asn-linked oligosaccharides structures 
have been directly associated with malignancy and metastatic potential of the neoplastic 
cells [207]. The β1,6-branched N-linked glycans results from the GnT-V activity, which is 
encoded by the mannoside acetylglucosaminyltransferase 5 (MGAT5) gene. During 
malignant transformation, MGAT5 is upregulated by the activation of the RAS-RAF-MAPK 
signalling pathway, which leads to the expression of branching in Asn-linked 
oligosaccharides mediated by GnT-V and to the promotion of tumour development and 
potential [208]. However, it is important to note that the occurrence of β1,6 branching in 
asparagine-linked oligosaccharides is dependent on tissue-specific regulation of GnT-V 
activity [209].  
The role of GnT-V-mediated branched N-glycans in the process of tumour 
development and progression has been highlighted through various mechanisms of action. 
In fact, the GnT-V-dependent N-glycan modifications have been reported to impair epithelial 
contact inhibition in immortalized lung epithelial cell line, being associated with significantly 
increased cellular motility and tumour formation in athymic mice [210]. Likewise, 
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overexpression of GnT-V enhances the invasiveness of glioma and colon cancer cell lines 
[211, 212], as well as in mouse mammary carcinoma cells [209]. Furthermore, early events 
in breast carcinogenesis were found to be regulated by GnT-V through modulation of her-
2-mediated signalling pathways [213]. In addition, transfection of GnT-V in mouse 
mammary cancer cell lines resulted in a significant induction of tumour growth and 
metastasis [214]. Accordingly, MGAT5-deficient mice displays significant suppression of 
mammary tumour growth and metastasis [215]. 
GnT-V-modified N-glycans have also been reported to modulate the cell signalling 
function of surface receptors, and consequently be implicated in cancer invasion and 
metastasis [205]. In fact, the extension of β1,6 GlcNAc branched N-glycans with poly N-
acetyllactosamine structures on the surface of glycoprotein receptors leads to their binding 
to the galectins, a family of carbohydrate-binding proteins, originating the lattices (galectin-
glycan structures) [216]. In turn, the constitutive endocytosis of the glycoprotein receptors 
is prevented, which contributes ultimately to the increased cell motility and tumour formation 
[217, 218]. 
The β1,6 GlcNAc branched N-glycans structures also modulates the cell-ECM and 
cell-cell interactions [125]. The presence of these glycans on α5β1 and α3β1 integrins 
enhances the migration and invasion potential in human fibrosarcoma and melanoma cells, 
respectively [219, 220].  The branched N-glycans also regulates the biological functions of 
the adhesion molecule E-cadherin, thereby affecting cell-cell interaction (as described 
below). At the clinical point of view, the β1,6 GlcNAc branched N-glycans structures have 
been reported as a predictors of poor outcome of breast carcinoma [221, 222].  
The bisecting GlcNAc structures, catalysed by GnT-III, have been shown to have an 
important role in a cancer context [223]. GnT-III activity has been reported to counteract the 
role of GnT-V in cancer, regulating cancer cell survival and progression. GnT-III, encoded 
by MGAT3, catalyses the addition of GlcNAc in a β1,4-linkage, suppressing additional 
processing and elongation of N-glycans such as the β1,6-GlcNAc-branched N-glycans. 
MGAT3 transfection into mouse melanoma B16 cells with high metastatic potential resulted 
in a significant suppression of lung metastasis in mice due to a reduction of β1,6 GlcNAc 
branching glycans through competition with GnT-V [223]. 
The crucial role of GnT-III in the suppression of tumour metastasis results from the 
impairment of the cell-ECM interaction and promotion of the cell-cell adhesion [224]. The 
overexpression of GnT-III on α5 subunit reduces the α5β1 integrin binding to fibronectin, 
compromising the α5β1 integrin-mediated cell migration [225]. A similar impact was also 
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reported in MKN45 gastric cancer cells on α3β1 integrin-mediated cell spreading on 
fibronectin [226]. In contrast, the enhancement of cell-cell adhesion is acquired by the 
stabilizing effect that GnT-III confers to E-cadherin (as described below) [47]. 
E-cadherin Post-translational modifications. 
Implications in cancer 
E-cadherin is a glycoprotein that is post-translationally modified by glycosylation. 
Glycans have been described to precisely regulate the tumour cell-cell-adhesion by directly 
interfering with E-cadherin biological functions. The human E-cadherin ectodomain 
comprises four potential N-glycosylation sites: two putative sites located at EC4 subdomain 
(Asn-554 and Asn-566) and the remaining two potential sites at the EC5 subdomain (Asn-
618 and Asn-633) [46]. 
The pattern of E-cadherin N-glycosylation was described to occurs in cell-density 
dependent manner, being modified with complex type or hybrid/high mannose 
oligosaccharides, in sparse and dense cultures, respectively [227]. These dynamic changes 
in the E-cadherin N-glycosylation profile are biologically relevant, since sparse cells 
(mimicking proliferative conditions) are known to form immature adherens junctions while 
dense cultures (mimicking differentiated state) form mature adhesion belts [227, 228].  
The N-glycan at Asn-633 was found to be required for E-cadherin expression, folding 
and trafficking [229]. E-cadherin unglycosylated at this specific site is arrested in ER as a 
misfolded protein being degraded via ERAD pathway [230]. In turn, N-glycosylation at Asn-
554 and Asn-566 were described to be important for cell cycle progression [231]. 
Additionally, N-glycosylation have been reported to affect the adhesive function of E-
cadherin through modifying the assembly and stability of adherens junctions. In fact, 
removal of N-glycans at Asn-554 and Asn-566 resulted in elevated tyrosine phosphorylation 
level of β-catenin and consequently a reduced β- and α-catenin expression at adherens 
junctions, thus impairing the adhesive function of E-cadherin [229]. 
Recent studies with the neural cadherin (N-cadherin) further suggest that initial EC1 
cadherin-dependent trans adhesive bonds established between opposing cadherin 
monomers are followed by lateral cadherin interactions controlled by N-glycosylation [232]. 
Removal of β1,6-branched N-glycans at EC2 and EC3 resulted in an increased N-cadherin 
cis-dimerization capability [233]. 
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Several reports highlighted that DPAGT1 gene expression and protein N-
glycosylation are coordinated with canonical Wnt signalling and E-cadherin- mediated cell-
cell adhesion via positive and negative feedback loops [234]. In fact, canonical Wnt 
signalling pathway regulates DPAGT1 transcription, which in turn affects N-glycosylation 
status of Wnt components to further promotes Wnt signalling- positive feedback [235]. 
Moreover, high expression levels of DPAGT1 induce extensive N-glycosylation of E-
cadherin with complex N-glycans, inhibiting E-cadherin mediated cell-cell adhesion [236]  
and impairing stability of adherens junctions [237]. In turn, reduced expression of DPAGT1 
leads to hypoglycosylation of E-cadherin which culminate in depletion of β- and γ-catenin 
from promoter of target genes, and thereby in inhibition of canonical Wnt signalling [228]. 
An additional positive feedback loop was described between E-cadherin and GnT-III 
expression where E-cadherin mediated cell-cell adhesion upregulates GnT-III expression 
and its products (bisecting N-glycans) [238, 239], which in turn downregulate the tyrosine 
phosphorylation of β-catenin, contributing to suppression of invasion and metastasis [240].  
Besides affecting the composition and maturity of adherens junctions, N-
glycosylation indirectly controls the assembly of tight junctions (TJ). Actually, reduced E-
cadherin N-glycosylation promotes recruitment of protein phosphatase 2A (PP2A) to 
adherens junctions [241]. As result, ZO-1 and other components of TJ become 
phosphorylated and participate in the assembly of TJ [241]. Furthermore, N-glycosylation 
impacts adherens junctions’ interactions with the cytoskeleton. E-cadherin 
hypoglycosylation improves the interaction of E-cadherin-β-catenin complex with PP2A and 
dynein which in turn associate with microtubules [242]. In contrast, E-cadherin-γ-catenin 
complexes establish association with the actin cytoskeleton via α-catenin and vinculin [241, 
242]. 
During malignant transformation, E-cadherin undergoes an extensive modification 
on its N-glycosylation profile [243]. We and others have been demonstrating that E-cadherin 
regulates the transcription of GnT-III that in turn through competition with GnT-V, can 
glycosylate E-cadherin and promote a membranous localization of E-cadherin [127], and 
improvement of the competence of adhesive complex [244]. The N-glycosylation mediated 
by GnT-III was also associated with inhibition of E-cadherin endocytosis [126] and a delayed 
turnover of E-cadherin at the cell surface. Furthermore, E-cadherin modified with bisecting 
GlcNAc N-glycans enhances intercellular adhesion by recruitment of catenins [126], and 
downregulates intracellular signalling pathways involved in cell motility, supporting its 
contribution to tumour suppression [231]. In addition, MGAT3 glycogene expression and 
GnT-III-mediated E-cadherin glycosylation also contributes to an epithelial phenotype that 
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prevents the EMT process [245, 246]. Interestingly from the clinical point of view, it was 
demonstrated that E-cadherin from human gastric carcinoma is modified with GnT-V 
mediated branching N-glycans playing an important role on E-cadherin-mediated tumour 
invasion and progression [126].  
GnT-V is known to be upregulated in gastric carcinoma [247], contributing to cancer 
cell invasion and metastases [215]. Gastric cancer cells overexpressing GnT-V display E-
cadherin mislocalization [126]. Furthermore, GnT-V-mediated glycosylation on E-cadherin 
was shown to interfere with β-catenin and p120 catenin recruitment, disturbing the stability 
of adherens junctions and compromising cell-cell adhesion. Moreover, β1,6GlcNAc 
branched N-glycans on cadherins also affect downstream signalling pathways [248], 
contributing  to increased cell migration and invasion [226]. Interestingly, patients with 
gastric carcinoma displaying loss of E-cadherin function (not explained at the genetic or 
structural level) exhibit an increase in β1,6GlcNAc-branched N-glycans on E-cadherin [126]. 
Taken together, it is clear that E-cadherin suffers a profound alteration on its N-
glycosylation profile that accompany malignant transformation. However, the specific role 
of each N-glycans (structure-function relationship) on E-cadherin function in cancer 
remained to be clearly elucidated and will be addressed in this PhD thesis. 
E-cadherin can also undergoes to increased fucosylation in cancer context. Some 
reports regarding E-cadherin core fucosylation was shown  to have a negative effect on the 
cell-cell adhesion [249], suggesting that core fucosylated E-cadherin can serve as a 
promising prognostic marker for lung cancer patients [250]. However, other study reported 
that transfection of α1,6-fucosyltransferase (FUT8) improves binding of E-cadherin to β-
catenin, through reduction of tyrosine 654 phosphorylation β-catenin and its transcriptional 
activity [251].  
Recently, E-cadherin was identified as a major target for O-mannosylation [161, 
252]. Lommel et al. demonstrated that O-mannosylation of E-cadherin is required for the 
morula to blastocyst transition before implantation [252]. Interestingly, O-mannosylation has 
shown to be crucial for E-cadherin-mediated cell-cell adhesion in a normal context [252]. 
Absence of O-mannosylated structures at the EC2-5 domains led to a disruption of E-
cadherin localization [161]. Nonetheless, unravelling the molecular role of O-mannosyl 
glycans on E-cadherin as well as their impact on the modulation of E-cadherin adhesive 
properties in cancer progression remains to be elucidated and will be assessed in this PhD 
thesis.
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Rational and Aims 
E-cadherin is a classical cell-cell adhesion molecule playing pivotal roles in epithelial 
tissue morphogenesis. The functional inactivation or downregulation of E-cadherin is 
considered to be a hallmark of the epithelial carcinogenetic process, being closely 
associated with tumour cell invasion and metastases, ultimately contributing to malignancy. 
Taking into account that around 70% of human sporadic gastric cancer cases (mainly 
diffuse subtype) displayed E-cadherin dysfunction that is not explained by altered 
epi/genetic mechanisms, the modification of E-cadherin by glycosylation may constitute an 
alternative mechanism for E-cadherin regulation in cancer.  
The specific role of each glycan structure in the dysregulation of E-cadherin functions 
in cancer remains to be elucidated. Moreover, the molecular role of the recently identified 
O-mannose glycans in the regulation of E-cadherin in cancer and its potential interplay with 
N-glycans is far from being determined. 
The general aim of the present work is to unravel the E-cadherin “sugar code” in a 
gastric cancer context, and thus sorting out the structural frameworks and biological roles 
of E-cadherin glycans, envisioning potential clinical applications.  
Specific aims 
1. To identify the E-cadherin-dependent signalling pathway involved in the 
regulation of GnT-III-mediated E-cadherin N-glycosylation 
 
The functional crosstalk between E-cadherin-mediated cell-cell adhesion and the 
bisecting GlcNAc N-glycans were reported to contribute to suppression of cancer invasion 
and metastasis. In fact, E-cadherin-mediated cell-cell adhesion upregulates GnT-III 
expression and its product (bisecting N-glycans), that promotes a membrane localization of 
E-cadherin and an improvement of the adhesive complex stability. However, the signalling 
pathways involved in this regulation, associated with tumour suppression, remains to be 
elucidated. 
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In chapter II, we aimed to assess the underlying signalling pathway (E-cadherin-
dependent) involved in the regulation of the bisecting GlcNAc N-glycans in the process of 
tumour progression of epithelial cancer cells. 
 
2. To determine the N-glycosylation site-specific occupancy of E-cadherin in a 
gastric cancer context and to disclose the biological role of each N-glycan on E-
cadherin (structure- function relationship). 
 
E-cadherin glycoprotein has four potential N-glycosylation sites that are potentially 
responsible for controlling its biological functions. In a gastric cancer context, E-cadherin 
undergoes different N-glycosylation patterns with implications in its adhesive functions. In 
cancer, E-cadherin is predominantly modified with β1,6 GlcNAc N-glycans catalysed by 
GnT-V activity which induced a mislocalization of E-cadherin into the cytoplasm, decreasing 
the stability of E-cadherin-catenin complex and impairing its adhesive properties. Therefore, 
the identification and characterization of the site-specific E-cadherin N-glycans occupancy, 
and its functional role on E-cadherin functions remain to be identified, being of utmost 
relevance for the clinic. 
In chapter III, we intended to evaluate the N-glycosylation site-specific occupancy 
on E-cadherin in a gastric cancer context. Furthermore, we aimed to unravel the specific 
function of each E-cadherin N-glycan structure in the modulation of E-cadherin functions in 
cancer (structure-function relationship), and therefore to decipher the E-cadherin N-glycan 
sugar code envisioning potential clinical applications. 
 
3. To evaluate the O-mannosylation profile of E-cadherin in a gastric cancer context 
and to disclose the molecular role of O-mannosyl glycans and their interplay with 
N-glycans in the regulation of E-cadherin biological functions in cancer.  
 
E-cadherin was recently identified as a major target of O-mannosylation being 
required for the morula to blastocyst transition before implantation. Interestingly, O-
mannosylation was shown to be important for E-cadherin-mediated cell-cell adhesion under 
physiological circumstance. Nonetheless, the E-cadherin O-mannosylation profile as well 
as the molecular role of E-cadherin O-mannosyl glycans in its adhesive properties and how 
this novel post-translational modification interplays with E-cadherin N-glycans in a cancer 
context remain to be elucidated. 
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In chapter IV, we aimed to disclose the role of O-mannosylation in gastric carcinoma, 
and to uncover the impact of E-cadherin O-mannosylation in the modulation of its biological 
functions. Furthermore, we intended to uncover the mechanistic interplay between O-
mannosyl glycans and β1,6 GlcNAc N-glycans on E-cadherin glycoprotein. We also 
pretended to find out such interplay in human diffuse gastric cancer patients and different 
mice models and to infer about the relationship between protein O-mannosylation and GnT-
V-mediated N-glycosylation processes. 
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Chapter II  
Insulin/IGF-I Signalling Pathways Enhances Tumour 
Cell Invasion through Bisecting GlcNAc N-glycans 
Modulation. An Interplay with E-cadherin. 
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Changes in glycosylation are considered a hallmark of cancer, and one of the key targets of glycosylation
modifications is E-cadherin. We and others have previously demonstrated that E-cadherin has a role in the regulation
of bisecting GlcNAc N-glycans expression, remaining to be determined the E-cadherin-dependent signaling pathway
involved in this N-glycans expression regulation. In this study, we analysed the impact of E-cadherin expression in
the activation profile of receptor tyrosine kinases such as insulin receptor (IR) and IGF-I receptor (IGF-IR). We
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with insulin and IGF-I in MDA-MD-435 cancer cells overexpressing E-cadherin induces a decrease of bisecting
GlcNAc N-glycans that was accompanied with alterations on E-cadherin cellular localization. Concomitantly, IR/IGF-
IR signaling activation induced a mesenchymal-like phenotype of cancer cells together with an increased tumor cell
invasion capability. Altogether, these results demonstrate an interplay between E-cadherin and IR/IGF-IR signaling
as major networking players in the regulation of bisecting N-glycans expression, with important effects in the
modulation of epithelial characteristics and tumor cell invasion. Here we provide new insights into the role that
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Introduction
The Insulin Growth Factor (IGF) system in mammals
comprises a dynamic network of proteins including ligands
(IGF-I and IGF-II) and at least four associated receptors. The
insulin receptor (IR), IGF-I receptor (IGF-IR), and insulin
receptor-related receptor (IRR) belong to the tyrosine-kinase
superfamily [1].
Insulin/IGF-I signaling pathways play a crucial role during
malignant transformation [2]. The activation of these pathways
has been related with increased proliferation, survival,
metastatic potential and angiogenesis [3]. Therefore, the
Insulin/IGF-I signaling pathway has been considered an
appealing therapeutic target in cancer [4]. In this context, it was
demonstrated that tumor growth in human tumor xenograft
models was significantly reduced by using antibodies that
inhibit the Insulin/IGF-I signaling [5,6]. Moreover, daily
treatment with OSI-906, a dual inhibitor of the IGF-I and insulin
receptors, resulted in tumor growth inhibition in the NCI-H292
xenografts [7]. Furthermore, recent studies have point out the
importance of the insulin/IGF-I signaling in the loss of epithelial
features of carcinoma cells [8,9]. It was shown that IGF-I
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increases invasive potential inducing TGF-β1-mediated
Epithelial to Mesenchymal Transition (EMT) in MCF-7 breast
cancer cells [8].
E-cadherin is a cell-cell adhesion molecule with pivotal roles
in the suppresion of tumor cell invasion and metastasis, being
also a key molecular player in the EMT process [10].
Dysfunction of E-cadherin is considered a major event of more
than 70% of human invasive carcinomas. Several mechanisms
have been recently proposed to underlie E-cadherin down-
regulation or inactivation in cancer, such as post-translational
modifications by N-glycosylation [11–15].
It has been our long last interest to understand the role that
glycans play during the carcinogenic process, particularly in the
modulation and regulation of E-cadherin biological functions. In
this context, we have previously demonstrated that E-cadherin
functions can be specifically modulated by the presence of
different oligosaccharide structures [15–17]. We have shown
that during the acquisition of the malignant phenotype, E-
cadherin suffered an increased modification with β1,6 GlcNAc
branched N-glycans, catalyzed by N-
acetylglucosaminyltransferase V (GnT-V) [18,19], that was
further demonstrated to induce a destabilization of E-cadherin-
mediated cell-cell adhesion (adherens junction) with
consequences to tumor progression [17]. Furthermore, it was
shown the existence a bidirectional cross-talk between E-
cadherin expression and the N-acetylglucosaminyltransferase
III (GnT-III) [19,20]. The modification of E-cadherin with
bisecting GlcNAc N-glycans, catalyzed by GnT-III, was shown
to enhance cell–cell adhesion with increased stability of
adherens junctions, which was associated with suppression of
tumor progression [17,21]. In addition, the modification of the
growth receptors with bisecting GlcNAc structures precludes
their membranar stabilization and consequently their signaling
activation, through the inhibition of further extension and
elongation of the N-glycans with β1,6 GlcNAc branched
structures [22,23] .
Taking into consideration the existence of a functional
feedback loop between E-cadherin-mediated cell-cell adhesion
and bisecting GlcNAc N-glycans in the suppression of cancer
cell invasion, it remains to be identified which are the
associated signaling pathways involved in this process. In this
study, we aim to identify the E-cadherin-dependent signaling
pathway involved in the regulation of N-glycosylation,
particularly in the expression of bisecting GlcNAc N-glycans
and their impact on the malignant phenotype of MDA-MB435
epithelial cancer cells. We herein demonstrate for the first time
that on one hand E-cadherin expression induces a significant
decrease in the phosphorylation levels of insulin and IGF-I
receptors, which was accompanied with an increased
modification of E-cadherin with bisecting GlcNAc structures,
and a consequent suppression of tumor cell invasion. On the
other hand, the activation of the insulin and IGF-1 signaling
pathways induces a significant decrease of the bisecting
GlcNAc N-glycans in general, and specifically on E-cadherin
molecule. Concomitantly, we also observed that activation of
Insulin/IGF-I signaling pathways leads to an increased tumor
cell invasion. Stimulation of cancer cells with insulin and IGF-I
growth factors led to a significant upregulation of the fibronectin
mesenchymal marker, and an alteration of E-cadherin and β-
catenin cellular localization.
Altogether, our results contribute to the identification of a
novel molecular mechanism, involving insulin and IGF-I
signaling in the modulation of bisecting GlcNAc N-glycans
expression on E-cadherin, and their consequente impact in the
modulation of the invasive phenotype.
Materials and Methods
Chemicals and antibodies
Mouse monoclonal anti-E-cadherin and anti-β-catenin
antibodies were obtained from BD Biosciences. Rabbit
monoclonal anti-p-IR/p-IGF-IR, anti-IR, anti-IGF-IR, anti-p-
Akt(Ser473), anti-Akt, anti-p-ERK 1/2, anti-ERK1/2 and anti-
fibronectin were obtained from Cell Signaling Technology.
Mouse monoclonal anti-α-tubulin was purchased from Sigma.
Rabbit polyconal IgG anti-actin and peroxidase-conjugated
anti-rabbit and anti-mouse IgG were purchased from Santa
Cruz Biotechnology. Biotinylated Phaseolus vulgaris
erythroagglutinin (E-PHA) and biotinylated Phaseolus vulgaris
leucoagglutinin (L-PHA) lectins were purchased from Vector
Laboratories. IGF-I was obtained from Immunotools and Insulin
from Sigma. Alexa Fluor 488 anti-mouse was obtained from
Invitrogen.
Cell Culture and transfection
Human MDA-MB-435 cells (which endogenously lacks E-
cadherin expression at both the mRNA and protein level) were
previously stably transfected with the empty vector (MDA-
MB-435+mock) or with wild-type E-cadherin (MDA-MB-435+E-
cad) [24]. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium, supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin, under a humidified atmosphere
containing 5% CO2. Cell lines stably transfected were
maintained under antibiotic selection. MKN45 gastric
carcinoma cell line stably transfected with MGAT5 or with an
empty vector (mock cells) [17] were kindly provided by Prof.
Taniguchi. These cells were cultured in RPMI 1640 medium
containing 10% fetal bovine serum, penicillin (100 units/ml) and
streptomycin (1000 μg/ml), under the selection of G418 (500
μg/ml) in 5% CO2.
Immunoprecipitation, Western blot and lectin blot
analysis
Cell cultures were washed with phosphate-buffered saline
(PBS) and then lysed in a solution containing 1% Triton X-100,
1% NP40, protease inhibitor cocktail (Roche 1 tablet/50 ml
buffer) and phosphatase inhibitor cocktail (Sigma, 1:100
dilution). Total protein was quantified using a BCA protein
assay kit (Pierce). For immunoprecipitation, equal amounts of
total protein (750 μg) from each cell lysate were precleared
with 25 μl of protein G-sepharose beads (Sigma) for 1–2 h.
After centrifugation, the supernatant was incubated overnight
with 5 µg of mouse monoclonal antibody against E-cadherin
(BD Biosciences). After that, incubation with protein G-
sepharose for 2 h was performed. Next, the beads were
Insulin/IGF-I Signaling and Bisecting N-Glycans
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washed three times with immunoprecipitation buffer and the
immune complexes were released by boiling for 5 min at 95°C
in Laemmli sampling. For Western blot, samples were
subjected to 7.5% SDS–PAGE and the separated proteins
were transferred to a nitrocellulose membrane. The blots were
then probed with primary and pexoxidase-conjugated
secondary antibodies or biotinylated lectins (Vector
Laboratories). The proteins were visualized using an ECL
chemiluminescence kit (GE Healthcare). Immunoreactive
bands from lectin blots were then visualized using the Vector
stain ABC kit (Vector Laboratories).
Analysis of mRNA expression by RT–PCR and real-time
PCR
Total RNA from MDA-MB435+mock and MDA-MB435+E-cad
cells were extracted with Tri-Reagent (Sigma) according to the
manufacturer’s protocol. Yield and quality of RNA were
determined spectrophotometrically. 1000 ng of total RNA were
reverse transcribed using the Superscript III RNase H Reverse
Transcriptase kit (Invitrogen) according to the manufacturer’s
instructions. Quantitative Real-Time-PCR (qRT-PCR) was
carried out in triplicates using source RNA from 3 distinct
biological replicas for the target genes CDH1 (E-cadherin,
Hs01023895_m1), Ocln (Occludin, Hs.PT.49.14927371),
CTNNB1 (β-catenin, Hs00355045_m1), Vim (Vimentin, Hs.PT.
47.14705389), CDH2 (N-cadherin, Hs.PT.49.15618412), FN 1
(Fibronectin, Hs.PT.47.1565512) and for the endogenous
control GAPDH (GAPDH, Hs.PT.51.1940505). qRT-PCR
analysis of mRNA expression was performed using TaqMan
Gene Expression Assays (CDH1, CTNNB1, Applied
Biosystems) or PrimeTime qPCR Assays ( Ocln, Vim, CDH2,
FN 1, GAPDH, Integrated DNA Technologies). Data was
analysed by the comparative 2(-ΔΔCT) method [25]. For all
data comparisons, the Student's T-Test was used (two tailed,
unequal variance).
Immunofluorescence
Cells were platted on six-well plates with coverslips. After
90% of confluence, cells were washed three times with PBS
supplemented with 100 mM CaCl2 and 100 mM MgCl2 (PBS/
CM), permeabilized with 0.1%Triton X-100, and blocked with
BSA 3% (in PBS/CM) for one hour. For E-cadherin or β-catenin
staining, cells were incubated with mouse anti-E-cadherin (BD
Biosciences; 1:200 diluted in BSA 5%; one hour of incubation)
or mouse anti-β-catenin (BD Biosciences; 1:100 diluted in BSA
5%; one hour of incubation) monoclonal antibody, respectively.
After primary antibody incubation, the cover slips were washed
in PBS and then Alexa Fluor 488 anti-mouse was used as
secondary antibody (Invitrogen; 1:500 diluted in BSA 5%; one
hour of incubation in the dark). Finally, the cover slips were
washed in PBS and mounted on slides using Vectashield with
DAPI (Vector Laboratories). Immunofluorescent images were
obtained using a Zeiss Imager.Z1 AxioCam MRm (Carl Zeiss)
and a TCS SP5 II (Leica) Laser Scanning Confocal microscope
(Figure S4).
Phospho-receptor tyrosine kinase array
Human Phospho-RTK Array kit for 42 RTKs was performed
for both MDA-MB-435+mock and MDA-MB-435+E-cad
according manufacturer’s protocol (R&D systems). The
proteins were visualized using an ECL chemiluminescence kit
(GE Healthcare).
Cell invasion assay
Cells (5 x 104) were seeded in the upper surface of transwell
inserts with 8 µm pore size (Costar) coated with Matrigel for 24
h. After stimulation with insulin or IGF-I, the cells on the upper
surface were removed and those from the lower surface were
fixed with ethanol for 10 min, stained with DAPI and observed
using an Axio Observer.Z1 microscope (Carl Zeiss). For
quantification, three fields were counted for each assay.
Densitometry and Statistical analysis
The protein levels were quantified by densitometry using
LabWorks 4.6 software (Bio-Rad). The measurements were
obtained from sub-exposed photographic films after
quimioluminescence reaction and the values were normalized
to the amount of housekeeping (actin or tubulin). Student's T-
Test and one-way ANOVA were performed with GraphPad
Prism 4.02 software (GraphPad Software Inc.). We considered
data from three independent experiments to be statistically
significant at P<0.05. Graphic data are presented as the mean
+ SEM.
Results
Exogenous E-cadherin expression induces an
epithelial-like phenotype in MDA-MB-435 cells
We used MDA-MB-435 cancer cell line, that endogenously
lacks E-cadherin expression, as a model. Stable transfection
with human full-length E-cadherin in MDA-MB-435 was
previously performed [24]. In order to characterize the MDA-
MB-435 mock and E-cadherin transfected cells, we performed
a Western blot analysis using anti-Ecadherin antibody. We
observed that MDA-MB-435+E-cad express E-cadherin,
whereas in MDA-MB-435+mock we did not observed
detectable levels of E-cadherin (Figure 1A). In addition, we
have observed, by phase contrast microscopy, that expression
of E-cadherin was associated with an epithelial-like phenotype
whereas MDA-MB-435+mock cells exhibited a fibroblastoid-like
appearance with presence of cytoplasmic protusions (Figure
1B). In order to confirm these phenotypical changes induced by
E-cadherin transfection, we performed qRT-PCR to determine
the expression levels of epithelial (occludin and β-catenin) and
mesenchymal (vimentin, fibronectin and N-cadherin) markers
at the mRNA level [26]. We observed that, the MDA-
MB-435+E-cad cells exhibited a significant decreased
expression of mesenchymal markers, such as fibronectin and
N-cadherin, comparing with MDA-MB-435+mock. (Figure 1C).
These results showed that, as expected, induced over-
expression of E-cadherin inhibits the spindle shape morphology
and induces an epithelial-like phenotype in MDA-MB-435 cells.
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Figure 1.  Effects of exogenous E-cadherin on the cell
morfology and expression of epithelial and mesenchymal
markers in MDA-MDA-435 cells.  (A) Total cell lysates from
MDA-MB-435+mock and MDA-MB-435+E-cad were obtained
and analyzed by Western blot for E-cadherin. MDA-
MB-435+mock cells do not show detectable levels of E-
cadherin. Actin was used as a loading control. (B) The same
amount of cells were seeded, and at the same time of culture
phase contrast images show the cell morphology of MDA-
MB-435+mock, which exhibit a mesenchymal-like phenotype,
and MDA-MB-435+E-cad exhibit an epithelial-like phenotype.
The inserts represent higher magnifications of the figure. Scale
bar = 20 µm. (C) The bar graph shows the relative amount of
E-cadherin, occludin, β-catenin, vimentin, fibonectin and N-
cadherin mRNA levels by qRT-PCR. MDA-MB-435+E-cad cells
exhibit a significant decreased expression of the mesenchymal
markers fibronectin and N-cadherin. Values were normalized to
the amount of mRNA in MDA-MB-435+mock. Error bars
indicate the means + S.E.M. (n = 3). ** = P < 0.01, *** =P <
0.001, Student's t-test.
doi: 10.1371/journal.pone.0081579.g001
Exogenous E-cadherin expression inhibits insulin/IGF-I
signaling pathways in MDA-MB-435 cells
Activity of receptors tyrosine kinase (RTK) has been
implicated in Epithelial-to-mesenchymal transition (EMT)
program, which is turn is closely associated with tumor cell
invasion and metastases [27]. We evaluated the impact of E-
cadherin expression in the phosphorylation profile of RTK, by
performing a phosphoproteome-array. Our results showed a
marked decrease in the phosphorylation levels of insulin
receptor and IGF-I receptor upon E-cadherin expression
(Figure 2A and Figure S1). These results were further validated
by Western blot analysis, showing a significant (P<0.01)
decrease of phospho-IR(Tyr1150-51)/phospho-IGF-
IR(Tyr1135-36) (Figure 2B and C). IR and IGF-IR can activate
different downstream signaling pathways such as,
Ras/Raf/MEK/ERK; PI3K/Akt and β-catenin [5,9]. In order to
identify which signaling pathway is being modulated by
exogenous E-cadherin expression, we analysed the protein
expression levels of phospho-ERK1/2, total ERK1/2, phospho-
Akt (Ser473), total Akt and β-catenin. The results demonstrated
that E-cadherin expression led to a significant (P<0.01)
decrease of ERK1/2 phosphorylation, and no significant
changes of phospho-Akt (Ser473) were observed. No changes
were observed for the expression of total Akt and ERK. In
addition, we observed a slight increase, of the β-catenin protein
expression levels upon induced E-cadherin over-expression
(Figure 2B and C). These results suggest a relationship
between E-cadherin expression and the modulation of IR/IGF-
IR phosphorylation levels. In addition, the impact on the
phosphorylation levels of ERK1/2 after E-cadherin expression
further support that, in this cancer cell model, the IR/IGF-IR-
mediated downstream pathway that is preferentially activated is
the Ras/Raf/MEK/ERK.
Stimulation with insulin and IGF-I growth factors
restore the phosphorylation of IR, IGF-IR and ERK 1/2,
leading to cytoplasmic expression of E-cadherin and β-
catenin
MDA-MB-435+E-cad were treated with growing
concentrations of insulin and IGF-I growth factors. We first
evaluated by Western blot whether these growth factors were
able to restore phosphorylation levels of IR/IGF-IR and their
downstream signaling pathway. The results showed that both,
insulin and IGF-I, significantly (P<0.01) increased the
phosphorylation levels of IR/IGF-IR (Figure 3A and 3C) and the
phosphorylation levels of ERK 1/2 (P<0.01) in MDA-
MB-435+E-cad cells (Figure 3B and 3C). Stimulation with
insulin and IGF-I were not able to modulate the levels of
phosphorylated Akt in our cell line model. Moreover, no
significant changes were observed in E-cadherin and β-catenin
proteins levels (Figure 3B and 3C). After stimulation with insulin
or IGF-I, we have observed an impact in the cellular
localization of E-cadherin and β-catenin. The results showed
that upon insulin/IGF-I treatment there was a trend to an
increased diffuse cytoplasmic expression of E-cadherin and β-
catenin, as observed by immunofluorescence, together with
some alterations in cellular morphology (appearance of
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Figure 2.  Effects of exogenous E-cadherin expression on the phosphoproteome profile of tyrosine kinase receptors and
downstream proteins.  (A) Total cell lysates from MDA-MB-435+mock and MDA-MB-435+E-cad were obtained and analyzed by
Phospho-RTK array using 300 µg of proteins. The phosphor-RTK coordinates are shown on the right side of figure illustrating the
localization of the spots containing immobilized antibodies on the nitrocellulose membrane. B17 and B18 represent the IR spots,
whereas B19 and B20 represent IGF-IR spots, both receptors show decreased phosphorylation levels upon E-cadherin expression.
(B) Total cell lysates from MDA-MB-435+mock and MDA-MB-435+E-cad were obtained and analyzed by Western blot for phospho-
IR(Tyr1150-51)/phospho-IGF-IR(Tyr1135-36), IR, IGFR, Akt, phospho-Akt (Ser 473), ERK 1/2, phospho-ERK 1/2 and β-catenin.
MDA-MB-435+E-cad cells show significant decreased levels of phospho-IR/phospho-IGF-IR and phospho-ERK1/2, comparing with
mock cells. Tubulin was used as a loading control. The bar graphs show the relative amount of proteins levels normalized to tubulin.
Error bars indicate the means + S.E.M. (n = 3). ** = P < 0.01, Student's t-test.
doi: 10.1371/journal.pone.0081579.g002
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cytoplasmic protusions, compatible with mesenchymal-like
features) (Figure 4).
Activation of Insulin and IGF-I signaling pathways
induces a decrease in the bisecting GlcNAc N-glycans
expression in general and specifically on E-cadherin
Previous studies have demonstrated that E-cadherin induces
an increased expression of bisecting GlcNAc N-glycans [19],
which in turn is associated with an increased stability of E-
cadherin-mediated cell-cell adhesion [17]. However, it
remained to be determined the E-cadherin-dependent signaling
pathway involved in this glycosylation modulation. Taking into
consideration the inhibition of insulin/IGF-I signaling pathways
induced by E-cadherin expression, we went further and
assessed the impact of Insulin and IGF-I signaling pathways in
the modulation of bisecting GlcNAc N-glycans expression, in
MDA-MB-435 cancer cells. We first evaluated, by lectin blot
analysis, the impact of insulin and IGF-I stimulation in the total
expression levels of bisecting GlcNAc N-glycans [21,28]. We
observed that both insulin (100 ng/mL) and IGF-I (50 ng/mL)
stimulation of MDA-MB-435+E-cad cells induced a significant
decrease (P<0.01) of the overall levels of bisecting GlcNAc N-
glycans (Figure 5A). The levels of expresion of bisecting
GlcNAc N-glycans in MDA-MB-435+Ecad cells stimulated with
higher concentrations of insulin and IGF are similar to those
expressed in mock cells. Furthermore, we evaluated the effect
of this bisecting GlcNAc N-glycans modulation specifically on
E-cadherin molecule. This was performed by
immunoprecipitation of E-cadherin followed by lectin blot
analysis using E-PHA lectin, that recognizes the bisecting
GlcNAc structures. The results showed that activation of insulin
and IGF-I signaling pathway led to a decreased modification of
E-cadherin with bisecting GlcNAc structures (Figure 5B).
Stimulation of MDA-MB-435+E-cad cells with Insulin
and IGF-I up-regulates mesenchymal markers and
enhances tumor cell invasion
Since we observed a reduction of E-cadherin modification
with bisecting GlcNAc N-glycans upon insulin and IGF-I
treatment, which was accompanied with alterations in E-
cadherin cellular localization and some alterations in cell
morphology, we next assessed the impact of insulin and IGF-I
signaling in cell differentiation and cellular function of MDA-
MB-435 cells expressing E-cadherin. We evaluated the effect
of insulin and IGF-I stimulation in the expression profile of EMT
markers as well as in tumor cell invasion. Our results showed
that both insulin and IGF-I stimulation induced a significant
down-regulation of the mRNA levels of some epithelial markers
(occludin and β-catenin) and an up-regulation of the
mesenchymal marker fibronectin as evaluated at the mRNA
levels (Figure 6A). Corroborating this result, stimulation with
insulin and IGF-I also increased the fibronectin expression at
the protein level, which has been closely associated with tumor
cell invasion [27] (Figure 6B). E-cadherin, vimentin and N-
cadherin did not undergo significant changes at the mRNA
levels (Figure 6A). Interestingly, our results further showed that
activation of insulin and IGF-I signaling, through growth factor
stimulation, significantly enhanced (P<0.01) tumor cell invasion
of MDA-MB-435+Ecad (Figure 7). Taken together, our results
demonstrated that insulin and IGF-I signaling could in fact
promote an invasive phenotype by changing the bisecting
GlcNAc N-glycosylation profile of E-cadherin and consequently
the expression pattern of epithelial/mesenchymal markers of
cancer cells.
Discussion
Insulin/IGF-I signaling pathways have been widely implicated
in the processs of tumor development and progression of
different types of cancer being considered an important target
with promising therapeutic aplications in cancer.
Aberrant glycosylation is considered as a key event in the
process of tumor cell invasion and metastasis [29]. One of the
most widely occurring glycosylation changes inducing
malignancy is enhanced β1,6GlcNAc branching of N-linked
structure, catalyzed by N-acetylglucosaminyltransferase V
(GnT-V), which is counteracted by the synthesis of bisecting
GlcNAc N-glycans catalyzed by N-
acetylglucosaminyltransferase III (GnT-III) [28]. Increased
bisecting GlcNAc N-glycans inhibits β1,6GlcNAc branching,
leading to suppression of metastasis [20]. In this process, one
of the target molecules is E-cadherin, in which the bisecting
GlcNAc N-glycans is associated with enhanced cell-cell
adhesion and increased stability of intercellular adherens-
junctions, consequently contributing to suppression of tumor
progression [15,17,21,30,31]. Previously, we and others have
shown that the E-cadherin glycoprotein has a role in the
regulation of bisecting GlcNAc N-glycans expression [19].
However, it remained to identify which signaling pathways (E-
cadherin-dependent) were involved in this regulation of
glycosylation, and associated with tumor supression. In the
present study we aimed to assess the underlying signaling
pathway (E-cadherin-dependent) involved in the regulation of
the bisecting GlcNAc N-glycans in the process of tumor
progression of epithelial cancer cells.
We have evaluated the impact of E-cadherin de novo
expression in the activity of different receptors tyrosine kinase
using an epithelial cancer cell model. Our results demonstrated
that MDA-MB-435 cancer cells, lacking endogenous E-
cadherin expression, exhibited a significant increased
phosphorylation of IR/IGF-IR RTK showing also decreased
levels of bisecting GlcNAc N-glycan structures. Upon
exogenous overexpression of E-cadherin, there was a
remarkable inhibition of the IR/IGF-IR phosphorylation
suggesting the existence of an inhibitory effect of E-cadherin in
the activity of Insulin and IGF-I signaling pathways. In fact, and
in accordance with our observation, in hormone refractory PC-3
prostate cancer cells, IGF-I induced a decrease of E-cadherin
expression levels [9]. However, in hepatocellular carcinoma
cells the scenario observed seems to be the contrary, since the
epithelial phenotype was strongly associated with expression of
IGF-2 and IR as well as activation of IGF-1R and IR [32].
These conflicting observations suggest that the
phosphorylation pattern of IR/IGF-IR appears to be tissue/cell-
specific.
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Figure 3.  Effects of stimulation with insulin and IGF-I on the phosphorylation of tyrosine kinase receptors and
downstream proteins.  (A,B) Total cell lysates from MDA-MB-435+mock, MDA-MB-435+E-cad and MDA-MB-435+E-cad
stimulated (24h) with insulin or IGF-1 were obtained and analyzed by Western blot for phospho-IR(Tyr1150-51)/phospho-IGF-
IR(Tyr1135-36), IR, IGFR, Akt, phospho-Akt (Ser 473), ERK 1/2, phospho-ERK 1/2, β-catenin and E-cadherin. Increased
phosphorylation levels of IR, IGF-IR, and ERK 1/2 were observed after stimulation with insulin or IGF-I. Tubulin was used as a
loading control. No changes were observed for the total expression levels of Akt and ERK1/2. (C) The bar graphs show the relative
amount of proteins levels normalized to tubulin. Error bars indicate the means + S.E.M. (n = 3). ** = P < 0.01, ANOVA t-test.
doi: 10.1371/journal.pone.0081579.g003
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Furthermore, our results showed that ERK 1/2 protein also
undergoes a significant decrease in the phosphorylation levels
upon E-cadherin expression, while no changes were observed
in phospho-Akt (Ser473). These observations suggest that in
MDA-MD-435 cancer cells, E-cadherin expression induces a
downregulation of Ras/Raf/MEK/ERK downstream pathway
through the significant decreased activity of the IR/IGF-IR
signaling.
The activation of the IR/IGF-IR signaling and the
downstream pathway Ras/Raf/MEK/ERK by insulin and IGF-I
treatment led to a slight increase in the cytoplasmic expression
of E-cadherin and β-catenin, that was accompanied with some
alterations of cell morphology with observation of cytoplasmic
extrusion compatible with an acquisition of a fibroblastoid-like
appearance. However, this variation in cellular localization after
stimulation with insulin or IGF-I appears to be not due to
changes at E-cadherin and β-catenin protein levels (Figure 3).
Curiously, after stimulation with Insulin or IGF-I, the mRNA
levels of β-catenin underwent a significant reduction. This
relationship between IR/IGF-IR signaling and β-catenin
localization could be associated with a possible involvement of
the activation of the WNT signaling pathway, as previoulsy
Figure 4.  Subcellular localization of E-cadherin and β-catenin after stimulation with insulin and IGF-I.  (A) Cell monolayers
from MDA-MB-435+mock, MDA-MB-435+E-cad and MDA-MB-435+E-cad stimulated (24h) with insulin or IGF-1 were fixed and
stained for E-cadherin, β-catenin and nucleus (DAPI). Diffuse cytoplasmic expression levels of β-catenin and E-cadherin are
observed (arrows) after stimulation with insulin or IGF-I, together with observation of cytoplasmic protusions compatible with a
fibroblastoid-like appearance (arrowheads). The representative images were obtained by fluorescence microscopy. White arrows
and magnified images indicate cytoplasmic staining. Bar = 10 µm. (B) Confocal microscopy showing the cytoplasmic staining of E-
cadherin and β-catenin after stimulation with insulin and IGF-I. Bar = 10 µm.
doi: 10.1371/journal.pone.0081579.g004
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described [33]. However, the mechanism underlying such
modulation in the β-catenin expression need to be further
investigated. Having identified IR/IGF-IR as one of the
signaling pathways which activation is modulated by E-
cadherin expression, we further evaluated the impact of this
pathway in the regulation of glycosylation particularly the
bisecting GlcNAc N-glycans, whose expression was described
to be, in turn, regulated in an E-cadherin-dependent manner
[19]. We have showed that Insulin and IGF-I stimulation
induced a significant decrease of the overall levels of bisecting
GlcNAc N-glycans expression. Furthermore, we demonstrated
that this decrease through IR/IGF-IR signaling specifically
Figure 5.  Effects of insulin and IGF-I stimulation on the expression levels of bisecting GlcNAc N-glycans, in general and
specifically on E-cadherin.  (A) Total cell lysates from MDA-MB-435+mock, MDA-MB-435+E-cad and MDA-MB-435+E-cad
stimulated (24h) with insulin or IGF-1 were obtained and analyzed by Lectin blot for E-PHA. The bar graphs show the relative
amount of bisecting GlcNAc N-glycans levels in the whole protein lysate. MDA-MB-435+E-cad cells stimulated with insulin (100
ng/mL) and IGF-I (50 ng/mL) showed a significant decrease of the overall levels of bisecting GlcNAc N-glycans. The values were
normalized to tubulin. Error bars indicate the means + S.E.M. (n = 3). ** = P < 0.01 ANOVA test. (B) Total cell lysates from MDA-
MB-435+mock, MDA-MB-435+E-cad and MDA-MB-435+E-cad stimulated (24h) with insulin or IGF-1 were obtained and
immunoprecipitated using E-cadherin antibody. The immunoprecipitates were analyzed by Western blot for E-cadherin and Lectin
blot for E-PHA. The bar graphs show the relative amount of E-cadherin-linked bisecting GlcNAc N-glycans levels. Activation of
insulin and IGF-I signaling pathway led to a decreased modification of E-cadherin with bisecting GlcNAc N-glycan structures.
doi: 10.1371/journal.pone.0081579.g005
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targets E-cadherin molecule inducing a decreased modification
of these bisecting GlcNAc N-glycans attached to E-cadherin
glycoprotein. To the best of our knowledge, this is the first
study showing such a relationship between IR/IGF-IR signaling
and the modulation of bisecting GlcNAc N-glycans expression
in general and specifically on E-cadherin. Interestingly, we
further observed that IR/IGF-IR activation induced a significant
increased tumor invasion capability of cancer cells. In addition,
the signaling activation of IR/IGF-IR concomitantly induced
modulation of expression of epithelial versus mesenchymal
markers. We showed that IR/IFG-IR signaling activation
induced an increased expression of the mesenchymal marker
Figure 6.  Effects of insulin and IGF-I stimulation on the mRNA expression levels of epithelial and mesenchymal
markers.  (A) The bar graphs show the relative amount of E-cadherin, occludin, β-catenin, vimentin, fibronectin and N-cadherin
mRNA levels by qRT-PCR. Significant down-regulation of the mRNA levels of epithelial markers (occludin and β-catenin) and an up-
regulation of the mesenchymal marker fibronectin were observed after insulin and IGF-I stimulation. Values were normalized to the
amount of mRNA in MDA-MB-435+E-cad. Error bars indicate the means + S.E.M. (n = 3). * = P < 0.05, ** = P < 0.01, ANOVA test.
Effects of stimulation with insulin and IGF-I on the fibronectin protein levels. (B) Total cell lysates from MDA-MB-435+E-
cad,MDA-MB-435+E-cad stimulated (24h) with insulin or IGF-1, and MDA-MB-435+mock were obtained and analyzed by Western
blot for fibronectin. Increased fibronectin expression levels are observed after stimulation with insulin or IGF-I. The bar graphs show
the relative amount of fibronectin levels normalized to tubulin.
doi: 10.1371/journal.pone.0081579.g006
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fibronectin (both at protein and mRNA levels), together with a
decreased expression of the epithelial marker occludin. These
Figure 7.  Effects of stimulation with insulin and IGF-I on
cell invasion.  Representative images of cell invasion through
Matrigel using 8 mm pore of a polycarbonate membrane.
Nuclei were stained with DAPI. We observed a significant
increase of tumor cell invasion of MDA-MB-435+Ecad after
stimulation with insulin or IGF-I. The bar graph shows the
amount of cells/field. Error bars indicate the means + S.E.M. (n
= 3). ** = P < 0.01 ANOVA test.
doi: 10.1371/journal.pone.0081579.g007
results are in agreement with some reports describing that cell
motility and proliferation have been associated with activation
of MEK/ERK by Insulin/IGF-I ligands [34]. In addition, our
observations are in accordance with reports showing that the
autocrine production of insulin-like growth factor-I (IGF-I)
reduces occludin levels and alters paracellular transport in
mammary epithelial cells in vitro [35].
Although we cannot exclude that IR/IGF-IR signaling
pathways may affect other important factors, the combination
of previous reports from our and other groups [17,19,20] with
the present results support a close interplay between E-
cadherin, its glycosylation with bisecting GlcNAc N-glycans and
IR/IGF-IR signaling in the process of tumour cell invasion.
Corroborating this hypothesis, the stimulation of mock-
transfected cells with insulin and IGF-I (Figures S2, S3 and S4)
did not affect the fibronectin mRNA transcription levels nor the
invasive phenotype (Figure S3). In addition, no changes were
observed on the β-catenin cellular localization after stimulation
of mock cells with insulin or IGF-I (Figure S4). Moreover, in
MKN45 gastric cancer cells transfected with MGAT5 (a cellular
model known to induce changes in E-cadherin glycosylation
and consequently in tumour cell behaviour[17]), we have
demonstrated that the overexpression of GnT-V leads to an
increased expression of the Insulin Receptor (Figure S3 E),
which further supports the relationship between post-
translational modifications of E-cadherin and IR/IGF-IR
signaling in the process of tumour cell invasion. Our
observations are the first to clearly demonstrate that bisecting
GlcNAc N-glycans expression appears to be regulated by the
interplay of E-cadherin and IR/IGF-IR signaling, which are
known to be crucial in the process of epithelial-mesenchymal
transitions and consequetly in the process of tumor cell
invasion and metastases. We here propose that E-cadherin
induces the expression of bisecting GlcNAc N-glycans in the
absence (switch-off) of IR/IGF-IR signaling, which in turn will
contribute to the stabilization of E-cadherin at the cell
membrane, ensuring an epithelial-like phenotype, ultimatly
promoting tumor suppression [17,36]. The signaling activation
of IR/IGF-IR pathway, through the activation of Ras/Raf/MEK/
ERK, induces a significant decreased expression of bisecting
GlcNAc N-glycans in general and specifically on E-cadherin,
which in turn leads to a destabilization of E-cadherin at the cell
mebrane together with increased expression of mesenchymal
markers. This alteration of E-cadherin glycosylation through IR/
IGF-IR signaling activation favors an increased tumor cell
invasion capability (Figure 8, proposed model).
In conclusion, our findings strongly support that Insulin/IGF-I
signaling is an appealing target with implication in the
modulation of glycosylation of key molecules involved in tumor
invasion, having therefore promising therapeutic aplications in
epithelial cancers.
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Figure 8.  Proposing model for the interplay between E-cadherin, IR/IGF-IR, and bisecting GlcNAc N-glycans on the
stabilization of both cell-cell adhesion and epithelial-like phenotype.  The figure summarizes our findings and shows that
exogenous E-cadherin expression leads to an inhibition of IR/IGF-IR signaling, concomitantly with increased levels of bisecting
GlcNAc N-glycans expression which were previously shown to stabilizes adherens-junctions, ensuring an epithelial-like phenotype
[18,35]. Stimulation with insulin or IGF-I activates IR/IGF-IR signaling and downstream protein ERK 1/2, promoting a decreased
expression of bisecting GlcNAc structures in general and specifically on E-cadherin which was previously shown to destabilize cell-
cell adhesion [18], leading to an invasive phenotype. Concomitantly, it was observed an increased expression of the mesenchymal
marker fibronectin and cytoplasmic β-catenin and E-cadherin.
doi: 10.1371/journal.pone.0081579.g008
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Supporting Information
Figure S1.  Effects of exogenous E-cadherin expression on
the phosphoproteome profile. Total cell lysates from MDA-
MB-435+mock and MDA-MB-435+E-cad were obtained and
analyzed by Phospho-RTK array using 300 µg of proteins. The
phosphor-RTK coordinates are shown on the top of figure
illustrating the localization of the spots containing immobilized
antibodies on the nitrocellulose membrane. The bar graphs
show the relative densities of black dots. The most pronounced
changes are observed in IR (coordinates B17 and B18) and
IGF-IR (coordinates B19 and B20).
(TIF)
Figure S2.  Effects of stimulation of Mock-transfected cells
with insulin and IGF-I on the phosphorylation of tyrosine
kinase receptors and downstream proteins. (A,B) Total cell
lysates from MDA-MB-435+mock cells and MDA-
MB-435+mock stimulated (24h) with insulin or IGF-1 were
obtained and analyzed by Western-blot for phospho-
IR(Tyr1150-51)/phospho-IGF-IR(Tyr1135-36), IR, IGFR, Akt,
phospho-Akt (Ser 473), ERK 1/2, phospho-ERK 1/2, β-catenin
and E-cadherin. Increased phosphorylation levels of IR, IGF-
IR, ERK 1/2 and Akt were observed after stimulation with
insulin or IGF-I. Tubulin was used as a loading control.
(TIF)
Figure S3.  Effects of stimulation of Mock-transfected cells
with insulin and IGF-I on cell invasion. (A) Representative
images of cell invasion through Matrigel using 8 mm pore of a
polycarbonate membrane. Nuclei were stained with DAPI. No
significant differences were observed on cellular invasion upon
insulin and IGF-I stimulation of mock-transfected cells. (B) The
bar graph shows the amount of cells/field. Effects of
stimulation with insulin and IGF-I on the fibronectin
protein and mRNA expression levels, respectively. (C) and
(D) A slight increase of fibronectin protein expression levels
were observed after stimulation with insulin or IGF-I, however,
no significant changes were observed at the mRNA
transcription levels after stimulation of MDA-MB-435+E-mock
cells with insulin and IGF-I . Effects of overexpression of
MGAT5 on the IR expression levels of MKN45 cell line. (E)
Total cell lysates from MKN45+mock and MKN45+MGAT5
were obtained and analyzed by Western blot for IR. An
increased expression of IR were observed after overexpression
of MGAT5. Tubulin was used as a loading control.
(TIF)
Figure S4.  Subcellular localization of E-cadherin and β-
catenin of Mock-transfected cells stimulated with insulin
and IGF-I. Cell monolayers from MDA-MB-435+mock
stimulated (24h) with insulin or IGF-1 were fixed and stained for
E-cadherin, β-catenin and nucleus (DAPI). No significant
differences were observed on the β-catenin subcellular
localization after insulin or IGF-I stimulation. The representative
images were obtained by fluorescence microscopy. Bar = 10
µm.
(TIF)
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Preventing E-cadherin aberrant N-glycosylation at Asn-554
improves its critical function in gastric cancer
S Carvalho1,2, TA Catarino1, AM Dias1,2, M Kato3, A Almeida4,5, B Hessling6, J Figueiredo1, F Gärtner1,2, JM Sanches7, T Ruppert6,
E Miyoshi8, M Pierce9, F Carneiro1,10,11, D Kolarich4, R Seruca1,10, Y Yamaguchi3, N Taniguchi3, CA Reis1,2,10 and SS Pinho1,2
E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational modiﬁcations by N-glycosylation
have been described to induce a deleterious effect on cell adhesion associated with tumor cell invasion. However, the role that site-
speciﬁc glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using transgenic
mice models and human clinical samples, we demonstrated that N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation
causes an abnormal pattern of E-cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four
potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modiﬁed with β1,6 GlcNAc-branched
N-glycans catalyzed by GnT-V. This aberrant glycan modiﬁcation on this speciﬁc asparagine site of E-cadherin was demonstrated
to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular
assembly and stability of the adherens junctions and cell–cell aggregation, which was further observed in human gastric
carcinomas. Interestingly, manipulating this site-speciﬁc glycosylation, by preventing Asn-554 from receiving the deleterious
branched structures, either by a mutation or by silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its
functional dysregulation and contributing to tumor suppression.
Oncogene advance online publication, 20 July 2015; doi:10.1038/onc.2015.225
INTRODUCTION
Epithelial cadherin (E-cadherin) is a calcium-dependent cell–cell
adhesion molecule with a critical role in epithelial tissue
morphogenesis.1–7 The mature E-cadherin protein is organized
into three major structural domains: an ectodomain of about 550
amino acids comprised of ﬁve tandemly repeated subdomains
(EC1–EC5), a single transmembrane domain and a short cytoplas-
mic domain of about 150 amino acids. The human E-cadherin
ectodomain is comprised of four potential N-glycosylation sites:
two putative sites located in the EC4 subdomain (Asn-554 and
Asn-566) and the remaining two potential sites in the EC5
subdomain (Asn-618 and Asn-633).6
Epithelial cell–cell adhesion is achieved through homophilic
interactions between cadherin molecules of neighboring cells. The
extracellular domains of E-cadherins on the same cell surface
establish lateral or cis- interactions and then among adjacent cells
to form trans adhesive bonds, leading to the formation of a zipper-
like structure.8–10 Cell–cell adhesion is further accomplished
through the molecular interaction of the cytoplasmic domain of
E-cadherin and the catenins β-, γ-, α- and p120-catenin. The
stability of this cadherin–catenin complex, and its interaction with
the actin cytoskeleton, forms the core adherens junctions, which is
essential for cell–cell adhesion and precludes individual epithelial
cell motility, thus providing a normal and homeostatic tissue
architecture.11,12
The functional inactivation or downregulation of E-cadherin
is considered to be a hallmark of the epithelial carcinogenic
process, being closely associated with tumor cell invasion and
metastases.13 Several mechanisms have been proposed to explain
the loss of function of E-cadherin in cancer,7 and among those
mechanisms, the modiﬁcation of E-cadherin by glycosylation has
been demonstrated to be instrumental for the regulation of
E-cadherin functions in the context of cancer.14,15 Moreover,
O-mannosylation of E-cadherin was recently demonstrated to be
important for E-cadherin-mediated cell–cell adhesion.16,17
In fact, during malignant transformation, the glycosylation
proﬁle of E-cadherin undergoes a signiﬁcant alteration,18 with
implications for its biological functions. Of those glycosylation
alterations, two are generally considered to be fundamental for
the regulation of the protein: the bisecting GlcNAc N-glycan
structures (catalyzed by the N-acetylglucosaminyltransferase III
(GnT-III) glycosyltransferase), and the β1,6 GlcNAc-branched
N-glycan structure (catalyzed by the GnT-V glycosyltransferase).
These two key glycan structures were recently found to precisely
control, in an opposite manner, the functions of E-cadherin in
cancer cells.15,19–24 E-cadherin has different N-glycosylation sites
that are potentially responsible for controlling its biological
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functions. Under normal physiological circumstances, E-cadherin
was described to be primarily modiﬁed with high-mannose/hybrid
N-glycans;25,26 however, the key site(s) that are crucial for the
regulation of its functions in the context of cancer remain to be
determined.
In this study, we report that E-cadherin becomes functionally
impaired when GnT-V glycosyltransferase catalyzed modiﬁcation
of site 1 (Asn-554) with β1,6 GlcNAc-branched N-glycan structures.
Further, the presence of a mutation of this speciﬁc N-glycosylation
site (which abrogates the availability of this site to be modiﬁed by
GnT-V) has a protective effect on E-cadherin function, preventing
its dysregulation.
RESULTS
Impact of GnT-V-mediated glycosylation in E-cadherin expression
in the mice stomach and in human gastric carcinoma
In the present study, we used GnT-V transgenic mouse models to
show that differential expression of E-cadherin in the gastric
mucosa is inﬂuenced by the presence of GnT-V. We used two
transgenic mouse models: MGAT5 knockout (with no GnT-V
activity) and MGAT5 transgenic mice that overexpress GnT-V
activity. We observed that the gastric mucosa of the wild-type
(WT) mice showed a moderate expression of β1,6 GlcNAc-
branched structures detected by the biotinylated Phaseolus
vulgaris leucoagglutinin (L-PHA) lectin. The gastric mucosa of the
MGAT5 knockout mice showed no L-PHA reactivity (Figure 1a). On
the other hand, mice overexpressing GnT-V showed high levels of
expression of β1,6 GlcNAc-branched structures in the gastric
mucosa. Regarding E-cadherin localization, MGAT5 knockout mice
showed E-cadherin normally expressed in the basolateral cell
membrane of gastric epithelial cells. In GnT-V-overexpressing
mice, E-cadherin was also displayed in the cytoplasm of cells at
the neck zone and in deep glands of the gastric mucosa
(Figure 1a). No major histopathological lesions were observed in
the gastric mucosa of these mouse models.
Similarly, the levels and proﬁle of E-cadherin modiﬁcations with
the aberrant β1,6-branched N-glycans (catalyzed by GnT-V) in
human gastric carcinomas (diffuse gastric cancer sub-type) and
the correlation with prognostic features were demonstrated by
performing in situ Proximity Ligation Assay (PLA) technique
(Figure 1b). PLA is a technology that extends the capabilities of
traditional immunoassays to include direct detection of proteins,
protein interactions and posttranslational modiﬁcations such as
glycosylation with high speciﬁcity and sensitivity.27 Our results
showed that gastric carcinoma cells display a marked increase of
positive PLA signals demonstrating an increased modiﬁcation of
E-cadherin with β1,6-branching N-glycans. The normal gastric
mucosa was either negative or showed a weak PLA signal,
suggesting that E-cadherin is not modiﬁed by GnT-V-mediated
branching glycans in normal gastric cells (Figure 1b). Furthermore,
and in order to evaluate whether the GnT-V-mediated glycosyla-
tion of E-cadherin is correlated with prognosis, a series of 19
patients with diffuse gastric cancer was analyzed and associated
with prognostic variables. Patients positive for E-cadherin+β1,
6-branched N-glycans (positive PLA) display a poorer survival rate
(assessed by Kaplan–Meier survival analysis) when compared with
diffuse gastric cancer patients negative for PLA E-cadherin/L-PHA
(P= 0.093; Figure 1, Graphic b1). Additionally, we further showed
that all patients who do not survive were positive for PLA
E-cadherin/ L-PHA, as represented in Table 1 (P= 0.077).
These results demonstrate the importance of this speciﬁc
E-cadherin aberrant glycoform in vivo in the pathogenesis of
gastric carcinoma.
Bioinformatics evaluation of E-cadherin N-glycosylation site
occupancy
Glycosylation is known to be a cell- and tissue-speciﬁc event and
the levels and pattern of glycosylation of a speciﬁc protein vary
accordingly with cell and tissue location28 (Supplementary
Figure S1). N-linked glycosylation does not occur at every
potential glycosylation site. Depending on the protein and on
the physiopathological context, some glycosylation sites are more
important than others for the regulation of protein function.29
Using an in silico bioinformatics analysis that takes three main
criteria into consideration, E-cadherin N-glycosylation site occu-
pancy could be predicted. The ﬁrst criterion is based on the
species homology of the E-cadherin peptide sequence (Figure 2a).
A comparison of the E-cadherin peptide sequence between
different species revealed that the N-glycosylation sites Asn-554
(site 1) and Asn-633 (site 4) are the most conserved among
species.
The second criterion used in the evaluation is the site-speciﬁc
modiﬁcation of N-linked glycans through the solvent accessible
surface area (ASA) calculation of four Asn residues. Very low ASA
values at Asn residue indicate a reduced probability of N-glycans
attachment. As shown in Figure 2b, the potential N-glycosylation
site Asn-618 (site 3) displays a low ASA value, suggesting a low
probability of being N-glycosylated.
The third criterion is the evaluation of the β-turn propensity at
the Asn-x-Ser/Thr acceptor sequence (Figure 2c). The variable x
represents the sequence position around the sequon and a high
value of β-turn propensity at an Asn residue can positively affect
the spatial conﬁguration of Asn and Ser/Thr side chains towards
the approach of an oligosaccharyltransferase. For x= 0 (Asn
residue), Asn-554 (site 1) and Asn-633 (site 4) show higher
β-turn propensity values demonstrating a high probability for the
occurrence of N-glycosylation. It has also been reported that the
presence of Pro at x= 3 position inhibits N-glycosylation.30,31
Taken these issues into account, Asn-566 (site 2) and Asn-618
(site 3) are not likely to be glycosylated.
Overall, the combination of these in silico parameters
(Figure 2d) suggests that N-glycosylation is likely to occur at
Asn-554 (site 1) and Asn-633 (site 4) and not likely to occur in the
other two putative sites (sites 2 and 3).
E-cadherin Asn-554 (site 1) and Asn-633 (site 4) are occupied with
complex- and high-mannose/hybrid-type N-glycans, respectively
In order to further characterize in vitro the E-cadherin
N-glycosylation site occupancy, we applied site-directed mutagen-
esis to generate different E-cadherin N-glycan mutants lacking
selected potential N-glycosylation sites by replacing asparagine
for glutamine residues in each N-glycosylation consensus
sequence (NXS/T) either individually or in different combinations
(Figure 3a).
The different E-cadherin N-glycan mutants were transfected
into gastric carcinoma AGS cell line (that lacks endogenous
E-cadherin both at mRNA and protein levels32), and the mobility
shift of the E-cadherin band was evaluated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE; Figure 3b).
Concerning the individual E-cadherin N-glycan mutants (M1, M2,
M3 and M4), the results showed that the E-cadherin mutant M1
(lacking site 1, Asn-554) revealed the most pronounced mobility
shift followed by the E-cadherin mutant M4 that displayed a slight
mobility compared with E-cadherin WT. E-cadherin mutants M2
and M3 did not exhibit a mobility shift compared with the WT.
These results suggest that sites 1 (Asn-554) and 4 (Asn-633) are
N-glycosylated. In addition, and consistent with the bioinformatics
prediction, site 2 (Asn-566) and site 3 (Asn-618) are not occupied
with N-glycans. Validating these observations, the multiple
E-cadherin N-glycan mutants M1234 (total N-glycan mutant) and
M14 (with Asn-554 and Asn-633 not present) showed the same
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Figure 1. Evaluation of the expression of E-cadherin and β1,6 GlcNAc-branched structures in the gastric mucosa of MGAT5 knockout and
MGAT5 overexpressing and in human normal gastric mucosa versus gastric carcinoma. (a) L-PHA histochemistry detecting the β1,6 GlcNAc-
branched N-glycans catalyzed by GnT-V showed a moderate expression of the β1,6-branched structures in the gastric mucosa of WT mice. No
positive L-PHA reactivity was observed in the gastric mucosa of MGAT5 KO mice, whereas a clear overexpression of β1,6 GlcNAc-branched
structures was detected in MGAT5 transgenic gastric mucosa. MGAT5 KO mice showed a normal E-cadherin expression at the basolateral cell
surface (arrowhead). In MGAT5 transgenic mice, immunoexpression of E-cadherin was displayed aberrantly in the cytoplasm of mucous neck
cells (not shown) and in deep glands of the gastric mucosa (arrow). (b) In situ PLA showed weak/absence PLA signal in normal gastric mucosa
and a marked positivity of PLA signal (brown dots for brightﬁeld and red dots for immunoﬂuorescence) in neoplastic cells from gastric
carcinoma, demonstrating a profound modiﬁcation of E-cadherin with the β1,6 GlcNAc-branched structures in human gastric cancer (×40,
original magniﬁcation). (b1) Survival rates of patients with diffuse gastric cancer (DGC) accordingly with PLA signal (positive versus negative).
Kaplan–Meier curves demonstrate the probability of overall survival for patients with DGC accordingly with the presence/absence of GnT-V-
mediated aberrant glycosylation of E-cadherin (P= 0.093).
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mobility shift that was slightly higher than that for E-cadherin M1.
E-cadherin M23 did not display a mobility shift compared with
E-cadherin WT, further suggesting that sites 2 and 3 are not
N-glycosylated.
Next we determined the susceptibility of the E-cadherin
N-glycan mutants towards different endoglycosidases, namely
PNGase F and Endo H. As shown in Figure 3c, E-cadherin WT
showed partial sensitivity to Endo H but, being predominantly
PNGase F-sensitive, indicating that E-cadherin WT is modiﬁed with
both complex and high-mannose/hybrid-type N-glycans. The
E-cadherin mutant M234 showed a slight shift upon Endo H but
exhibited a signiﬁcant mobility shift after PNGase F digestion.
On the other hand, treatment of M123 with Endo H resulted
in a substantial mobility shift that was not further enhanced by
PNGase F. These observations indicate that Asn-554 is modiﬁed
mostly by complex-type structures, whereas Asn-633 appears to
contain mainly high-mannose/hybrid-type N-glycans. This is also
consistent with the higher mobility shift of M1 compared with M4
(Figure 3b).
These observations were further supported by a glycomics
analysis of the released N-glycans of E-cadherin WT, M123 and
M234 by porous graphitized carbon (PGC) nano-liquid chromato-
graphy–electronspray ionization tandem mass spectrometry
(nanoLC-ESI MS/MS). The respective E-cadherin proteins were
immunoprecipitated, SDS–PAGE separated and electro-blotted
onto polyvinylidene diﬂuoride (PVDF) membranes prior on-blot
PNGase F digestion as described earlier.33,34 E-cadherin WT and
M234 showed higher levels of sialylated and complex type
N-glycans, respectively (Figure 3d). E-cadherin WT showed
the highest levels of complex type, triantennary N-glycans
(Supplementary Figure S2, Supplementary Tables S1 and S2).
These structures were found reduced in M123 and could not be
detected in M234 (Supplementary Figure S2), further indicating
the presence of tetra-antennary N-glycans in M234 (though these
analyses do not allow an absolute glycan quantitation).
Regarding M134, M124 and M14 (all with a mutation at sites 1
and 4), no detectable changes were observed after Endo H/PNGase
F treatment, supporting the hypothesis that Asn-566 (site 2) and
Asn-618 (site 3) are not N-glycosylated. As expected, E-cadherin
with all potential N-glycosylation sites mutated (M1234) was
neither Endo H nor PNGase F sensitive. Taken together (see also
Supplementary Figure S3), these results indicate that, in gastric
cancer cells, E-cadherin is modiﬁed with mostly complex-type
N-glycans at site 1 (Asn-554) and with mainly high-mannose/
hybrid-type at site 4 (Asn-633), whereas sites 2 and 3 (Asn-566 and
Asn-618) were not N-glycosylated. A statistical analysis suggests
that glycosylation sites carrying highly processed complex-type
glycans are signiﬁcantly more solvent-accessible than those
carrying less processed high-mannose-type glycans.35 Consistent
with this, ASA of Asn-633 is lower than that of Asn-554 (Figure 2b).
Site-speciﬁc occupancy of Asn-554 with complex type N-glycans
has a deleterious effect on E-cadherin localization and dimerization
The glycosylation of E-cadherin with complex-type N-glycans, such
as bisecting GlcNAc and the β1,6 GlcNAc-branched N-glycans
structures, has been reported to precisely regulate E-cadherin
functions in an opposing manner.15,20 Having conﬁrmed that site
1 (Asn-554) of E-cadherin is the one that is mainly occupied with
complex-type N-glycans (Figure 3, Supplementary Figure S2), we
proceeded to further evaluate the functional impact of this site-
speciﬁc N-glycan occupancy by comparing the mutants M1 and
M234, representing the absence versus the presence of a complex
N-glycan on site 1, respectively. By immunoﬂuorescence analysis,
we evaluated the cellular localization of E-cadherin and cell
morphology, and the results showed that AGS cells expressing the
E-cadherin M1 mutant (Figure 4a) or M123 (Supplementary
Figure S4A) exhibited a membrane localization of E-cadherin that
showed a more focused membrane staining than the E-cadherin
WT (as revealed by confocal microscopy). By contrast, AGS cells
expressing E-cadherin M234 (or E-cadherin M4, Supplementary
Figure S4A) displayed an aberrant E-cadherin expression with
mislocalization into the cytoplasm. Quantitative analyses of in situ
immunoﬂuorescence images that consider internuclear proﬁles
further showed a focused membrane localization of E-cadherin
after mutation at Asn-554 (E-cadherin M1) and a decreased
E-cadherin membrane expression in M234 (Figure 4A1). Regarding
the E-cadherin M2, M3 and M23 mutants, no alterations were
observed in the cellular localization of E-cadherin compared with
E-cadherin WT (Supplementary Figure S4A).
We then attempted to determine whether cis-dimer formation
of E-cadherin was affected by the occupancy/mutation of site 1
with complex-type N-glycans, by performing a cis-dimerization
assay using BS3, a membrane-impermeable chemical cross-linker.
The formation of E-cadherin cis-dimers was observed after AGS
cells expressing E-cadherin WT, M1 or M234 were treated with BS3
(Figure 4b). However, the levels of E-cadherin cis-dimerization
were signiﬁcantly higher in E-cadherin M1 than in E-cadherin WT
and M234 (Figure 4B1) or than in M4 (Supplementary Figures S4B
and B1), indicating that the mutation of Asn-554 (M1) enhanced
the formation of E-cadherin cis-dimers.
In addition, a calcium switch assay was performed (Supplementary
Figure S5). These results showed that the calcium-binding property
appear to be independent of E-cadherin glycosylation; however, it
is observed that E-cadherin M234 showed a more evident impact
in the calcium-binding property of E-cadherin.
Consistent with this, the deletion of site 1 (M1) induced a
signiﬁcantly increased rate of cell–cell adhesion together with the
formation of larger compact cellular aggregates when compared
with E-cadherin WT and M234 (Figures 4c and c1; Supplementary
Figure S4C).
Table 1. Relationship between aberrant glycosylation of E-cadherin
mediated by GnT-V and prognostic variables of diffuse gastric cancer
patients
Variable PLA E-cadherin/L-PHA
Negative Positive P
No. of patients (%)
Depth of invasion
pT1 2 (25%) 6 (75%) 0.298
pT2 0 (0%) 4 (100%)
pT3–4 3 (42.9%) 4 (57.1%)
Lymph node involvement
Absent (pN0) 2 (28.6%) 5 (71.4%) 0.865
Present (pN+) 3 (25%) 9 (75%)
Lymphatic permeation
Negative 2 (22.2%) 7 (77.8%) 0.701
Positive 3 (30%) 7 (70%)
Venous invasion
Negative 2 (18.2%) 9 (81.8%) 0.345
Positive 3 (37.5%) 5 (62.5%)
Status
Alive 5 (38.5 %) 8 (61.5%) 0.077
Dead 0 (0%) 6 (100%)
Abbreviations: Gnt-V, N-acetylglucosaminyltransferase V; L-PHA, biotiny-
lated Phaseolus vulgaris leucoagglutinin; PLA, Proximity Ligation Assay.
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Site-speciﬁc occupancy of Asn-554 with complex-type N-glycans
impairs a competent adhesion complex formation
We further evaluated whether the mutation of Asn-554 and/or the
occupancy of this speciﬁc N-glycan site could affect the molecular
organization and assembly of the cadherin–catenin complex. No
signiﬁcant differences were observed in the total expression levels
of the catenins, β- and p120-catenin, among the different
E-cadherin N-glycan mutants (Figure 4d). However, an increased
E-cadherin/β-catenin interaction was veriﬁed in E-cadherin M1 in
comparison with E-cadherin WT (0.7-fold) and a signiﬁcantly
decreased interaction was found between E-cadherin and
β-catenin when Asn-554 (site 1) was N-glycosylated (M234 or
M4, Figures 4e and e1; Supplementary Figures 4D and D1).
In addition, we veriﬁed a 1.3- and 0.9-fold increased inter-
action between E-cadherin and p-120-catenin when Asn-554
(site 1) was mutated (M1) when compared with E-cadherin WT
and E-cadherin M234, respectively, suggesting that mutation
of site 1 resulted in an increased recruitment of catenins by
E-cadherin (Figures 4e and e1). These differences in the
recruitment of catenins by E-cadherin reﬂect the positive impact
on the assembly and stability of the cadherin–catenin complex
induced by the mutagenesis of Asn-554 (site 1).
Preventing Asn-554 site-speciﬁc glycosylation improves
E-cadherin functions
Having demonstrated the deleterious effects of site 1 N-glycan
occupancy for the biological functions of E-cadherin in gastric
tumor cells (Figure 4), we further identiﬁed the speciﬁc type of
complex N-glycans that are attached to Asn-554. Figure 5a
Figure 2. Prediction of E-cadherin N-glycan site occupancy based on bioinformatics. (a) Species homology of the E-cadherin peptide
sequence. The potential N-glycosylation sites Asn-554 and Asn-633 are well conserved. (b) Calculation of ASA of the four Asn residues. The
potential N-glycosylation site Asn-618 displays a low ASA value. (c) Evaluation of β-turn propensity of the region adjacent to the Asn-X-Ser/Thr
acceptor sequence. Horizontal axis (x) indicates sequence position around the sequon (x= 0: Asn), and vertical axis (y) shows the β-turn
propensity. For x= 0, high values of β-turn propensity mean high possibility for N-glycosylation to occur. (d) Prediction of E-cadherin N-glycan's
occupancy. Asn-554 and Asn-633 are the two putative N-glycosylation sites more likely to be occupied.
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demonstrates that E-cadherin M234 showed an increased
reactivity with the L-PHA lectin compared with M1, which is
indicative of the presence of β1,6 GlcNAc-branched structures at
Asn-554 (site 1). Both E-cadherin WT and M234 show similar β1,6
GlcNAc-branched expression patterns, as both retain the Asn-554
complex glycan. In contrast, no positive reactivity with L-PHA on
the E-cadherin band in the M1 mutant was observed, showing
that site 1 is speciﬁcally modiﬁed with β1,6 GlcNAc-branched
structures. Despite that it was not possible to unambiguously
substantiate the β1,6 GlcNAc nature of the branching in M234
with the minimal amounts of E-cadherin material available for
glycomic analyses, the triantennary N-glycans were only detected
in E-cadherin WT and M123 and not in M234. Nevertheless, the
combined data presented here clearly indicate that also a subtle
increase of a speciﬁc structure feature on E-cadherin induces a
strong functional response.
To conﬁrm these results, we performed silencing of the MGAT5
gene using the small interfering RNA (siRNA) technique
(Figure 5b). As shown in Figure 5c, the knockdown of GnT-V
resulted in a signiﬁcant decrease in the expression of β1,6 GlcNAc-
Figure 3. N-glycosylation sites Asn-554 and Asn-633 are N-glycosylated being occupied with complex-type N-glycans and high-mannose/
hybrid- type N-glycans, respectively. (a) Schematic representation of different E-cadherin N-glycan mutants lacking selected putative
N-glycosylation sites by replacing asparagine residue with glutamine in each N-glycosylation consensus sequence (NXS/T) either individually
or in different combinations. EC4, subdomain EC4; EC5, subdomain EC5; CD, cytoplasmic domain; E-cadherin WT, E-cadherin wild type;
E-cadherin M1, lacking Asn-554; M2, lacking Asn-566; M3, lacking Asn-618; M4, lacking Asn-633; M14, lacking Asn-554 and Asn-633; M23,
lacking Asn-566 and Asn-618; M234, lacking Asn-566, Asn-618, and Asn-633; M123, lacking Asn-554, Asn-566, Asn-618; M1234, lacking
Asn-554, Asn-566, Asn-618, and Asn-633. (b) Evaluation of the mobility shift of E-cadherin N-glycan mutants in AGS cells compared with WT.
E-cadherin N-glycan mutant M1 and M4 showed an increased mobility compared with E-cadherin WT. No detectable changes were observed
regarding cadherin M2 and M3. E-cadherin M1 (arrowhead) displayed a higher mobility shift than E-cadherin M4 (arrow). (c) Characterization
of N-glycosylation proﬁle of E-cadherin N-glycan mutants in AGS cells. Total cell lysates from selected transfectants were treated with Endo H
and PNGase F and analyzed for mobility shifts by western blotting. E-cadherin WT was sensitive to Endo H (arrowhead) and PNGase F (arrow)
being modiﬁed with high-mannose-, hybrid- and complex-type N-glycans. E-cadherin M234 was mostly sensitive to PNGase F (arrow)
and resistant to Endo H while E-cadherin M123 was predominantly Endo H-sensitive (arrowhead). See also Supplementary Figure S3.
(d) N-glycomics analysis using PGC nanoLC ESI MS/MS analyses showed E-cadherin WT to carry high-mannose, complex neutral and complex
sialylated N-glycans in similar amounts. E-cadherin WT and M234 showed higher levels of sialylated and complex-type N-glycans, respectively.
The data presented is referred to one biological replicate, which according to the well-established methodology, can be considered
reproducible and signiﬁcant. See also Supplementary Figure S2 and Supplementary Tables S1 and S2.
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branched structures (decreased L-PHA reactivity) in total cell
lysates compared with non-silenced (NS) cells. The decreased
L-PHA reactivity was also observed in total cell lysates of AGS
Mock siRNA cells when compared with NS cells (Supplementary
Figure S6). As a consequence of the GnT-V knockdown, we
observed a competitive increase in the expression of bisecting
GlcNAc structures (increased biotinylated Phaseolus vulgaris
erythroagglutinin (E-PHA) reactivity) in the total cell lysates of the
GnT-V knockdown cells compared with NS cells, as previously
described. The silencing of MGAT5 led to a decrease in the
reactivity of E-cadherin M234 with the L-PHA lectin compared with
the control (NS), which further supports the conclusion that site 1
is speciﬁcally modiﬁed with β1,6 GlcNAc-branched structures
catalyzed by GnT-V enzymatic activity (Figure 5d). Furthermore,
our results showed that, upon MGAT5 knockdown, the gastric
tumor cells expressing E-cadherin M234+siGnT-V displayed a
notable change of its pattern of expression, showing a decreased
cytoplasmic staining and an increase in membrane expression
compared with NS cells (Figure 5e). In addition, we also
demonstrated that, after the knockdown of GnT-V, the ratio of
E-cadherin cis-dimers in gastric tumor cells expressing E-cadherin
M234+siGnT-V increased to levels similar to that for E-cadherin M1
(Figures 5f and f1), suggesting that the inhibition of GnT-V-
mediated modiﬁcation with β1,6 GlcNAc-branched structures at
Asn-554 (site 1) induces increased E-cadherin cis-dimer formation
and, consequently, the strengthening of cell–cell adhesion.
These results reveal that the GnT-V selectively modiﬁes
N-glycosylation site 1 (Asn-554) on E-cadherin in the context of
gastric tumor cells and that its silencing clearly increases
E-cadherin-mediated cell–cell adhesion and expression.
DISCUSSION
In the present study, using two different MGAT5 mouse models,
we showed that the pattern of E-cadherin expression in gastric
mucosa cells depends on the presence of β1,6 GlcNAc-branched
N-glycans that are formed as the result of enzymatic catalysis by
GnT-V (MGAT5). MGAT5 transgenic mice (which overexpress GnT-
V-mediated glycosylation) display an abnormal pattern of
E-cadherin cellular expression in gastric epithelial cells that
overexpress β1,6 GlcNAc-branched N-glycans compared with
MGAT5 knockout mice (with absence GnT-V-mediated enzymatic
activity). Additionally, we veriﬁed that human diffuse gastric
carcinoma is characterized by an aberrant pattern of E-cadherin
N-glycosylation mediated by GnT-V. Moreover, we observed that
diffuse gastric cancer patients displaying an aberrant glycosylation
of E-cadherin mediated by GnT-V tend to exhibit a poorer survival
rate when compared with gastric cancer patients without GnT-V-
mediated glycosylation on E-cadherin.
We further investigated the speciﬁc N-glycosylation site(s) that
are required for controlling E-cadherin functions in gastric cancer,
particularly the key E-cadherin N-glycosylation site that can be
modiﬁed with the deleterious β1,6 GlcNAc-branched structures
catalyzed by the action of the GnT-V glycosyltransferase. Through
combination of bioinformatics prediction tools with mutagenesis
and glycans enzymatic digestion approaches as well as glycomic
analyses, our results consistently revealed that, among the four
potential N-glycosylation sites available in the extracellular
domain of E-cadherin, Asn-554 (site 1) and Asn-633 (site 4) are
N-glycosylated, respectively, with complex-type and high-
mannose N-glycans structures. Conversely, Asn-566 (site 2) and
Asn-618 (site 3) of E-cadherin are not occupied with N-glycans,
suggesting that these N-glycosylation sites are not critical for
controlling the biological functions of E-cadherin in gastric tumor
cells. Consistent with our observations, previous reports have
shown that E-cadherin from a CHO cell line is modiﬁed with
N-glycans at Asn-554 and Asn-633ref. 36 and that Asn-633 is
modiﬁed with high-mannose N-glycans that were demonstrated
to be important for the folding of E-cadherin.14 In addition, our
glycomics data showed that E-cadherin WT carries triantennary,
sialylated N-glycans, whereas the glycosylation was found to be
altered on the M123 and M234 mutants. These data indicate that
site-speciﬁc mutations of the N-glycosylation sites on E-cadherin
appear to alter the protein conformation and thus also the
accessibility for the glycosyltransferases required for the formation
of described N-glycans.
We clearly demonstrated that site 1 (Asn-554) in the extra-
cellular domain of E-cadherin is the selected site modiﬁed with the
β1,6 GlcNAc-branched structures and the key site for the
functional regulation of E-cadherin in gastric tumor cells.
Whenever site 1 (Asn-554) is modiﬁed with β1,6 GlcNAc-
branched structures, the localization and functions of E-cadherin
are impaired (Figure 6) by: compromising its cis-dimerization
capability, by decreasing the rate of cell–cell aggregation, and also
by interfering in the molecular assembly and stability of the
adhesion complex, that altogether promotes its cellular misloca-
lization and non-functional role. In fact, a mutation of this speciﬁc
site 1 (E-cadherin M1 or M123) resulted in a protective effect,
precluding the functional impairment of E-cadherin through the
recovery of E-cadherin-mediated cell–cell adhesion, an increased
stability of adherens junctions and the correct membrane
localization of the molecule. Similarly, the silencing of the MGAT5
gene that encodes GnT-V also resulted in a restoration of
E-cadherin expression and functions. Although the GnT-V knock-
down is likely to affect various cell surface receptors, in this study
we focused on E-cadherin, showing that upon GnT-V knockdown,
the E-cadherin N-glycan mutant M234 (in which site 1 is available)
loses the β1,6 GlcNAc-branched structures and consequently has
increased cis-dimerization capability, increases recruitment of
catenins and, importantly, it reaches the cell membrane, behaving
similar to the M1 mutant. These results on M234 (and M4) mutant
also suggest that loss of high-mannose glycan in site 4 may also
contribute to this process, as it was previously shown the
importance of this site for E-cadherin folding.14 Therefore,
blocking Asn-554 (site 1), either by mutation or by GnT-V
silencing, resulted in a protective effect on E-cadherin to not
become aberrantly glycosylated thus avoiding its functional
dysregulation (Figure 6). Taken together, these observations are
in agreement with the results using transgenic mice regarding an
E-cadherin phenotype where the MGAT5 knockout resembles
the M1 mutant and the M234+siGnT-V, whereas the GnT-V
overexpressing mice are parallel with the M234 or M4 mutant.
Furthermore and importantly from the clinical standpoint, we
showed that gastric cancer patients with poor prognosis
displayed a marked increased modiﬁcation of E-cadherin
with β1,6-branching N-glycans highlighting the importance of
this speciﬁc E-cadherin aberrant glycoform in the gastric
carcinogenic process.
Overall, this is the ﬁrst study to clearly demonstrate that, among
the four putative N-glycosylation sites, site 1 (Asn-554) in the EC4
domain of E-cadherin is the one that is selectively modiﬁed by the
GnT-V glycosyltransferase in gastric carcinoma cells leading to its
functional impairment. The molecular mechanism governing the
speciﬁc biosynthesis of the β1,6 GlcNAc-branched structures at
site 1 of E-cadherin, and not on any of the other three sites,
remains unknown. Nevertheless, it is possible that, because this
N-glycosylation site is the most extracellular (the furthest from the
membrane), it is therefore more likely to regulate adhesion with
neighboring cells. Additionally, the pathological context of gastric
tumor cells may also account for this selective remodeling of
E-cadherin N-glycosylation site 1 by GnT-V, which probably occurs
depending on the physiopathological context and in a tissue- and
cell-speciﬁc manner.19,37–39
Taken together, we discover how site-speciﬁc E-cadherin
glycosylation modiﬁcation can directly modulate E-cadherin-
mediated cell–cell adhesion, a key pathophysiological event in
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cancer progression. Moreover, preventing E-cadherin site-speciﬁc
glycosylation modiﬁcations was shown to improve its tumor-
suppressive functions in gastric cancer. These results may open
new avenues for the discovery of a promising (glyco)biomarker for
improving early diagnosis, clinical surveillance and patients' risk
stratiﬁcation, as well as for the development of targeted-speciﬁc
therapeutic strategies applied to the clinical setting.
MATERIALS AND METHODS
Tissue immunohistochemistry
Formalin-ﬁxed parafﬁn-embedded tissue from normal, MGAT5 knockout
(C57BL/6 background; generously provided by Professor Michael Pierce)
and MGAT5 transgenic mouse stomach (C57BL/6 background; generously
provided by Professor Eiji Miyoshi) were used for E-cadherin and L-PHA
staining as previously described.15
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In situ PLA
A series of human stomach samples from both normal mucosa (n= 4) and
gastric carcinoma diffuse-type (n= 19) were obtained from the S. João
Centre Hospital, Porto, Portugal and subjected to in situ PLA.27 This study
was approved by the committee of S.João Centre Hospital. An informed
consent was obtained for all the following subjects.
An antibody against E-cadherin (Mouse anti-E-cadherin, clone 4A2C7)
and L-PHA biotinylated lectin against the β1,6 GlcNAc-branched N-glycan
structure (Vector Laboratories, Burlingame, CA, USA) were used. The PLA
probes used were, respectively, anti-mouse immunoglobulins PLUS and
anti-biotin-MINUS, conjugated to oligonucleotides. Images were acquired
using brightﬁeld and/or ﬂuorescence microscope. The PLA signal was
evaluated by three independent observers and scored as follows: negative,
when absent/low expression of PLA signal was observed; and positive,
when moderate/high expression of PLA signal was observed.
Prediction of N-glycosylation site occupancy
Amino-acid sequences of E-cadherin from various species are extracted
from NCBI Reference Sequences40 and selected by means of BLAST
search.41 Multiple top-hit sequences are aligned using Clustal W.42 3D
homology modeling of E-cadherin was performed using the MODELLER
version 9.8 software (San Francisco, CA, USA).43 The crystal structures of the
N-terminal domain of human E-cadherin (PDB ID 1o6s) and C-cadherin
ectodomain (PDB ID 1l3w) were used as templates. The solvent ASA of the
model was calculated using the DSSP program (San Franscisco, CA, USA).44
A sliding window method was used to calculate the averaged ASA
(window size = 5), and the value was assigned to the central amino-acid
residue. The β-turn propensity was predicted by the Chou Fasman
method45 using updated PDB data.46
Plasmids construction and site-directed mutagenesis
A plasmid pcDNA3-E-cad containing human full-length E-cadherin cDNA
(GenBank accession no. Z13009) was used to produce the E-cadherin
N-glycan site mutations singly and in different combinations. PCR-based
site-directed mutagenesis was carried out using the QuickChange XL
Site-directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). The
mutagenesis primers used to the replacement of asparagine for glutamine
in the potential N-glycosylation sites (Asn-554, Asn-566, Asn-618 and Asn-
633) were created according to the manufacturer's instructions. All
mutations were conﬁrmed by DNA sequencing.
Release of N- and O-glycans and nanoPGC LC-ESI-MS/MS analysis
The N-glycans of immunoprecipitated E-cadherin WT and the respective
mutants were released from PVDF membranes after SDS–PAGE separation
and electro-blotting onto PVDF membranes to immobilize glycoproteins as
described previously.34,35 The released N-glycans were dissolved in 10 μl of
pure water, and 5 μl were injected and analyzed by PGC nanoLC-ESI-MS/MS
(Ultimate 3000 UHPLC system, Dionex, Sunnyvale, CA, USA) coupled to an
amaZon ETD Speed ion trap equipped with a CaptiveSpray ionization
source in negative ion mode (all Bruker Daltonics, Bremen, Germany).
The instrument was set up to perform collision-induced dissociation
fragmentation. An m/z range from 380 to 1850 Da was used for data-
dependent precursor scanning with the SPS target mass set to 900m/z.
The capillary voltage was set at 1.3 kV, and the three most intense signals
were selected for collision-induced dissociation experiments (MS/MS scan
range 50–2500m/z). MS as well as MS/MS data were recorded in the
instrument's 'ultra scan mode'. Glycans were loaded onto a PGC precolumn
(Hypercarb KAPPA 30× 0.32mm, 5 μm particle size) and separated on an
analytical PGC column (Hypercarb PGC Column, Thermo, 100mm× 75 μm,
3 μm particle size, both Thermo Fisher, Waltham, MA, USA). The samples
were loaded onto the precolumn at a ﬂow rate of 6 μl/min in 100% buffer
A (10 mM ammonium bicarbonate). The starting conditions for the
analytical column were 2% buffer B (10 mM ammonium bicarbonate in
60% acetonitrile) at a ﬂow rate of 0.8 μl/min. The gradient conditions
were as follows: increase of buffer B from 3% to 15.8% (6 min), further
increase to 40.3% B (6–55min), followed by a steeper increase to 90%
B (55–60min). The column was held at 90% B for 6 min. At the same time,
the precolumn was ﬂushed with 90% Buffer C (10mM ammonium
bicarbonate in 90% acetonitrile) at a ﬂow rate of 6 μl/min before re-
equilibrating the precolumn as well as the analytical column in 98% buffer
A for 5 min. Glycans were automatically identiﬁed using an in-house
established N-glycan spectral database and the spectral library tool
integrated in Compass Data Analysis 4.1 (Bruker Daltonics). N-glycan
structures not present in the database were assigned manually if sufﬁcient
data could be acquired. If no unambiguous identiﬁcation of a structure
was possible based on the MS/MS and LC data but just on MS data only,
the respective portion of the N-glycan is labeled accordingly in the
Supplementary Tables S1 and S2. Glycan compositions were determined
using the GlycoMod tool available on the ExPASy server47 (http://web.
expasy.org/glycomod/; with a mass tolerance of 0.3 Da in the negative ion
mode, reduced N-glycan oligosaccharides, respectively, and restricted to
the monosaccharide residues hexose (Hex), N-acetyl hexosamine (HexNAc),
deoxyhexose, N-acetyl neuraminic acid (NeuAc), N-glycolyl neuraminic acid
(NeuGc) and sulfate.
The accessed glycan structures were then manually validated from
tandem MS fragmentation spectra using the Glycoworkbench software
tool (Eurocarb, Cambridge, UK).48 Data reporting has been performed as
proposed by the MIRAGE guidelines.49,50
Data processing and relative quantitation of PGC glycomics data
The peak area of each glycan composition and isoform was calculated
using the respective extracted ion chromatograms using Compass
QuantAnalysis (Bruker Daltonics). The integration of every extracted ion
chromatogram was validated manually, in particular for peaks with very
low abundance. The generated data were imported in CSV format,
converted in Excel (Microsoft Ofﬁce Excel 2013, Redmond, WA, USA) and
expressed as a relative abundance value for each individual N-glycan
Figure 4. N-glycosylation at Asn-554 affects E-cadherin biological functions. (a) Immunoﬂuorescence analysis showing that AGS cells expressing
E-cadherin WT displayed an epithelial morphology and a membrane localization of E-cadherin (arrowhead). E-cadherin M1 showed a correct
localization of E-cadherin at the cell membrane (arrowhead) with a more focused membrane staining than the WT (confocal microscopy).
N-glycan mutant with Asn-554 (site 1) occupied with N-glycan structures (M234) is characterized by an incomplete localization
of E-cadherin at the cell–cell contacts together with some cytoplasmic staining (arrow). White size bars ~ 5 μm. (a1) Evaluation of the
internuclear proﬁles of E-cadherin M1 and E-cadherin M234. Mutation at site 1 (E-cadherin M1) induces an increased membrane localization of
E-cadherin compared with M234, which shows a decreased E-cadherin membrane expression. (b) Evaluation of cis-dimer-formation capacity
of E-cadherin using BS3. Mutation of Asn-554 (M1) leads to a signiﬁcant increase of cis-dimerization of E-cadherin. (b1) Bar graphs. Amounts of
E-cadherin cis-dimer were determined from the ratio of densities of E-cadherin cis-dimer/E-cadherin monomer. Results are described as mean± s.
d. of three independent experiments. The E-cadherin cis-dimer formation in E-cadherin M1 and M234 are expressed as the fold increase,
compared with the E-cadherin WT, which was taken as 1 (Student's t-test: *P⩽0.05; **P⩽ 0.01; ***P⩽0.001). (c) In vitro cell–cell aggregation assay.
Mutation at Asn-554 (M1) resulted in a signiﬁcant increase of cell–cell aggregation than E-cadherin WT and M234 showing larger cell aggregates.
(c1) Bar graphs. Quantiﬁcation of cell–cell aggregation by measuring the relative number of cells per aggregate (three or more cells). Results are
described as the mean± s.d. of three independent experiments. Student's t-test: *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001). (d) Evaluation of the β- and
p120-catenin total protein expression levels in the total protein lysates from AGS Mock, AGS E-cadherin WT and E-cadherin N-glycan mutants M1
and M234 cells. No signiﬁcant differences were observed among the E-cadherin WT and E-cadherin N-glycan mutants. (e) E-cadherin
immunoprecipitation followed by β- and p120-catenin Western-blot. The results showed that mutation of site 1 (Asn-554), M1, is associated with
an increased interaction between E-cadherin and the β- and p120-catenin. A decreased interaction between E-cadherin and β-catenin (of about
1.0-fold) in M234 mutant compared with E-cadherin M1 was also veriﬁed. (e1) Bar graphs. Amounts of association were determined from the
ratios of densities of β- or p120-catenin after normalization to E-cadherin. Results are described as mean± s.d. of three independent experiments.
The E-cadherin/catenin interaction levels in E-cadherin M1 and M234 are expressed as the fold increase, compared with E-cadherin WT, which
was considered as 1 (Student's t-test: *P⩽0.05; **P⩽ 0.01; ***P⩽ 0.001). See also Supplementary Figure S4.
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structure, respectively, within each E-cadherin type. The N-glycans were
classiﬁed into three categories (high mannose, neutral or sialylated).
Cell culture and transfection
MDCK (Madin Darby canine kidney), BT20 (breast tumor cell line),
HT29 (human colon cancer cell line) and AGS cells (human
adenocarcinoma epithelial cell line) were grown in monolayer culture
and maintained at 37 °C in an atmosphere of 5% CO2 in RPMI 1640
GlutaMAX (or Dulbecco’s modiﬁed Eagle’s medium for BT20 cells), HEPES
medium (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine
serum (Gibco, Invitrogen) and 1% penicillin–streptomycin (Gibco, Invitrogen).
These cells were obtained from American Type Culture Collection (Manassas,
VA, USA), which were tested and authenticated by the cell bank using their
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standard short tandem repeats–based techniques. Cells were also
monitored by microscopy to maintain their original morphology and also
tested for mycoplasma contamination.
Cells were transfected at 40–50% conﬂuence with E-cadherin WT and
E-cadherin N-glycan mutants using Lipofectamine 2000 (Invitrogen),
according to the manufacturer's instructions.
Westerns blotting, lectin blotting and immunoprecipitation
Cell protein lysates from different E-cadherin N-glycan mutants were
subjected to 7.5% SDS–PAGE electrophoresis, transferred to nitrocellulose
membranes and probed with the primary antibody against E-cadherin,
β-catenin, p120-catenin and tubulin, as previously described.15
The expression of β1,6 GlcNAc-branched N-glycan structures and the
bisecting GlcNAc N-glycans were detected by lectin blotting analysis,
where membranes were incubated, respectively, with L-PHA (that
speciﬁcally recognizes β1,6 GlcNAc-branched N-glycans, product of
GnT-V) and E-PHA (that speciﬁcally recognizes bisecting GlcNAc N-glycans,
product of GnT-III) lectins (1 μg/ml; Vector Laboratories).15 For the β1,6
GlcNAc-branched N-glycans analysis on E-cadherin immunoprecipitated,
equal amounts of total protein (750–1500 μg) from each cell lysate were
used and the membranes were probed with L-PHA lectin.15
PNGase F and Endo H digestion
Total cell lysates (30 μg) were combined with denaturating buffer and
incubated at 100 °C for 10min. Samples were then digested for 3 h with 1
unit of PNGase F or Endo H (New England Biolabs, Hertfordshire, UK) at 37 °C.
Endo H is an endoglycosidase that cleaves within the chitobiose core of high
mannose and some hybrid oligosaccharide structures in N-linked glycopro-
teins. PNGase F is an amidase that cleaves between the innermost GlcNAc
and asparagine residues of high-mannose, hybrid and complex oligosacchar-
ides from N-linked glycoproteins. The deglycosylated proteins were loaded
onto 7.5% SDS–PAGE and immunoblotting with anti-E-cadherin. For controls,
the samples were incubated without the enzymes.
Calcium switch
AGS expressing E-cadherin WT, M1 and M234 were washed with
phosphate-buffered saline (PBS), incubated with EGTA 2mM for 10min
and supplemented with medium. Cells were then lysed after 2, 4 and 24 h
Figure 5. Knockdown of GnT-V induces the recovery of E-cadherin expression and functions. (a) Immunoprecipitation of E-cadherin M234
showed an increased L-PHA reactivity compared with the M1 mutant, revealing a signiﬁcant increase in β1,6 GlcNAc-branched N-glycan
structures modiﬁcation in comparison with E-cadherin M1. (b) MGAT5 mRNA expression of AGS cells expressing E-cadherin WT, M1 and M234
after MGAT5 silencing. Around 70–80% of MGAT5 silencing was observed in WT, M1 and M234 mutants. NS, non-silencing. The relative mRNA
expression of siRNA cells expressing E-cadherin WT, M1 and M234 are expressed as the fold increase, compared with the respective non-
silencing cells, which was taken as 1 (Student's t-test: *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001). (c) Lectin blot analysis of GnT-V and GnT-III products
on total cell lysate from AGS cells expressing E-cadherin WT, M1 and M234 after MGAT5 knockdown. A decreased L-PHA reactivity after MGAT5
knockdown and a competitive increase of E-PHA reactivity were observed. (d) MGAT5 silencing resulted in a remarkable decreased L-PHA
reactivity for the E-cadherin band from the E-cadherin WT and E-cadherin M234, suggesting that Asn-554 is occupied with β1,6 GlcNAc-
branched N-glycans. (e) Immunoﬂuorescence analysis of AGS cells expressing E-cadherin WT, M1 and M234 after MGAT5 knockdown. After
MGAT5 silencing, E-cadherin M234 showed an increased localization at the cell–cell membrane. White size bars ~ 5 μm. (f) Evaluation of the
impact of MGAT5 silencing on cis-dimer formation of E-cadherin. Knockdown of MGAT5 leads to a similar ratio of E-cadherin cis-dimer
formation in AGS cells expressing E-cadherin M1 and M234. (f1) Bar graphs. Amounts of E-cadherin cis-dimer were determined from the ratio
of densities of E-cadherin cis-dimer/E-cadherin monomer. Results are reported as the mean± s.d. of two independent experiment. See also
Supplementary Figure S6.
Figure 6. Proposing model for the site-speciﬁc E-cadherin N-glycosylation in cancer context. The site-speciﬁc occupancy of E-cadherin Asn-554
with β1, 6 GlcNAc-branched structures catalyzed by GnT-V impairs its biological functions leading to a decreased E-cadherin cis-dimerization
capability, a decreased cellular aggregation and an impairment of the molecular assembly of adherens junctions. Locking this site-speciﬁc
modiﬁcation either by Asn-554 mutation or by GnT-V silencing recovers the biological functions of E-cadherin by increasing E-cadherin
cis-dimerization, aggregation and the stability of the E-cadherin–catenin complex.
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with buffer containing PBS, 1% Triton X-100 and 1% NP40, and 30 μg of
total cell lysate were subjected to 7.5% SDS–PAGE.
E-cadherin cis-dimer formation
Cells were plated in six-well plates to conﬂuence. They were washed
with PBS and incubated with 2.5 mM BS3 (Sigma, St Louis, MO, USA) for
3 h on ice. The resulting cells were then incubated with 10mM Tris
(pH 7.5) for 15min on ice. Cells were then lysed with buffer containing PBS,
1% Triton X-100 and 1% NP40, and 30 μg of total cell lysate were subjected
to 6% SDS–PAGE. E-cadherin cis-dimer formation was detected by
immunoblotting.
Immunoﬂuorescence
AGS cells transfected with the different E-cadherin N-glycans mutants
were plated on six-well plates with coverslips. Cells were ﬁxed with
methanol and blocked with bovine serum albumin 5% in PBS. Cells were
incubated with mouse anti-E-cadherin monoclonal antibody.15 Immuno-
ﬂuorescent images were obtained using a Zeiss Imager.Z1 AxioCam MRm
(Carl Zeiss, Jena, Germany).
For the quantitative analyses of in situ immunoﬂuorescence images, a
1D (one dimension) representative proﬁle of protein level of expression
and distribution was obtained. To undertake this analysis, original
immunoﬂuorescence images from cell populations were used to extract
internuclear proﬁle map from single cells and pairs of cells.51
Slow-aggregation assay
AGS cells transfected with E-cadherin WT and the different E-cadherin
N-glycan mutants (5× 104) were seeded onto an agar gel (0.66% w/v) in a
96-well plate. Aggregation formation was evaluated after 24 h using inverted
phase-contrast microscope. Experiments were carried out in triplicate.
siRNA transfection
siRNA targeting MGAT5 and control siRNA were purchased from
Dharmacon (Lafayette, CO, USA). siMGAT5 (0–200 nM) was transfected
into AGS cells expressing Mock, E-cadherin WT, M1 and M234 with
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruc-
tions. Efﬁciency of MGAT5 knockdown was optimal with 80 nM of siRNA
after 48 h.
Statistical analysis
PLA analyses were performed using the SPSS statistical software (IBM,
Armonk, NY, USA). Statistical associations between clinicopathological
features and aberrant E-cadherin N-glycosylation mediated by GnT-V were
assessed using the χ2 test. Survival curves were estimated using the
Kaplan–Meier method.
Statistical analyses were performed using the Graph Pad program
(GraphPad Software, Inc., La Jolla, CA, USA). Student’s tests were used to
calculate signiﬁcance in an interval of 95% conﬁdence level. All statistics
were compared with the E-cadherin WT group, and values of Po0.05 were
considered to be statistically signiﬁcant (Student's t-test: *P⩽ 0.05;
**P⩽ 0.01; ***P⩽ 0.001).
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Abstract 
 
E-cadherin plays a major role in malignant cell transformation and impairment of its 
biological functions is a well-established molecular event occurring during gastric 
carcinogenesis. Glycosylation modifications were identified as a fundamental mechanism 
of E-cadherin dysregulation in cancer with promising clinical applications. Nevertheless, it 
remains to be determined the role of the recently identified O-mannosyl glycans in the 
regulation of E-cadherin functions in cancer and how this novel post-translational 
modification interplay with E-cadherin N-glycans in a cancer context. In this study we found 
that the overall O-mannosylation profile of cancer proteins is reduced in gastric cancer 
patients comparing with normal gastric mucosa. Moreover, and concomitantly with the 
acquisition of a poorly-differentiated gastric cancer phenotype, E-cadherin suffers a 
decrease on the expression of O-mannosyl glycans with effects on the impairment of its 
biological functions. Interestingly, when the O-mannosylation pathway was promoted 
through protein O-mannosyltransferase 2 (POMT2) overexpression, a recovery of E-
cadherin localization at cell-cell borders together with an improvement on the adherens 
junctions assembly and competence were observed. We further demonstrated that O-
mannosylation regulates the critical functions of E-cadherin in cancer in coordination with 
N-glycosylation. Genetic manipulation of the O-mannosylation pathway, either by POMT2 
overexpression or silencing, resulted in alterations in the expression of complex branched 
N-glycans modulating E-cadherin functions. Likely, overexpression of branched N-glycans, 
led to a significant decrease of O-mannosyl glycans on E-cadherin. This mechanistic 
interplay between O-mannosyl glycans and branched N-glycans was further demonstrated 
to occur at E-cadherin site-specific level. Preventing E-cadherin Asn-554 from receiving the 
deleterious branched structures, resulted in an increased O-mannosylation profile of E-
cadherin that culminated in a protective effect on the glycoprotein by precluding its 
functional dysregulation and contributing to tumor suppression. These results were further 
confirmed using Mgat5 transgenic mouse models and also in human gastric carcinomas. 
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Introduction 
 
Epithelial cadherin (E-cadherin) is a cell surface glycoprotein with key roles in normal 
homeostasis, through the establishment and maintenance of competent intercellular 
adhesions, cell polarity and normal tissue architecture (1-4). E-cadherin molecule 
establishes homophilic interactions through its ectodomains establishing strong adhesive 
complexes (5, 6). Molecular interactions of the E-cadherin cytoplasmic domain with 
cytosolic proteins, called catenins, also provides anchorage to the actin cytoskeleton 
contributing to the establishment of stable and mature adherens junctions (4, 7).  
E-cadherin plays a major role in malignant cell transformation. Reduced levels of E-
cadherin expression and impairment of its functions have been reported to be a well-
established molecular event that occurs during tumour development and progression, 
leading to an increased ability of cells to invade neighbouring tissues and to metastasize 
(8-10).  
Posttranslational modifications of E-cadherin through glycosylation have been 
pinpointed to play an instrumental role in the dysregulation of E-cadherin functions in a 
cancer context. (11-13). Indeed, altered pattern of protein glycosylation originates different 
E-cadherin glycoforms that have been associated with the impairment of its critical functions 
in gastric cancer (14). 
Modifications of E-cadherin with β1,6 GlcNAc-branched N-glycans, catalysed by the N-
acetylglucosaminyltransferase V (GnT-V), has major deleterious effects on E-cadherin-
mediated cell-cell adhesion leading to the impairment of the stability and competence of the 
intercellular adhesive complex (14-16). The importance of this specific E-cadherin aberrant 
N-glycoform was demonstrated to be associated with invasive and metastatic potential of 
tumour cells and thus with the pathogenesis of gastric carcinoma (17). Moreover, it was 
recently reported by us that among the four potential N-glycosylation sites on the 
extracellular domain of E-cadherin, the Asn-554 is the key site that, within a gastric cancer 
context, is selectively modified with the deleterious β1,6 GlcNAc-branched N-glycans 
catalysed by Gnt-V, directly affecting E-cadherin functions (17). Interestingly from the 
clinical standpoint, prevention of E-cadherin aberrant glycosylation at Asn-554 was found 
to preclude its functional dysregulation by improving its critical function in gastric cancer 
(17).  
Beyond N-glycosylation, E-cadherin was recently identified as a major target of O-
mannosylation (18, 19). Protein O-mannosylation is a posttranslational process that is 
initiated at the endoplasmic reticulum (ER) by the covalent attachment of mannose 
structures to serine (Ser) or threonine (Thr) residues of secretory and/or membrane proteins 
catalysed by the homologous protein O-mannosyltransferase 1 (POMT1) and 2 (POMT2) 
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(20, 21). These O-mannose core structures may be further extended via different linkages 
originating distinct extended O-mannosylated structures (22). According to the literature, 
the most well characterized O-mannosylated mammalian protein is α-dystroglycan (α-DG), 
an integral glycoprotein of the dystrophin-glycoprotein complex. The α-DG links the 
extracellular matrix (ECM) to the actin cytoskeleton by interacting with ECM proteins in a 
glycosylation-dependent manner. Disruption of the O-mannosylation pathway causing the 
hypoglycosylation of α-DG results in the impairment of α-DG-mediated epithelial cell-
basement membrane interaction, and underlies various forms of congenital muscular 
dystrophies (CMD) (23-25). A wide spectrum of O-mannosylated proteins were recently 
identified, and among them, cadherins revealed as major O-mannosylated glycoproteins 
(18, 19, 26). Lommel et al. demonstrated that O-mannosylation of E-cadherin is required 
for the morula to blastocyst transition before implantation. Moreover, O-mannosylation was 
found to be important for E-cadherin-mediated cell-cell adhesion in a normal context (18). 
Absence of O-mannosylated structures at the EC2-5 domains leaded to E-cadherin 
abnormal localization (19). Taken in consideration the instrumental role of glycosylation as 
a mechanism for regulating E-cadherin functions in cancer (11, 12), it is of utmost 
importance to unravel the yet uncover molecular role of O-mannosyl glycans and their 
interplay with N-glycans in the regulation of E-cadherin biological functions in cancer.  
In this study, we report that O-mannosylation is overall reduced in gastric cancer 
compared with normal gastric mucosa. Particularly, E-cadherin suffers a decrease in the O-
mannosylation profile concomitantly with the acquisition of a poorly-differentiated gastric 
cancer phenotype. This deficiency on O-mannosylated glycans on E-cadherin compromises 
the stability of the adherens junctions associated with tumour progression. Furthermore, we 
also demonstrate the existence of a coordinated interplay between complex N-glycans and 
O-mannosyl glycans on E-cadherin with biological relevance in a cancer context. 
Interestingly, prevention of the addition of β1,6 GlcNAc-branched N-glycans at the Asn-554 
of E-cadherin promotes the modification with O-mannosyl glycans, leading to a recovery of 
E-cadherin functions. Further, this interplay between branched N-glycans and O-mannosyl 
glycans were observed both in transgenic animal models and in human diffuse gastric 
cancer patients. 
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Material and Methods 
 
Tissue immunohistochemistry and lectin staining  
Formalin-fixed paraffin-embedded tissue from normal human gastric mucosa, 
human diffuse gastric cancer (n=3; both obtained from the S. João Centre Hospital, Porto, 
Portugal); MGAT5 knockout and MGAT5 transgenic mouse stomach (C57BL/6 background; 
generously provided by Professor Michael Pierce and Eiji Miyoshi, respectively) were used 
for E-cadherin and L-PHA staining as previously described (14). For O-mannosylated 
proteins staining, the sections were incubated with T[α1- Man]- specific polyclonal antibody 
(dilution 1:50) for one hour at RT. This study was approved by the ethical committee of 
Centro S. João Centre Hospital, Porto, Portugal and an informed consent was obtained for 
all the subjects. 
 
Cell lines 
Human gastric carcinoma cell lines MKN28, Kato III, and AGS cells transfected with 
E-cadherin WT and E-cadherin N-glycan mutants, as previously described (17), were grown 
in RPMI 1640 GlutaMAX supplemented with 10% fetal bovine serum (Gibco, Invitrogen) 
and 1% penicillin-streptomycin (Gibco, Invitrogen), and maintained at 37 ºC in an 
atmosphere of 5% CO2. MKN45 gastric cell line stably transfected with GnT-V and with the 
empty vector (mock cells) were cultured in the previous conditions under the selection of 
G418 (500 µg/mL) (27-29). 
These cells were obtained from American Type Culture Collection (Manassas, VA, 
USA), which were tested and authenticated by the cell bank using their standard short 
tandem repeats-based techniques. Cells were also monitored by microscopy to maintain 
their original morphology and also tested for mycoplasma contamination. 
 
Cell transfection and siRNA transfection 
Kato III suspension cells were transfected with plasmid pTW49 using Lipofectamine 
2000 (Invitrogen), according to the manufacturer´s instructions. siRNA targeting POMT2 
(ON-TARGETplus Human POMT2siRNA-SMARTpool) and control siRNA (ON-
TARGETplus Non-targeting pool) were purchased from Dharmacon. siPOMT2 (0-200 nM) 
was transfected into MKN28 cell line with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer´s instructions. Efficiency of POMT2 knockdown was optimal with 80 nM of 
siRNA after 48h. 
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RNA expression and quantification 
Total RNA was extracted from cell lines using TRI reagent (Sigma-Aldrich), 
according to manufacturer´s protocol. RNA yield and quality were determined 
spectophotometrically and 1000 ng of total RNA were reverse transcribed to single stranded 
cDNA using Superscript II Reverse Transcriptase and random hexamer primers (Invitrogen, 
Oregon, USA). Quantitative Real-Time PCR was carried out in triplicates using source RNA 
from three biological replicas, for the target genes POMT2, POMT1 and MGAT5 and for the 
endogenous control 18S. Data was analyzed by the ΔΔCT method (30). Statistical analysis 
was performed using GraphPad PRISM 5.0 software and significance was evaluated with 
Student´ s T-Test. 
 
Cell and Tissue Lysate Preparation 
Fresh tissue from normal human gastric mucosa and diffuse gastric cancer were 
obtained from the S. João Centre Hospital, Porto, Portugal. Tissues were dissected into 
smaller pieces, immersed in liquid nitrogen to snap freeze, and stored at -80ºC for later use. 
To proceed to lysate preparation, tissues were washed briefly with PBS1x to remove any 
blood, and homogenized with an electric homogenizer with ice cold NP-40 lysis buffer 
containing protease inhibitors (for ~ 5 mg piece of tissue, ~300 µL of lysis buffer was added).  
To prepare lysate from cell culture, the cell culture dish were washed with ice-cold PBS, 
and the adherent cells were scraped off with ice cold NP-40 lysis buffer. Regarding Kato III 
suspension cells, cell suspension from culture dish was transferred into tube, washed with 
ice-cold PBS and homogenized with ice cold NP-40 lysis buffer. The samples were 
maintained on ice during 20 minutes, then centrifuged at 13200 rpm for 20 minutes at 4ºC, 
and the supernatant was transferred to a fresh tube. Total protein was quantified using a 
BCA protein assay kit (Pierce). 
 
Immunoblotting, lectin blotting 
Protein lysates were subjected to 7.5% SDS-PAGE electrophoresis, transferred to 
nitrocellulose membranes and probed with the primary antibody against E-cadherin and β-
actin/ α-tubulin, as previously described (14). POMT2 expression was evaluated incubating 
the membranes with polyclonal rabbit anti-POMT2 (1:500). 
The expression of β1,6 GlcNAc-branched N-glycans structures were detected by 
lectin blotting, where membranes were incubated with L-PHA lectin (1-5 µg/mL; Vector 
Laboratories). Expression of O-Mannosyl glycans was evaluated by PNGase F digestion to 
remove N-glyans (overnight, 37ºC) followed by lectin blotting using Biotinylated 
Concanavalin A (Con A) (1-5 µg/mL; Vector Laboratories).  For the β1,6 GlcNAc-branched 
N-glycans analysis on E-cadherin immunoprecipitated, equal amounts of total protein (500-
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1000 µg) from each cell lysate were used and the membranes were probed with L-PHA 
lectin. Regarding the evaluation of O-Man glycans on E-cadherin, E-cadherin 
immunoprecipitated was subject to PNGase F digestion overnight at 37ºC, and the 
membranes were probed with Con A lectin.  
 
Immunofluorescence 
Cells were grown on six-well plates with coverslips. Cells were fixed with methanol 
and blocked with bovine serum albumin (BSA) 5% in PBS. Cells were then incubated with 
mouse anti-E-cadherin monoclonal antibody (BD Bioscience; 1:200 diluted in BSA 5%) for 
one hour at RT. After primary antibody incubation, the cover slips were washed in PBS and 
then Alexa Fluor 488 anti-mouse was used as secondary antibody (Invitrogen; 1:500 diluted 
in BSA 5%; one hour of incubation in the dark). Finally, the cover slips were washed in PBS 
and mounted on slides using Vectashield with DAPI (Vector Laboratories). 
Immunofluorescent images were obtained using a Zeiss Imager.Z1 AxioCam MRm (Carl 
Zeiss, Jena, Germany). 
 
Slow-aggregation assay 
Wells of a 96-well-plate were coated with 50 μl of an agar solution. Cells (1,25 x 104) 
were seeded onto an agar gel (0.66% w/v) in a 96-well plate. Experiments were carried out 
in triplicate.  
 
Statistical analysis 
Statistical analyses were performed using the Graph Pad program (GrapPad 
Software, Inc., La Jola, CA, USA). Student´s tests were used to calculate the significance 
in an interval of 95% confidence levels. Values of P < 0,05 were considered to be statistically 
significant (Student´s t-test: *P≤0,05; **P≤0,01; ***P≤0,001). 
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Results 
 
Protein O-Mannosylation is reduced in human gastric carcinoma 
 
In order to assess the significance of protein O-mannosylation in a cancer context, we 
evaluated the overall O-mannosylation profile in normal gastric mucosa and in diffuse 
gastric cancer, using the T[α1-Man]-specific polyclonal antibody. This antibody was 
generated to direct against a threonine O-mannosyl-conjugated epitope and specifically 
detects O-mannosylated proteins (18). Normal gastric mucosa (from the body region of the 
stomach), displaying a normal basolateral cell membrane localization of E-cadherin, 
exhibited a strong reactivity of O-mannosylated proteins at the cytoplasm and/or at the cell 
membrane (Figure 1A). Conversely, in diffuse gastric cancer cases showing an 
abnormal/aberrant pattern of E-cadherin expression, a significant decrease of O-
mannosylated proteins was observed. Interestingly, O-mannosylated proteins were 
detected in normal adjacent mucosa, predominantly in cells displaying a normal pattern of 
E-cadherin membrane localization.  
Afterwards, we evaluated the expression levels of POMT2 protein and O-mannosyl 
glycans in vivo, in gastric carcinomas (Figure 1B). As expected, the total E-cadherin 
expression is decreased in diffuse gastric cancer comparing with normal gastric mucosa. 
Likewise, the total levels of POMT2 protein expression are reduced in diffuse gastric 
carcinoma, comparing with normal mucosa. Further, the O-mannosyl glycans profile was 
evaluated by removal of N-glycans with PNGase F treatment followed by Concanavalin A 
(Con A) lectin blot, which thereby recognizes O-Man glycoproteins. Figure 1B showed that 
O-mannosylation profile decreased in diffuse gastric carcinoma (see also Supplementary 
Figure 1). 
These observations suggest that human normal gastric mucosa, particularly from the 
body region of the stomach, is characterized by a high expression of O-mannosylated 
proteins that are decreased in human diffuse gastric carcinoma.  
 
O-mannosylation of E-cadherin decreases in poorly-differentiated gastric 
cancer phenotype. 
 
To further evaluate the role of O-mannosylation in cancer, we investigated the 
expression of O-mannosyl glycans in two distinct gastric cancer cell lines that represent 
different stage of gastric cancer differentiation, behavior and progression: the MKN28 
gastric cancer cell line, which is a well differentiated tubular adenocarcinoma with normal 
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E-cadherin functions, and the Kato III gastric cancer cell line, which is an undifferentiated 
gastric signet ring cell line with abnormal E-cadherin expression and functions (31-33).  
MKN28 gastric cancer cells exhibited an epithelial morphology forming larger compact 
cellular aggregates, whereas Kato III cell line is characterized by sparse cells displaying 
some fibroblatoid-like appearance with reduced cell-cell aggregation capability (Figure 2A). 
Regarding the E-cadherin cellular localization, the immunofluorescence staining revealed 
that MKN28 cells showed a strong membranous staining of E-cadherin, whereas the 
expression of E-cadherin in Kato III cells is reduced at the cell-cell contacts with 
mislocalization into the cytoplasm.   
Concerning the O-mannosylation profile, a significant decrease in the total protein 
expression of POMT2 was observed in Kato III cells (Figure 2B). Accordingly, this 
undifferentiated gastric cancer cell line exhibited lower levels of O-mannosyl glycans 
expression (revealed after removal of N-glycans by PNGase F digestion), when compared 
with the well-differentiated MKN28 cells (Figure 2B, Supplementary Figure 2A). Concerning 
the mRNA transcription levels of POMTs, lower levels of POMT2 mRNA transcription were 
observed in Kato III cell line when compared with MKN28 (Figure 2C). No significant 
differences were detected on POMT1 mRNA expression levels (Supplementary Figure 2B).  
Having demonstrated a decreased POMT2 and O-mannosyl glycans expressions in 
undifferentiated gastric cancer cells, we further evaluated the levels of O-mannosyl glycans 
specifically on E-cadherin protein. Figure 2D demonstrates that E-cadherin from MKN28 
cells showed a significant increased reactivity with the Con A- mannose binding lectin after 
release of N-glycans, when compared with E-cadherin from Kato III (see also 
Supplementary Figure 2C). These results suggest that E-cadherin is highly O-mannosylated 
in a well-differentiated cancer context and this modification decreases during the acquisition 
of an undifferentiated cancer phenotype.  
 
Modulation of POMT2 expression impacts O-mannosylation profile of E-
cadherin regulating its biological functions in cancer. 
 
Having demonstrated the distinct O-mannosylation profiles of E-cadherin associated with 
different cancer phenotypes (Figure 2D), together with the observed differences on the 
levels of POMT2 gene transcription among the two cancer cells phenotypes (Figure 2C), 
we further evaluated the impact of O-mannosylation in the regulation of E-cadherin 
biological functions in a cancer context. For doing so, POMT2 expression was modulated 
either by silencing of POMT2 gene in MKN28 cells (Figure 3) or by POMT2 overexpression 
in Kato III cells (Figure 4). 
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The figure 3A showed a significant reduction of POMT2 mRNA transcription levels after 
POMT2 gene silencing, as well as a decrease in POMT2 protein expression (Figure 3B). 
Likely, the expression of overall O-mannosyl glycans was reduced after POMT2 silencing 
(Figure 3B). Furthermore, knockdown of POMT2 resulted in a decreased modification of E-
cadherin with O-mannosyl glycans (Figure 3C, see also Supplementary Figure 3A). 
Consequently, by immunofluorescence analysis we verified an abnormal E-cadherin 
localization at the cell membrane and this mislocalization was accompanied with loss of 
cell-cell contacts (Figure 3D). In addition, POMT2 knockdown resulted in a significant 
decreased interaction of E-cadherin with p120-catenin (Figure 3E). No significant 
differences were observed regarding the recruitment of β-catenin by E-cadherin upon 
POMT2 silencing. Overall, these results indicated that the reduction of O-mannosylation of 
E-cadherin after POMT2 silencing resulted in an impairment of E-cadherin cellular 
localization, disturbing the assembly of the adherens junctions through a decreased 
recruitment of catenins by E-cadherin. 
To further evaluate the impact of O-mannosylation on E-cadherin functions, the opposite 
approach was performed by overexpressing POMT2 gene in Kato III gastric cancer cells 
(Figure 4A). The results showed that POMT2 overexpression resulted in an increased 
expression of POMT2 protein as well as an increase in overall O-mannosylated 
glycoproteins (Figure 4B). Looking specifically to E-cadherin glycoprotein, we observed that 
POMT2 overexpression lead to an increased O-mannosylation of E-cadherin (Figure 4C, 
see also Supplementary Figure 3A). This increased modification of E-cadherin with O-
mannosyl glycans was accompanied with a recovery of E-cadherin localization at the cell-
cell borders (Figure 4D). Moreover, the recruitment of β-catenin and p-120-catenin by E-
cadherin was also significantly improved after POMT2 overexpression (Figure 4E). 
These results reveal that O-mannosylation of E-cadherin is essential for its correct 
localization at the cell membrane playing also a crucial role in the molecular assembly and 
stability of the adherens junctions. 
 
N-glycosylation and O-mannosylation as inter-players in the regulation of E-
cadherin functions in cancer. The impact of site-specific N-glycosylation on 
E-cadherin O-mannosylation. 
 
Our previous studies demonstrated that addition of GnT-V-mediated β1,6 
GlcNAc-branched N-glycans on E-cadherin contributed to the abrogation of its critical 
functions in cancer (14, 17). Furthermore, recent studies reported that E-cadherin is also 
major target of O-mannosylation that appears to be important for cadherin-mediated 
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adhesive functions (18). In this study we evaluated the interplay between these two major 
forms of E-cadherin modification: GnT-V-mediated N-glycosylation and O-mannosylation 
and their role in the regulation of E-cadherin functions in gastric cancer. 
The analysis of the levels of β1,6 GlcNAc-branched N-glycans (using L-PHA lectin) and 
O-mannosyl glycans (using Con A lectin after PNGaseF digestion) on E-cadherin from the 
two distinct gastric cancer phenotypes showed that in a well-differentiated cancer 
phenotype (MKN28), E-cadherin appears to be predominantly modified with O-mannosyl 
glycans than β1,6 GlcNAc branched N-glycans (Figure 5A). On the contrary, E-cadherin 
from a poorly-differentiated gastric cancer phenotype (Kato III) mainly exhibited β1,6 
GlcNAc branched N-glycans. Interestingly, this interplay is also verified at the level of 
POMT2 and MGAT5 gene transcription, where POMT2 gene is more expressed in MKN28 
cells than in Kato III cells whereas MGAT5 gene is highly expressed in Kato III cells when 
compared with MKN28 cells (Supplementary Figure 4A).  
Afterwards we went to assess the impact of POMT2 modulation (either by silencing or 
overexpression) in the levels of β1,6 GlcNAc-branched N-glycans attached to E-cadherin. 
The results showed that POMT2 knockdown in MKN28 cells resulted in a significant 
increased expression of β1,6 GlcNAc branched N-glycans on E-cadherin (Figure 5B), 
although a slight decrease of MGAT5 gene at the mRNA transcription level was verified 
(Supplementary Figure 4B). Conversely, the overexpression of POMT2 gene in Kato III cells 
led to a significant decrease of MGAT5 mRNA expression (Supplementary Figure 4C), and 
no significant differences in β1,6 branched N-glycans on E-cadherin were verified (Figure 
5C).  
To further clarify this potential interplay between branched N-glycans and O-mannosyl 
glycans expression on E-cadherin, another cell line model was necessary. The MKN45 
gastric cancer cell line stably transfected with MGAT5 and thus with overexpression of GnT-
V-mediated β1,6 GlcNAc-branched N-glycans was used. Interestingly, Figure 5D 
demonstrated that the overexpression of MGAT5 leads to a significant increased 
modification of E-cadherin with GnT-V-mediated branched N-glycans concomitantly with a 
significant decrease of O-mannosyl glycans expression on E-cadherin. No significant 
differences were observed on POMT2 mRNA expression after MGAT5 overexpression 
(Supplementary Figure 4D).  
Taken together, these results suggest the existence of an inverse relationship between 
E-cadherin N-glycosylation mediated by GnT-V and O-mannosylation that appears to occur 
at the E-cadherin post-translational level and not necessarily at the genetic level.  
Recently, we demonstrated that among the four potential N-glycosylation sites of E-
cadherin, Asn-554 is the selected site modified with β1,6 GlcNAc-branched N-glycans 
resulting in deleterious effects on E-cadherin functions in cancer (17). Moreover, we also 
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reported that preventing this aberrant glycosylation mediated by GnT-V at Asn-554 
improves E-cadherin biological functions in cancer (17). Taking into consideration these 
results, and in order to evaluate the relationship between E-cadherin O-mannosylation and 
E-cadherin N-glycosylation at a site-specific level, we analyzed the expression of O-
mannosyl glycans in different E-cadherin N-glycan mutant forms. The results showed that 
E-cadherin M1 mutant, with mutation on Asn554 and displaying no reactivity to L-PHA lectin 
(no expression of branched N-glycans) exhibited an increased presence of O-mannosyl 
glycans on E-cadherin as detected by the higher reactivity to Con A lectin (after removal of 
N-glycans) when compared to E-cadherin WT and M234 (Figure 5E). In contrast, E-
cadherin M234 mutant, displaying Asn554 occupancy with branched N-glycans catalyzed 
by GnT-V exhibited the lowest expression levels of O-mannosyl glycans on E-cadherin. 
These results strongly support that deletion of Asn-554, which precludes the addition of 
β1,6 GlcNAc branched N-glycans at this specific site, induces an increased modification of 
E-cadherin with O-mannosylation. And, the presence of β1,6 GlcNAc branched N-glycans 
at E-cadherin Asn-554, are remarkably associated with a decreased O-mannosylation on 
E-cadherin in cancer. Additionally, our results further showed that removal of N-glycans by 
PNGase F treatment lead to a lower mobility shift of E-cadherin WT and M1 band comparing 
with E-cadherin M234, indicating that these E-cadherin N-glycoforms WT and M1 may 
undergo further modification that E-cadherin M234 does not (Figure 5E). 
 
Inverse relationship between branched N-glycans and O-mannosyl glycans in 
the stomach of transgenic mice models and in human gastric cancer. 
 
In order to assess in vivo the biological relevance of afore described crosstalk between 
these two major types of glycosylation of E-cadherin, we used both MGAT5 transgenic mice 
models and human gastric carcinomas clinical samples.  
Previously, we have demonstrated that GnT-V-mediated glycosylation causes an 
abnormal pattern of E-cadherin expression in the gastric mucosa of GnT-V transgenic mice 
(17). In this study, we evaluated the correlation between the expression of GnT-V-mediated 
glycosylation and O-mannosylation in the gastric mucosa of MGAT5 knockout (KO) mice 
and MGAT5 overexpressing mice comparing with wild-type (WT) (Figure 6A). The results 
showed that gastric mucosa of MGAT5 KO, characterized by no reactivity to L-PHA lectin 
(no synthesis of β1,6 GlcNAc branched N-glycans) and displaying a normal E-cadherin 
expression in the basolateral cell membrane, showed higher levels of O-mannosylated 
proteins, detected by immunoreactivity to T[α1-Man] antibody. On the other hand, mice 
overexpressing MGAT5 with a strong staining to L-PHA lectin and an aberrant pattern of E-
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cadherin expression, displayed reduced levels of O-mannosylated proteins. These results 
indicated that MGAT5 expression affects the expression of O-mannosylated proteins.  
In a human context, we have previously reported that GnT-V-mediated branched 
glycosylation is a fundamental mechanism of E-cadherin dysregulation in gastric 
carcinogenesis, associated with a poorer survival rate of patients. (14, 17). In this study, we 
evaluated whether the O-mannosylation profile is affected in these gastric cancer patients.  
The results presented on Figure 6B, showed that human normal gastric mucosa displayed 
almost no reactivity to L-PHA lectin, but a high positivity to T[α-Man] antibody, indicating 
high expression of O-mannosylated proteins concomitantly with negligible levels of proteins 
modified with β1,6GlcNAc-branched N-glycans. In a cancer context, the opposite was 
observed. Neoplastic cells of diffuse gastric carcinoma with an abnormal/aberrant pattern 
of E-cadherin expression, showed high levels of expression of β1,6GlcNAc-branched 
N-glycans and an insignificant expression of O-mannosylated proteins (negative T[α-Man] 
reactivity). Furthermore, cells from normal adjacent mucosa with a normal cell membrane 
localization of E-cadherin exhibited no reactivity to L-PHA together with positivity to T[α-
Man] antibody, indicating the expression of O-mannosylated proteins but not 
β1,6GlcNAc-branched N-glycans. Additionally, the L-PHA lectin blotting represented in 
Figure 6B1 demonstrated high expression levels of overall β1,6GlcNAc-branched 
N-glycans on diffuse gastric cancer lysates, when compared with normal gastric mucosa, 
further corroborating the existence of an inverse correlation between O-mannosyl glycans 
(Figure 1C) and branched N-glycans (Figure 6B1) in diffuse gastric carcinomas. . 
Overall, these results support the existence of biological interplay between GnT-V-
mediated glycosylation and O-mannosylation affecting the critical functions of a key tumor 
suppressor protein in gastric carcinogenesis, E-cadherin.  
 
Discussion 
 
E-cadherin dysregulation is a hallmark of cancer development and progression and 
glycosylation modifications have been recently pinpointed as a fundamental mechanism of 
E-cadherin regulation with promising clinical applications (11).  
The molecular mechanisms that govern E-cadherin regulation in cancer through the 
newly described O-mannosyl glycans is far from being elucidated (19). Moreover, the 
potential interplay between the two major types of E-cadherin post-translational 
modifications, N-glycosylation and O-mannosylation, and its relevance in cancer is 
completely unknown.  
In this study we have demonstrated that the pattern of O-mannosylation in gastric cancer 
is overall reduced, both at the glycan level as well as at the protein (POMT2) and genetic 
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level (POMT2 gene). Particularly, we found that E-cadherin suffered a decreased O-
mannosylation that accompanied the acquisition of a poorly-differentiated cancer 
phenotype. This decrease in the O-mannosyl glycans attached to E-cadherin resulted in the 
impairment of E-cadherin functions in cancer cells through interfering in its normal cellular 
localization and in the stability of adherens junctions. Therefore, a novel functional link is 
established between E-cadherin dysfunction in cancer and reduced O-linked mannose 
residues attached to the glycoprotein. When O-mannosylation was promoted within an 
undifferentiated gastric cancer phenotype, a recovery of E-cadherin membrane localization 
and biological functions was observed. The increased modification of E-cadherin with O-
mannosyl glycans promotes a correct localization of E-cadherin at the cell-cell contacts 
together with an improvement in the molecular assembly and stability of the intercellular 
adhesive complex. These results are in accordance with Lommel et al. that described that 
O-mannosylation of E-cadherin is highly relevant to the formation and maintenance of 
adherens junctions during the morula-to-blastocyst transition and in normal MDCK cells 
(18).  
In addition, we here provide new evidences for the existence of a yet uncovered interplay 
between O-mannosylation and N-glycosylation that appears to operate in a coordinated and 
site-specific manner on E-cadherin glycoprotein, with impact in the modulation of its critical 
functions in gastric cancer. 
In fact, GnT-V-mediated branched N-glycosylation has been described as an 
instrumental mechanism of E-cadherin dysregulation in cancer (11, 12, 34, 35). The 
modification of E-cadherin with β1,6 GlcNAc branched N-glycans was observed in gastric 
cancer patients associated with poor survival rates (17) and has been described to induce 
E-cadherin cellular mislocalization and an incorrect assembly of adherens-junctions, thus 
compromising cell-cell adhesion and downstream signalling pathways that ultimately 
contribute to tumour invasiveness and metastases (14, 15, 17, 36).  
In the present study, we consistently demonstrated that the manipulation of the O-
mannosylation pathway (either by POMT2 silencing or overexpression) in different gastric 
cancer cellular phenotypes consistently resulted in alterations of the expression of branched 
N-glycans on E-cadherin in an inverse and coordinated manner. POMT2 knockdown 
resulted in an increased GnT-V-mediated branched N-glycans on E-cadherin, Likewise, 
when the branched N-glycosylation pathway is manipulated, by inducing MGAT5 
overexpression, a significantly decreased levels of O-mannosyl glycans attached to E-
cadherin was observed. This mutual regulatory mechanism between GnT-V-mediated N-
glycosylation and O-mannosylation is a new mechanism of E-cadherin functional regulation 
in cancer. Additionally, we demonstrated that this inverse relationship between the two 
forms of E-cadherin glycosylation may occur in a site-specific manner. 
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In a previous work we reported that among the four potential N-glycosylation sites of E-
cadherin, the Asn-554 is selectively occupied with β1,6 GlcNAc-branched N-glycans. 
Preventing the addition of these branched N-glycans at Asn 554 resulted in a protective 
effect on E-cadherin, precluding its functional dysregulation in cancer (17). In this study, we 
demonstrated that the presence of the deleterious branched N-glycans at Asn-554 of E-
cadherin directly affects its O-mannosylation pattern that becomes reduced. The prevention 
of this site-specific glycosylation modificationby a mutation (17), potentiates the O-
mannosylation profile of E-cadherin associated with a recover of its functions. The presence 
of β1,6 GlcNAc branched N-glycans at E-cadherin Asn-554 may introduce conformational 
changes than can induced reduced levels of O-mannosylation.  
Interestingly, this coordinated mechanism was further observed in vivo, in the stomach 
of two different MGAT5 transgenic mouse models. The MGAT5 knockout mice 
characterized by no GnT-V-mediated branched glycosylation, revealed a remarkable 
reactivity to O-mannosylated proteins. Conversely, MGAT5 overexpressing and WT mice 
with high to moderate levels of branched N-glycans showed reduced levels of O-
mannosylated glycoproteins. Moreover, and relevant from the clinical point of view, this 
interplay between the two glycosylation forms was also demonstrated in patients with 
diffuse gastric carcinoma. Gastric neoplastic cells, characterized by an aberrant E-cadherin 
expression at the cytoplasm (meaning dysfunctional), exhibited increased expression of 
β1,6 GlcNAc-branched N-glycans concomitantly with negligible levels of O-mannosyl 
glycans. The opposite was observed in normal gastric mucosa. These results strongly 
suggest that GnT-V-mediated glycosylation negatively affects protein O-mannosylation and 
vice-versa. 
Taken together, our observations support a new mechanism of E-cadherin regulation in 
cell biology. In a normal epithelial cell phenotype, E-cadherin undergoes a preferential O-
mannosylation modification, which contributes to the proper adhesive functions of E-
cadherin that are needed in homeostasis. In the ER lumen, POMT2/POMT1 complex 
catalyses the addition of mannose residues at the E-cadherin EC4 domain and along the 
Golgi apparatus E-cadherin does not undergo complex branched N-glycosylation catalysed 
by GnT-V. These predominance of O-mannosyl glycans rather than complex branched N-
glycans contribute to a protective effect on E-cadherin, precluding its functional 
dysregulation (Figure 7). During malignant transformation, these balanced levels of O-
mannosyl glycans and complex branched N-glycans in E-cadherin are lost. In a cancer cell, 
both the POMT2 gene and enzyme are downregulated and consequently the pattern of E-
cadherin O-mannosylation decreases. Further, and owing to increased MGAT5 expression 
and GnT-V activity frequently observed in a cancer cell, E-cadherin is predominantly 
targeted by GnT-V-mediated glycosylation at the Golgi apparatus, where β1,6 GlcNAc-
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branched N-glycans are added to Asn-554 of E-cadherin. The presence of these deleterious 
branched N-glycans structures together with reduced levels of O-mannosyl glycans on EC4 
ectodomain lead to loss of E-cadherin suppressive functions in cancer, thus contributing to 
tumour progression and metastases (Figure 7). 
Overall, this study proposes a newly identified mechanism of E-cadherin (dys) regulation 
in cancer that is precisely coordinated through the interplay between O-mannosylation and 
N-glycosylation machinery that operates at the protein site-specific level and with direct 
implications in cancer cell biology. Moreover, these differential patterns of E-cadherin 
glycosylation can constitute promising (glyco) biomarkers for gastric cancer patients´ clinical 
management. 
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Figure Legends 
 
Figure 1 
 
 
Figure 1. Expression of E-cadherin and O-mannosylated proteins in human normal 
gastric mucosa and diffuse gastric cancer. 
(A) Immunoexpression of E-cadherin and O-mannosylated proteins. 
Immunohistochemical analysis of the normal gastric mucosa showed E-cadherin 
expression at the basolateral cell surface, as expected. T[α1-Man] immunohistochemistry 
detecting O-mannosylated proteins revealed a remarkable staining of O-mannosylated 
proteins in the cytoplasm (arrow) and in the cell membrane (arrowhead) in the body region 
of normal gastric mucosa. No reactivity to T[α1-Man] antibody was verified in neoplastic 
cells displaying an aberrant expression of E-cadherin at the cytoplasm. However, intact 
glands of normal adjacent mucosa with E-cadherin expression at the cell membrane 
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exhibited cytoplasmic staining of O-mannosylated proteins, although less intense than 
normal gastric body mucosa. Original magnification: 600x. (B) Evaluation of POMT2 protein 
and O-mannosyl glycans expression in total lysate from normal gastric mucosa and diffuse 
gastric carcinoma tissues. A significant decreased expression of E-cadherin and POMT2 at 
the protein level was observed in diffuse gastric carcinoma. Then, to evaluate the 
expression of O-mannosyl glycans, a blotting using Con A mannose-binding lectin was 
performed. Con A lectin recognizes α-linked mannose residues from O-Man and N-
glycoproteins. So, tissue lysates were treated with PNGase F to remove N-glycans before 
the lectin blotting. As result, lower levels of O-mannosyl glycans expression were detected 
in diffuse gastric carcinoma, when compared with lysate from normal gastric mucosa. See 
also Supplementary Figure S1. 
 
Figure 2 
 
 
Figure 2. E-cadherin O-mannosylation profile decreases in poorly differentiated 
gastric cancercells.  
(A) Morphology, E-cadherin localization and cell aggregation capacity of MKN28 and 
Kato III cell lines. MKN28 cells are characterized by an epithelial morphology and the 
capacity to form large compact cell aggregates. E-cadherin immunofluorescence revealed 
a strong membranous staining in MKN28 cells (arrowhead). In contrast, Kato III cell line 
displayed a spherical morphology and a decreased cell aggregation capacity, when 
compared with MKN28 cells. Regarding the E-cadherin expression, Kato III cells exhibited 
an abnormal localization of E-cadherin at the cell-cell contacts with some cytoplasmic 
staining (arrow). White size bars ~ 5µm. (B) Evaluation of POMT2 protein and O-mannosyl 
glycans expression in the total cell lysates from MKN28 and Kato III cells. A significant 
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decrease of POMT2 protein and O-mannosyl glycans expression were observed in total cell 
lysate from Kato III, when compared with MKN28. (C) POMT2 mRNA expression. POMT2 
mRNA expression was significantly decreased in Kato III cells (P= 0,0293). The data 
presented is referred to three independent biological replicates. (D) E-cadherin O-
mannosylation decreases in poorly differentiated gastric cancer cell line. E-cadherin 
immunoprecipitated from MKN28 cells showed an increased Con A lectin reactivity, after 
PNGAse F digestion, when compared with E-cadherin immunoprecipitated from Kato III 
cells, revealing a significant increase in O-mannosyl structures modifications (4,4-fold; P= 
0,0081). Bar graphs, amounts of O-mannosyl glycans on E-cadherin were determined from 
the ratios of densities of Con A lectin reactivity (with PNGase F treatment) after 
normalization to E-cadherin. Results are described as mean ± s.d of two independent 
experiments. See also Supplementary Figure S2. 
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Figure 3 
 
 
Figure 3. POMT2 knockdown impairs E-cadherin normal localization and assembly 
of the E-cadherin-catenin complex by reducing O-mannosyl glycans on E-cadherin 
(A) POMT2 mRNA expression of MKN28 cells after POMT2 silencing by using the small 
interfering RNA (siRNA) technique. Around 75% of POMT2 silencing was observed. NS, 
non-silencing. The relative POMT2 mRNA expression of siPOMT2 cells is expressed as the 
fold increase, compared with non-silencing cells, which was taken as 1. The data presented 
is referred to three independent biological replicates. (B) Immuno- and lectin blot analysis 
of POMT2 protein and O-mannosyl glycans on total cell lysate from MKN28 cells after 
POMT2 silencing. A significant decreased of POMT2 protein and O-mannosyl glycans 
expression after POMT2 silencing were observed. (C) POMT2 silencing resulted in a 
significant decreased Con A-mannose binding lectin reactivity for the E-cadherin band after 
removal of N-glycans. Bar graphs, amounts of O-mannosyl glycans on E-cadherin were 
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determined from the ratios of densities of lectin reactivity (with PNGase F treatment) after 
normalization to E-cadherin. Results are described as mean ± s.d of two independent 
experiments. P-value= 0,05. (D) Immunofluorescence analysis of MKN28 cells after POMT2 
silencing demonstrated a reduced and incomplete E-cadherin localization at the cell 
membrane. White size bars ~ 5µm. (E) E-cadherin immunoprecipitation followed by p-120-
catenin and β-catenin western-blot after POMT2 silencing. Knockdown of POMT2 resulted 
in a decreased interaction between E-cadherin and p-120-catenin (of about 0,55-fold). No 
significant differences were observed regarding the interaction of E-cadherin with β-catenin 
after POMT2 knockdown. Amount of association were determined from the ratios of 
densities of p-120-catenin and β-catenin after normalization to E-cadherin.  
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Figure 4 
 
 
 
Figure 4. POMT2 overexpression induces the recovery of E-cadherin biological 
functions.  
(A) Confirmation of the overexpressed POMT2 mRNA transcripts in Kato III cells. The 
relative POMT2 mRNA expression is expressed as the fold increase, compared with mock 
cells, which was taken as 1. The data presented is referred to three independent biological 
replicates. (B) Overexpression of POMT2 induces an increased expression of POMT2 at 
the protein level and O-mannosyl glycans. (C) Evaluation of the impact of POMT2 
overexpression in E-cadherin O-mannosylation. POMT2 overexpression leads to a 
significant increased reactivity of E-cadherin immunoprecipitated to Con A lectin blotting 
after PNGase F treatment, suggesting an increase of E-cadherin O-mannosylation (around 
5.7- fold). Bar graphs, amounts of O-mannosyl glycans on E-cadherin were determined from 
the ratios of densities of lectin reactivity (with PNGase F treatment) after normalization to 
E-cadherin. Results are described as mean ± s.d of two independent experiments. P-value= 
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0,0376  (D) Immunofluorescence analysis of Kato III cells overexpressing POMT2 
demonstrated an increased localization of E-cadherin at the cell-cell membrane. White size 
bars ~ 5µm. (E) Evaluation of β-catenin and p-120-catenin recruitment by E-cadherin after 
POMT2 overexpression. Kato III cells overexpressing POMT2 displayed an increased 
interaction between E-cadherin and β-catenin and p-120-catenin (around 8.0-fold and 1.5-
fold, respectively). See also Supplementary Figure S3. 
 
Figure 5 
 
 
Figure 5. Interplay between GnT-V-mediated E-cadherin N-glycoylation and POMT2-
mediated E-cadherin O-mannosylation in vitro.  
(A) Evaluation of reactivity of E-cadherin immunoprecipitated from MKN28 and Kato III 
cells to Con A (after removal of N-glycans) and L-PHA lectins. E-cadherin 
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immunoprecipitaded from MKN28 cells and Kato III cells displayed a higher reactivity to 
Con A and L-PHA lectins, respectively. (B and C) Reactivity of E-cadherin 
immunoprecipitated after POMT2 knockdown (B) or POMT2 overexpression (C) to L-PHA 
lectin. Knockdown of POMT2 resulted in an increased expression of β1,6 GlcNAc branched 
N-glycans on E-cadherin (around 4.0-fold; P-value=0,0250. Bar graphs, amounts of β1,6 
GlcNAc branched N-glycans on E-cadherin were determined from the ratios of densities of 
L-PHA lectin reactivity after normalization to E-cadherin. Results are described as mean ± 
s.d of two independent experiments. (D) Overexpression of MGAT5 in MKN45 cells induced 
an increased positivity to L-PHA lectin (1,85-fold) and a decreased reactivity to Con A lectin 
after PNGase F treatment (0,52-fold). Bar graphs, amounts of β1,6 GlcNAc branched N-
glycans and O-mannosyl glycans on E-cadherin were determined from the ratios of 
densities of Con A and L-PHA lectins reactivity (with PNGase F treatment) after 
normalization to E-cadherin. Results are described as mean ± s.d of two independent 
experiments. (E) Evaluation of E-cadherin O-mannosylation and E-cadherin N-glycosylation 
mediated by GnT-V regarding site-specific N-glycosylation occupancy. E-cadherin M1 
immunoprecipitated exhibited an increased reactivity to Con A-mannose binding lectin (after 
PNGase F treatment) when compared with E-cadherin WT and M234. See also 
Supplementary Figure 4. Lectin histochemistry detecting β1,6 GlcNAc-branched N-glycans 
demonstrated higher reactivity of E-cadherin M234 to L-PHA lectin. In addition, E-cadherin 
M1 showed an increased mobility shift compared with E-cadherin WT and M234. 
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Figure 6. The interplay between GnT-V – mediated N-glycosylation and O-
mannosylation in vivo.  
Evaluation of the expression of β1,6 GlcNAc-branched structures and O-mannosylated 
proteins in the gastric mucosa of MGAT5 knockout (KO) and MGAT5 overexpressing mice 
and in human normal gastric mucosa versus gastric carcinoma. (A) Histochemical analysis 
detecting β1,6 GlcNAc-branched N-glycans showed an absent, a strong, and a moderate 
L-PHA lectin staining in the gastric mucosa of MGAT5 KO, MGAT5 transgenic, and WT 
mice, respectively. Concerning the T[α-Man] immunoreactivity, gastric mucosa from WT 
and MGAT5 transgenic mice showed low expression of O-mannosylated proteins. In 
contrast, MGAT5 KO gastric mucosa displayed a clear overexpression of O-mannosylated 
proteins. E-cadherin is expressed at the cell membrane of WT and MGAT5 KO, while in 
MGAT5 transgenic mice E-cadherin is also aberrantly expressed at the cytoplasm. (B) 
Evaluation of the interplay between N-glycosylation and protein O-mannosylation in human 
gastric mucosa. L-PHA histochemistry detecting the β1,6 GlcNAc-branched N-glycans 
catalyzed by GnT-V showed no reactivity in the human normal gastric mucosa and a marked 
positivity in neoplastic cells from gastric carcinoma. Regarding the expression of O-
mannosylated proteins, we verified that neoplastic cells from diffuse gastric carcinoma 
positive to L-PHA lectin and showing an aberrant expression of E-cadherin at the cytoplasm, 
exhibited no reactivity to T[α-Man] antibody. In contrast, cells from normal adjacent mucosa 
and human normal gastric mucosa characterized by a cell membrane localization of E-
cadherin and almost no expression of β1,6 GlcNAc-branched N-glycans, are positive to T[α-
Man]  antibody. Original magnification: 400x (B1) Evaluation of β1,6 GlcNAc-branched 
glycans expression in total lysate from normal gastric mucosa and diffuse gastric carcinoma 
tissues. An increased expression of β1,6 GlcNAc-branched N-glycans detected by L-PHA 
lectin blotting was verified in lysate from diffuse gastric carcinoma. 
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Figure 7 
 
 
 
 
Figure 7. Proposing model for the pattern of E-cadherin O-mannosylation and the 
interplay with GnT-V-mediated N-glycosylation in a cancer context.  
In a normal epithelial cell, E-cadherin undergoes a preferential O-mannosylation 
modification contributing to the proper adhesive functions of E-cadherin. In the ER lumen, 
the mannose residues are added at the E-cadherin EC4 domain by action of 
POMT2/POMT1 complex, and along the Golgi apparatus E-cadherin does not undergo 
complex branched N-glycosylation catalysed by GnT-V. The predominance of O-mannosyl 
glycans rather than complex branched N-glycans contributes to a protective effect on E-
cadherin. During malignant transformation, both the POMT2 gene and enzyme are 
downregulated and consequently the pattern of E-cadherin O-mannosylation decreases. 
Further, and owing to increased MGAT5 expression and GnT-V activity frequently observed 
in a cancer cell, E-cadherin is predominantly modified with β1,6 GlcNAc-branched N-
glycans at E-cadherin Asn-554 by action of GnT-V. The presence of these deleterious 
branched N-glycans structures combined with reduced levels of O-mannosyl glycans on 
EC4 ectodomain lead to loss of E-cadherin suppressive functions in cancer, thus 
contributing to tumour progression and metastases. 
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General Discussion 
 
Cancer is an important health problem that causes substantial patient death 
worldwide due to its incidence, prevalence and survival. Regarding gastric cancer, it is 
considered the sixth most common type of cancer, and is the fourth leading cause of cancer-
related worldwide [1]. Despite declining trend in incidence of gastric cancer, the outcomes 
of patients remain poor due to lack of effective biomarkers to early detect gastric cancer [2, 
3]. In recent years, with the development of modern biomedical technologies, several 
studies provided new insights about novel biomarkers with diagnostic and prognostic value, 
such as cancer antigen 19-9 (CA19-9) – Slea antigen, a serological marker used in gastric 
cancer [4-6]. However, owing to the low sensitivity and specificity required for early 
detection of gastric carcinoma, the discovery of new cancer specific biomarkers are needed 
in order to improve early gastric cancer diagnosis, prognosis, and the development of new 
and targeted-specific therapies. 
Advances about molecular events of gastric cancer, involving the alteration of 
pathogenesis, invasion and metastasis, have been enabling continuous efforts to identify 
molecular biomarkers for early gastric cancer diagnosis [3]. Regarding the diffuse subtype 
of gastric cancer, the main molecular carcinogenic event is the reduction of intercellular 
adhesiveness in the non-cohesive neoplastic cells [7]. Defective intercellular structures and 
cell-cell adhesion can lead to the dissociation of the primary tumour, and to the ability of 
neoplastic cells to invade surrounding tissues and to metastasize. These neoplastic 
properties have been reported to be closely related with dysregulation of the invasion 
suppressor protein- E-cadherin [8, 9].  
E-cadherin, a calcium-dependent cell-cell adhesion molecule, plays major roles in 
maintaining the epithelial tissue architecture and cell polarity [10, 11]. The downregulation 
or inactivation of E-cadherin functions in diffuse gastric cancer have been reported to occur 
through various genetic/epigenetic mechanisms such as: somatic mutations of the CDH1 
gene [12], CDH1 transcriptional silencing [13], miRNAs [14], CDH1 promoter 
hypermethylation [15, 16], and E-cadherin trafficking dysregulation [17, 18]. Besides these 
genetics and epigenetics mechanisms, E-cadherin-mediated carcinogenesis has been also 
associated with aberrant activation of signalling pathways and interaction with cytoskeleton 
components, integrin, growth-factors receptors, among others [19-22] Nevertheless, there 
is still a high percentage of human sporadic gastric cancer cases (around 70%), 
predominantly diffuse subtype, which displayed E-cadherin dysfunction that is not explained 
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by any of the aforementioned mechanisms of E-cadherin epi/genetic dysregulation [23]. 
This clinical gap of knowledge fosters the identification of an alternative mechanism 
responsible for the dysregulation of E-cadherin in a gastric cancer setting. We and others 
have been proposed an alternative post translational mechanism of E-cadherin 
dysregulation in cancer- the glycosylation [24]. Glycans are involved in fundamental 
molecular and cell biology processes occurring in cancer, such as cell-adhesion [25-27], 
cell-matrix and host-pathogen interactions [25], immune modulation [28, 29], endocytosis, 
and signal transduction [30]. Therefore, minor alterations in cell glycan signature may 
support neoplastic progression by promoting proliferation, invasion, metastasis, and 
angiogenesis [30, 31].  
E-cadherin is a glycoprotein that is post-translationally modified by glycosylation. 
During malignant transformation, E-cadherin undergoes an extensive modification on its N-
glycosylation profile which regulates the tumour cell-cell adhesion by interfering with its 
biological functions [32]. Moreover, the adhesive function of E-cadherin has been described 
to be influenced by the pattern of N-glycosylation through modifying the assembly and 
stability of the adherens junctions [33, 34]. Liwosz et al. reported that modification of E-
cadherin with complex N-glycans are associated with formation of dynamic but immature 
adherens junctions whereas reduced pattern of E-cadherin N-glycosylation promotes the 
establishment of stable adherens junctions [33]. The extension of N-glycans branching are 
thus inversely related with the epithelial adhesion [35]. According to the literature, there are 
two major forms of complex N-glycans that modify E-cadherin protein: the bisecting GlcNAc 
N-glycans structures, catalysed by GnT-III, and the β1,6 GlcNAc-branched N-glycans, 
catalysed by GnT-V [26, 27]. Pinho et al reported a regulatory mechanism between E-
cadherin expression, and the remodelling of its N-glycan structures through the enzymatic 
competition between GnT-III and GnT-V in cancer [27, 36]. 
Taking into account the literature about E-cadherin N-glycosylation mediated by 
GnT-III, some questions arise and that need to be further elucidated. Which signalling 
pathway-dependent E-cadherin is involved in the bidirectional crosstalk between E-
cadherin and the enzyme GnT-III? Furthermore, concerning the GnT-V-mediated E-
cadherin N-glycosylation, predominant in human gastric cancer patients, which is the 
precise N-glycosylation site of E-cadherin modified with these deleterious N-glycans? 
Having the new evidences about E-cadherin O-mannosylation in homeostasis, how does 
O-mannosylation contribute to the E-cadherin regulation in cancer? 
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Chapter II- Insulin/IGF-I Signalling Pathways Enhances Tumour Cell Invasion through 
Bisecting GlcNAc N-glycans Modulation. An Interplay with E-Cadherin 
E-cadherin and GnT-III expression are involved in a bidirectional cross-talk where E-
cadherin mediated cell-cell adhesion regulates MGAT3 transcription [27], increasing GnT-
III expression and its products (bisecting GlcNAc N-glycans) on E-cadherin [27, 37, 38], 
which in turn downregulates the tyrosine phosphorylation of β-catenin, contributing to 
suppression of tumour invasion and metastasis [39]. However, it remained to identify the 
signalling pathway (E-cadherin dependent) involved in this functional crosstalk. Therefore, 
the chapter II of this PhD thesis aimed to assess the underlying signalling pathway involved 
in the regulation of the bisecting GlcNAC N-glycans in the process of tumour progression 
of epithelial cells.  
Phosphoproteome analysis showed that MDA-MB-435 cancer cells, that 
endogenously lacks E-cadherin expression, displayed a significant increased 
phosphorylation of insulin receptor (IR)/ IGF-I receptor (IGF-IR) receptors tyrosine kinase 
(RTK). Moreover, after exogenous E-cadherin expression, IR/IGF-IR phosphorylation levels 
are remarkably inhibited. These results suggested an inhibitory effect of E-cadherin in the 
activity of Insulin and IGF-I signalling pathways. According to the literature, Insulin/IGF-I 
signalling pathway has been strongly associated with malignant transformation [40], being 
also related with loss of epithelial features of carcinoma cells [41, 42]. IGF-I was reported 
to increase the invasive potential inducing TGF-β1-mediated EMT and decreased E-
cadherin expression [41]. Besides modulation of Insulin/IGF-I signalling pathway, 
decreased phosphorylation levels of ERK ½ were also verified upon E-cadherin 
overexpression. So, E-cadherin expression in MDA-MD-435 cancer cells induces a 
downregulation of Ras/Raf/MEK/ERK downstream signalling pathway through the 
significant decreased activity of the IR/IGF-IR signalling.  
More importantly, we further demonstrated that the IR/IGF-IR signalling pathway 
also plays a role in the modulation of the GnT-III-mediated N-glycosylation in general and 
specifically on E-cadherin. Stimulation of IR/IGF-IR signalling induced a decreased overall 
expression of bisecting GlcNAc N-glycans and specifically on E-cadherin glycoprotein, 
promoting a mislocalization of E-cadherin into the cytoplasm. These results suggest that 
the bidirectional crosstalk between E-cadherin and bisecting GlcNAc N-glycans is mediated 
by the IR/IGF-IR signalling pathway. Furthermore, we observed that IR/IGF-IR activation 
also modulates the expression of epithelial and mesenchymal markers and induces 
increased capacity of tumour cell invasion.  
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In summary, the work presented in chapter II supported a close interplay between 
E-cadherin, its glycosylation with bisecting GlcNAc N-glycans and IR/IGF-IR signalling 
pathway in the process of tumour cell invasion, further clarifying the positive feedback loop 
established between E-cadherin and GnT-III that modulates E-cadherin-mediated cell-cell 
adhesion. In the absence of IR/IGF-IR signalling, E-cadherin induces the expression of 
bisecting GlcNAc N-glycans overall and specifically on E-cadherin, contributing to the 
stabilization of E-cadherin at the cell membrane, and at last promoting tumour suppression. 
In a cancer context, upregulation of Ras/Raf/MEK/ERK induces IR/IGF-IR signalling 
activation which in turn decrease the expression of bisecting GlcNAc N-glycans in general 
and specifically on E-cadherin, leading to E-cadherin mislocalization into the cytoplasm and 
the expression of mesenchymal markers that favour tumour cell invasion.  
The further contribution of GnT-III-mediated N-glycosylation in tumour suppression 
was also supported with our previous observations showing an inhibition of E-cadherin 
endocytosis, delayed turnover of E-cadherin at the cell surface, and improvement of 
intercellular adhesion by recruitment of catenins [26]. Furthermore, MGAT3 glycogene 
expression and GnT-III-mediated E-cadherin glycosylation also contribute to an epithelial-
like phenotype that prevents the EMT process [43, 44].  
 
Chapter III - Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its 
critical function in gastric cancer 
 
The enzymatic activity of GnT-V is known to be upregulated in gastric cancer [45], 
contributing to cancer cell invasion and metastasis [46]. Pinho et al reported that GnT-V-
mediated E-cadherin N-glycosylation interfere with β-catenin and p120-catenin recruitment, 
disturbing the stability of the adherens junctions and impairing normal E-cadherin cellular 
localization, ultimately compromising the E-cadherin-mediated cell-cell adhesion [26]. In 
addition, studies demonstrated that β1,6 GlcNAc  branched N-glycans on cadherins 
reduces the N-cadherin clustering at the cell surface and compromises the outside-in-signal 
transduction-pathway of ERK-mediated by N-cadherin [47], contributing to increased cell 
migration and invasion [48]. In a gastric cancer setting in which E-cadherin display aberrant 
expression not due to genetic and structural alterations, the gastric cancer cells exhibit an 
increased expression of β1,6 GlcNAc branched N-glycans in general and specifically on E-
cadherin [26]. Taken together is of utmost relevance for the clinic the precise identification 
and characterization of the site-specific E-cadherin N-glycans occupancy that functionally 
impact the E-cadherin functions. The study presented in chapter III intended to determine 
General Discussion 
135 
 
the role that site-specific glycosylation of E-cadherin has in its defective function in a gastric 
cancer context.  
In this study, we demonstrated that human patients with diffuse gastric cancer 
displayed an aberrant expression of E-cadherin which is specifically modified with β1,6 
GlcNAc N-glycans structures that is correlated with a poorer survival rate of patients, when 
compared with diffuse gastric cancer patients without aberrant modifications mediated by 
GnT-V on E-cadherin. This specific E-cadherin aberrant glycoform in vivo was thus showed 
to be important in the pathogenesis of gastric carcinoma and in the survival rates of patients.  
The human E-cadherin ectodomain comprises four potential N-glycosylation sites: 
two putative sites at the EC4 subdomain (Asn-554 and Asn-566) and the remaining two 
potential sites at the EC5 subdomain (Asn-618 and Asn-633) [36]. Previous reports 
demonstrated that the N-glycan at Asn-633 is required for E-cadherin expression, folding 
and trafficking [49]. Unglycosylation of E-cadherin at this specific site induces its arrest in 
ER as a misfolded protein being targeted via ERAD pathway [49]. In turn, N-glycans situated 
at Asn-554 and at Asn-566 in human breast carcinoma cell line were described to be 
important for the cell cycle progression [50], and for the adhesive function of E-cadherin 
[34].  
In the study presented on chapter III, an in silico bioinformatics analysis combined 
with the in vitro site-directed mutagenesis approach in a gastric cancer cell line revealed 
that among the four potential N-glycosylation sites available in the extracellular domain of 
E-cadherin, the sites Asn-554 and Asn-633 are N-glycosylated and the other two potential 
sites (Asn-566 and Asn-618) are not occupied with N-glycans. Furthermore, the enzymatic 
digestion approach showed that Asn-554 displayed complex type N-glycans while Asn- 633 
is occupied with high mannose N-glycans. Ultimately, the glycomics analysis by advanced 
mass spectrometry approach corroborated these results revealing that E-cadherin WT and 
M234 showed higher levels of sialylated and complex-type N-glycans. Our observations 
combined with the literature indicated that the E-cadherin N-glycan site occupancy is tissue 
specific.  
Importantly, we further identified that Asn-554 is the selected site modified with β1,6 
GlcNAc-branched N-glycans, catalysed by GnT-V, being the key site for the functional 
dysregulation of E-cadherin in gastric tumour cells. This site-specific N-glycosylation 
mediated by GnT-V compromises the cis-dimerization capability, decreases the rate of cell-
cell aggregation and interferes with the molecular assembly and stability of the adhesion 
complexes. Consistent with our observations, several reports demonstrated that 
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modification of E-cadherin with β1,6 GlcNAc-branched N-glycans has major deleterious 
effects on E-cadherin-mediated cell-cell adhesion leading to the impairment of the stability 
and competence of the intracellular adhesive complex [26]. Concerning the cadherin-
dependent adhesive interactions established between cadherin molecules, it was reported 
that the presence of β1,6 GlcNAc-branched N-glycans at the EC2 and EC3 subdomains of 
N-cadherin affects the potential of cis-dimerization [51, 52]. 
Furthermore, this study demonstrated that locking the specific N-glycosylationsite 
modified by GnT-V either by Asn-554 mutation or by silencing of GnT-V, resulted in a 
protective effect, by precluding the functional impairment of E-cadherin through the recovery 
of E-cadherin expression at the cell membrane, increased capacity of cis-dimerization and 
increased interaction with catenins. In accordance, Guo et al demonstrated that removal of 
β1,6 GlcNAc-branched N-glycans at N-cadherin extracellular domain resulted in an 
increased N-cadherin cis-dimerization capability [52]. 
The precise molecular mechanism by which N-glycans affects the molecular 
organization of E-cadherin-catenin complexes on the cytoplasmic side need to be carefully 
addressed. On the E-cadherin extracellular domains, N-glycans may interfere with the 
dimerization by steric hindrance leading to modulation of homotypic interactions, which 
consequently governs the dynamics of intracellular binding [53, 54]. Langer et al suggested 
that initial adhesion conferred by prevalence of cis dimers on cell membrane and modulated 
by N-glycosylation may alter the kinetics of cadherin-mediated intercellular binding. 
enhancing further additional cadherin interactions [51]. Taken together, these observations 
suggested that the β1,6 GlcNAc-branched N-glycans at E-cadherin Asn-554 may introduce 
conformational changes which reduced cis interactions decreasing the intracellular 
adhesive interactions. Nevertheless, removal of these specific N-glycans at E-cadherin Asn-
554 by site –directed mutagenesis (E-cadherin M1) increased cis interactions that are 
followed by enhanced interaction with catenins. 
Besides the contribution of β1,6 GlcNAc-branched N-glycans at E-cadherin Asn-554 
on E-cadherin adhesive functions, the high mannose glycans present at E-cadherin Asn-
633 may also play an important role on E-cadherin, more specifically on E-cadherin protein 
folding, as previously described [49]. Therefore, to achieve proper E-cadherin-mediated 
cell-cell adhesion, it is crucial the existence of high mannose glycans at E-cadherin Asn-
633 and the absence of β1,6 GlcNAc-branched N-glycans at E-cadherin Asn-554. The 
impairment of this site-specific E-cadherin N-glycosylation pattern may affect the proper 
folding and the adhesive properties of E-cadherin. It is also important to note that E-cadherin 
M234, which display β1,6 GlcNAc-branched N-glycans at E-cadherin Asn-554 and absence 
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of high mannose N-glycans at E-cadherin Asn-633 exhibited a recovery of E-cadherin 
cellular localization and increased cis-dimerization after GnT-V silencing. This observation 
opens new questions about which mechanisms operate at Asn-554 that enable such 
recovery. Perhaps, action of other glycosyltransferases at each specific site may confer 
compensatory effects that lead to a proper N-glycosylation pattern of E-cadherin. 
These in vitro results were further corroborated in the different MGAT5 transgenic 
mouse models. MGAT5 overexpressing mice display an abnormal pattern of E-cadherin 
cellular expression in gastric epithelial cells that overexpress β1,6 GlcNAc-branched N-
glycans, resembling the mutant M234 or M4. In contrast, E-cadherin from MGAT5 knockout 
mice, localized at the basolateral cell membrane, resembles the M1 mutant. 
The present study contributed to understand how site-specific E-cadherin 
glycosylation modification can directly modulate E-cadherin-mediated cell-cell adhesion in 
cancer development and progression. Interestingly, from the clinical point of view, 
preventing E-cadherin site-specific glycosylation modifications was shown to improve its 
tumour suppressive functions in gastric cancer. This study contributes to the discovery of a 
promising glycobiomarker (site-specific) for improving early diagnosis of gastric cancer 
patients as well as for the development of targeted-specific therapeutic strategies. 
Chapter IV – O-Mannosylation and N-glycosylation: two coordinated mechanisms 
regulating the critical functions of E-cadherin in cancer 
  
E-cadherin was recently identified as a major target of O-mannosylation. Vester-
Christensen et al. reported 37 members of the cadherin superfamily with O-Man glycosites 
[55]. The O-man-modified sites identified are situated in the EC domains EC2-5 of both 
classic type 1 and 2 cadherins and appear to display evolutionary conservation among 
cadherins. No O-Man-modified sites were identified in the EC1 domain of cadherins [55]. 
Concerning the biological functions of O-Man glycans on cadherin family, Lommel et 
al demonstrated that O-mannosylation of E-cadherin is required for the morula to blastocyst 
transition before implantation [56]. Prevention of O-mannosylation during the embryo 
development resulted in the arrest of morula-to-blastocyst transition process, being the 
absence of O-Man correlated with the disruption of E-cadherin at the adhesion sites. 
Furthermore, it was demonstrated that O-mannosylation is essential for E-cadherin-
mediated cell adhesion in homeostasis. Moreover, it was showed that in a normal context, 
the O-linked mannose residues of E-cadherin are not elongated further [56]. Single O-
mannosyl glycans were also reported in noncanonical heart cadherin from rabbit skeletal 
muscle [57]. Taking into consideration the fundamental role of glycosylation in regulating E-
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cadherin functions in cancer, the understanding of how O-mannosylation contributes to the 
E-cadherin regulation in cancer is of utmost importance and remains unknown. The present 
work (chapter IV) aimed to unravel the role of O-mannosylation pattern in a gastric cancer 
context and its effects in the regulation of the biological functions of E-cadherin. Moreover, 
we aimed to elucidate the interplay between the two major types of E-cadherin post-
translational modifications, N-glycosylation and O-mannosylation, and its relevance in 
cancer cell biology.  
In the present work we demonstrated a reduced pattern of overall protein O-
mannosylation in diffuse gastric cancer patients, concomitantly with an aberrant expression 
of E-cadherin into the cytoplasm. Furthermore, we showed that E-cadherin is highly O-
mannosylated in a well differentiated context and its O-mannosylation profile remarkably 
decreases in a poorly-differentiated gastric cancer phenotype. Interestingly, poorly-
differentiated cancer cells also display a decreased expression of POMT2 both at transcript 
and protein level. Concerning the biological functions of E-cadherin, the increased 
expression of O-mannosyl glycans on E-cadherin, by POMT2 overexpression, leads to a 
recovery of E-cadherin expression at the cell membrane in poorly-differentiated gastric 
cancer cell line, increasing the stability of the adherens junctions. In contrast, reduced 
expression of O-mannosyl glycans on E-cadherin, by POMT2 silencing, induces a 
mislocalization of E-cadherin and impairment of the assembly of the adhesion complex. 
Therefore, E-cadherin is O-mannosylated in homeostasis being crucial for E-cadherin-
mediated cell-cell adhesion [56], and this post-translational modification is impaired during 
the acquisition of a malignant phenotype compromising the E-cadherin mediated adhesive 
properties.  
Importantly, this work also provides new evidences about the interplay between O-
mannosylation and GnT-V-mediated N-glycosylation in human gastric cancer patients. 
Neoplastic cells of human diffuse gastric carcinomas, characterized by a dysregulation of 
E-cadherin not explained by epi/genetic mechanisms, express high levels of β1,6 GlcNAc 
branched N-glycans and significant reduced levels of O-mannosylated proteins. The 
opposite was observed in human normal gastric mucosa displaying almost no expression 
of β1,6 GlcNAc branched N-glycans and high levels of expression of O-mannosylated 
proteins. Moreover, genetic manipulation of MGAT5 gene in mice models revealled that 
MGAT5 expression affects the expression of O-mannosylated proteins. This study provides 
for the first time direct evidences about the interplay of MGAT5 expression and the O-
mannosylation pathway. Furthermore, in an in vitro context, we showed that genetic 
manipulation of POMT2, either by POMT2 overexpression or silencing, has an impact on 
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GnT-V-mediated N-glycosylation, and particularly on E-cadherin. In turn, the 
overexpression of GnT-V induces a significant decrease of O-mannosyl glycans on E-
cadherin. Taken together, a mechanistic interplay between O-mannosylation and GnT-V-
mediated N-glycosylation pathways is herein postulated. In accordance, there is a 
competition between PMTs and OST enzyme complexes for the donor substrate [58, 59]. 
Moreover, O-mannosylation has been reported to precede the N-glycosylation process 
having the potential to alter the N-glycosylation site occupancy [60]. 
Concerning the site-specific E-cadherin glycosylation and taking into account the 
close proximity of the potential N-glycosylation and O-mannosylation sites of E-cadherin, 
we showed that preventing E-cadherin Asn-554 from receiving the β1,6 GlcNAc branched 
N-glycans structures results in an increased O-mannosylation profile of E-cadherin 
precluding its functional dysregulation and contributing to tumour suppression (chapter III + 
chapter IV), further supporting the existence of a coordinated interplay between O-
mannosylation and N-glycosylation on the regulation of E-cadherin functions.  
Under normal physiological circumstances, E-cadherin is primarily modified with high 
mannose/ hybrid N-glycans [53, 54], specifically on E-cadherin Asn-633 (chapter III), further 
undergoing O-mannosylation [56]. This specific glycosylation profile of E-cadherin 
contributes to a stable E-cadherin mediated cell-cell adhesion, essential in homeostasis. 
During malignant transformation, the glycosylation profile of E-cadherin undergoes 
significant changes [32]. E-cadherin exhibits complex branched N-glycans [33], specifically 
β1,6 GlcNAc branched N-glycans on E-cadherin Asn-554 (chapter III). Furthermore, taking 
into consideration the overexpression of MGAT5 in a cancer context  and having evidences 
that MGAT5 affects the O-mannosylation pathway, the addition of O-Man residues to E-
cadherin in the ER is impaired (chapter IV), and along the Golgi complex E-cadherin is 
predominantly modified by GnT-V- mediated N-glycosilation at Asn-554 (chapter III). The 
presence of β1,6 GlcNAc branched N-glycans on E-cadherin Asn-554 combined with the 
reduced levels of O-mannosyl glycans on E-cadherin impairs E-cadherin biological 
functions contributing to malignancy. Prevention of E-cadherin Asn-554 modification by 
GnT-V potentiates the O-mannosylation profile of E-cadherin associated with a recover of 
its functions. These two studies (chapter III and IV) enabled the disclosure of E-cadherin 
glycosignature in gastric cancer, regarding the N- and O-mannosyl glycans, which 
constitute promising glycobiomarkers for gastric cancer patients. 
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Concluding Remarks 
The general aim of the present thesis was to contribute to the disclosure of the E-
cadherin glycosignature in cancer and thus to contribute to the clinical explanation for those 
gastric carcinoma cases with E-cadherin dysfunction but without known epi/genetic 
alterations which encompasses the majority of the diffuse subtype gastric cancer. To 
achieve this general goal, we set specific aims from which resulted the following main 
conclusions. 
1. The pattern of E-cadherin glycosylation undergoes significant alterations with 
implication for its biological functions, namely N-glycosylation mediated by GnT-III. E-
cadherin has been reported to have an important role in the regulation of bisecting GlcNAc 
N-glycans expression, by a positive bidirectional crosstalk.  
In this PhD thesis, we have found that exogenous E-cadherin expression inhibits IR, 
IGF-IR and ERK ½ phosphorylation. The activation of these signalling pathways results in 
E-cadherin mislocalization and decreased expression of bisecting GlcNAc N-glycans. 
Furthermore, insulin/IGF-I signalling induces a mesenchymal-like phenotype and increases 
the invasion potential of cancer cells. Altogether, our results provide new evidences about 
a novel networking player, insulin and IGF-I signalling, in the modulation of bisecting 
GlcNAc N-glycans expression on E-cadherin and its implications in cancer cell behaviour. 
2. Human diffuse gastric cancer patients exhibited dysfunction of E-cadherin at least 
probably due to a markedly modification with β1,6 GlcNAc branched N-glycans, that 
contributes to the pathogenesis of gastric cancer.  
 
In this doctoral thesis, we have characterized in detail the occupancy of the potential 
N-glycosylation sites of E-cadherin. Among the four potential N-glycosylation sites, only 
Asn-554 and Asn-633 were found to be occupied with complex and high mannose/hybrid- 
type N-glycans, respectively in a gastric cancer context. We have also identified that Asn-
554 is the key site that is selectively modified with β1,6 GlcNAc branched N-glycans, 
catalysed by GnT-V. This site-specific glycosylation affects the E-cadherin biological 
functions in gastric cancer cells by interfering E-cadherin cellular localization, cis-dimer 
formation, assembly of the E-cadherin-catenin complex, and cell-cell aggregation capacity. 
Furthermore, we have shown that prevention of this deleterious glycan modification, either 
by site directed mutagenesis or GnT-V silencing, the E-cadherin biological functions are 
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recovered. Altogether, our results provide a functional and structural mapping of E-cadherin 
N-glycans in gastric cancer, contributing to the characterization of the role of each N-glycan 
(in a site-specific manner) in the regulation of E-cadherin biological functions in cancer. 
3. Owing to the newly described O-mannosylation of E-cadherin in homeostasis, we 
further explored the role of O-mannosyl glycans on E-cadherin in a gastric cancer context 
and the interplay between O-mannosylation and GnT-V-mediated N-glycosylation.  
 
We have shown that the overall protein O-mannosylation profile of human diffuse 
gastric cancer patients is remarkably reduced. Moreover, the E-cadherin O-mannosylation 
decreases during the acquisition of a poorly-differentiated gastric cancer phenotype, with 
effects in the impairment of its biological functions. Furthermore, we have verified that GnT-
V-mediated N-glycosylation negatively affect protein O-mannosylation. Altogether, our 
results proposes the identification of O-mannosylation process as a novel mechanism of E-
cadherin dysregulation in cancer that is precisely coordinated through the interplay between 
O-mannosylation and N-glycosylation machinery.
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Future Perspectives 
The present work provides evidences supporting that the dysregulation of E-
cadherin in human gastric cancer is also explained by post-translational modifications 
through glycosylation. The pattern of E-cadherin glycosylation can be therefore considered 
as a potential clinical biomarker with promising applications to the early diagnosis, 
prognosis and also as appealing targets for the development of new therapeutic strategies 
in a gastric cancer setting. The identification of E-cadherin glycoprotein modified specifically 
with β1,6 GlcNAc branched N-glycans, being correlated with poorer survival (chapter III), 
followed by a remarkably reduction of protein O-mannosylation profile (chapter IV) could 
serve as a promising diagnostic and prognostic tool  with utility in the clinical management 
of gastric cancer patients (from functional glycomics to clinical applications). 
Furthermore, having identified the specific N-glycosylation site of E-cadherin 
modified with the deleterious N-glycans in a gastric cancer context, open the possibility for 
the production of (bi-functional) antibodies that specifically direct against Asn-554- β1,6 
GlcNAc branched N-glycans- conjugated epitope, detecting specifically the deleterious E-
cadherin glycoforms, envisioning a promise diagnostic tool. In addition, the disclosure of the 
precise E-cadherin glycopeptide responsible for the defective functions of E-cadherin in 
gastric cancer might also be viewed in future as an appealing therapeutic target, through 
preventing this site-specific N-glycan occupancy. 
Interestingly from the clinical point of view is the fact that several reports have 
demonstrated that the extracellular domain of E-cadherin is frequently cleaved by proteases 
to generate a soluble ectodomain fragment which has been found to be increased in the 
serum of cancer patients. Considering that the E-cadherin glycoforms modified with β1,6 
GlcNAc N-glycans predominate in gastric carcinoma, it would be very interesting to further 
explore the presence of such aberrant E-cadherin glycoform in the serum of cancer patients.
References 
143 
 
References 
1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015). Cancer incidence and 
mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J 
Cancer, 136,  E359-86. 
2. Durães, C., Almeida, G., Seruca, R., et al. (2014). Biomarkers for gastric cancer: 
prognostic, predictive or targets of therapy? Virchows Archiv, 464,  367-378. 
3. Carneiro, P., Figueiredo, J., Bordeira-Carriço, R., et al. (2013). Therapeutic targets 
associated to E-cadherin dysfunction in gastric cancer. Expert Opinion on Therapeutic 
Targets, 17,  1187-1201. 
4. Kato, K., Taniguchi, M., Kawakami, T., et al. (2011). Gastric Cancer with a Very High 
Serum CA 19-9 Level. Case Reports in Gastroenterology, 5,  258-261. 
5. Cidón, E. and Bustamante, R. (2011). Gastric Cancer: Tumor Markers as Predictive 
Factors for Preoperative Staging. Journal of Gastrointestinal Cancer, 42,  127-130. 
6. Reis, C.A., Osorio, H., Silva, L., et al. (2010). Alterations in glycosylation as 
biomarkers for cancer detection. Journal of Clinical Pathology, 63,  322-329. 
7. Lordick, F., Allum, W., Carneiro, F., et al. (2014). Unmet needs and challenges in 
gastric cancer: the way forward. Cancer Treat Rev, 40,  692-700. 
8. Carneiro, P., Fernandes, M.S., Figueiredo, J., et al. E-cadherin dysfunction in gastric 
cancer - Cellular consequences, clinical applications and open questions. FEBS Letters, 
586,  2981-2989. 
9. Jiang, W.G., Sanders, A.J., Katoh, M., et al. Tissue invasion and metastasis: 
Molecular, biological and clinical perspectives. Seminars in Cancer Biology,  
10. van Roy, F. and Berx, G. (2008). The cell-cell adhesion molecule E-cadherin. Cell 
Mol Life Sci, 65,  3756-88. 
11. Halbleib, J.M. and Nelson, W.J. (2006). Cadherins in development: cell adhesion, 
sorting, and tissue morphogenesis. Genes Dev, 20,  3199-214. 
12. Berx, G., Becker, K.F., Hofler, H., et al. (1998). Mutations of the human E-cadherin 
(CDH1) gene. Hum Mutat, 12,  226-37. 
13. Alves, C.C., Carneiro, F., Hoefler, H., et al. (2009). Role of the epithelial-
mesenchymal transition regulator Slug in primary human cancers. Front Biosci (Landmark 
Ed), 14,  3035-50. 
14. Paterson, E.L., Kolesnikoff, N., Gregory, P.A., et al. (2008). The microRNA-200 
family regulates epithelial to mesenchymal transition. ScientificWorldJournal, 8,  901-4. 
References 
144 
 
15. Machado, J.C., Oliveira, C., Carvalho, R., et al. (2001). E-cadherin gene (CDH1) 
promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene, 
20,  1525-8. 
16. Oliveira, C., Sousa, S., Pinheiro, H., et al. (2009). Quantification of epigenetic and 
genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. 
Gastroenterology, 136,  2137-48. 
17. van Hengel, J. and van Roy, F. (2007). Diverse functions of p120ctn in tumors. 
Biochim Biophys Acta, 1773,  78-88. 
18. Simoes-Correia, J., Figueiredo, J., Oliveira, C., et al. (2008). Endoplasmic reticulum 
quality control: a new mechanism of E-cadherin regulation and its implication in cancer. 
Hum Mol Genet, 17,  3566-76. 
19. Cavallaro, U. and Christofori, G. (2004). Cell adhesion and signalling by cadherins 
and Ig-CAMs in cancer. Nat Rev Cancer, 4,  118-132. 
20. Giles, R.H., van Es, J.H., and Clevers, H. (2003). Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1653,  1-
24. 
21. Reynolds, A.B. and Roczniak-Ferguson, A. (0000). Emerging roles for p120-catenin 
in cell adhesion and cancer. Oncogene, 23,  7947-7956. 
22. Christofori, G. (2003). NEW EMBO MEMBER’S REVIEW: Changing neighbours, 
changing behaviour: cell adhesion molecule-mediated signalling during tumour 
progression. The EMBO Journal, 22,  2318-2323. 
23. Corso, G., Carvalho, J., Marrelli, D., et al. (2013). Somatic Mutations and Deletions 
of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of 
Clinical Oncology, 31,  868-875. 
24. Pinho, S.S., Carvalho, S., Marcos-Pinto, R., et al. (2013). Gastric cancer: adding 
glycosylation to the equation. Trends Mol Med, 19,  664-76. 
25. Zhao, Y., Sato, Y., Isaji, T., et al. (2008). Branched N-glycans regulate the biological 
functions of integrins and cadherins. FEBS Journal, 275,  1939-1948. 
26. Pinho, S.S., Figueiredo, J., Cabral, J., et al. (2013). E-cadherin and adherens-
junctions stability in gastric carcinoma: Functional implications of glycosyltransferases 
involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. 
Biochimica et Biophysica Acta (BBA) - General Subjects, 1830,  2690-2700. 
27. Pinho, S.S., Reis, C.A., Paredes, J., et al. (2009). The role of N-
acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-
cadherin. Human Molecular Genetics, 18,  2599-2608. 
28. Liu, F.-T. and Rabinovich, G.A. (2005). Galectins as modulators of tumour 
progression. Nat Rev Cancer, 5,  29-41. 
References 
145 
 
29. Ohtsubo, K. and Marth, J.D. Glycosylation in Cellular Mechanisms of Health and 
Disease. Cell, 126,  855-867. 
30. Pinho, S.S. and Reis, C.A. (2015). Glycosylation in cancer: mechanisms and clinical 
implications. Nat Rev Cancer, 15,  540-555. 
31. Hakomori, S. (2002). Glycosylation defining cancer malignancy: New wine in an old 
bottle. Proceedings of the National Academy of Sciences of the United States of America, 
99,  10231-10233. 
32. Pinho, S.S., Osório, H., Nita-Lazar, M., et al. (2009). Role of E-cadherin N-
glycosylation profile in a mammary tumor model. Biochemical and Biophysical Research 
Communications, 379,  1091-1096. 
33. Liwosz, A., Lei, T., and Kukuruzinska, M.A. (2006). N-glycosylation affects the 
molecular organization and stability of E-cadherin junctions. J Biol Chem, 281,  23138-49. 
34. Zhao, H., Liang, Y., Xu, Z., et al. (2008). N-Glycosylation affects the adhesive 
function of E-Cadherin through modifying the composition of adherens junctions (AJs) in 
human breast carcinoma cell line MDA-MB-435. Journal of Cellular Biochemistry, 104,  162-
175. 
35. Vagin, O., Tokhtaeva, E., Yakubov, I., et al. (2008). Inverse correlation between the 
extent of N-glycan branching and intercellular adhesion in epithelia: contribution of the 
Na,K-ATPase β(1) subunit. The Journal of biological chemistry, 283,  2192-2202. 
36. Pinho, S.S., Seruca, R., Gartner, F., et al. (2011). Modulation of E-cadherin function 
and dysfunction by N-glycosylation. Cell Mol Life Sci, 68,  1011-20. 
37. Akama, R., Sato, Y., Kariya, Y., et al. (2008). N-acetylglucosaminyltransferase III 
expression is regulated by cell-cell adhesion via the E-cadherin–catenin–actin complex. 
PROTEOMICS, 8,  3221-3228. 
38. Iijima, J., Zhao, Y., Isaji, T., et al. (2006). Cell-Cell Interaction-dependent Regulation 
of N-Acetylglucosaminyltransferase III and the Bisected N-Glycans in GE11 Epithelial Cells: 
INVOLVEMENT OF E-CADHERIN-MEDIATED CELL ADHESION. Journal of Biological 
Chemistry, 281,  13038-13046. 
39. Kitada, T., Miyoshi, E., Noda, K., et al. (2001). The Addition of Bisecting N-
Acetylglucosamine Residues to E-cadherin Down-regulates the Tyrosine Phosphorylation 
of β-Catenin. Journal of Biological Chemistry, 276,  475-480. 
40. Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat 
Rev Cancer, 8,  915-928. 
41. Walsh, L.A. and Damjanovski, S. (2011). IGF-1 increases invasive potential of MCF 
7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to 
mesenchymal transition. Cell Communication and Signaling : CCS, 9,  10-10. 
References 
146 
 
42. Lee, J., Ju, J., Park, S., et al. (2011). Inhibition of IGF-1 Signaling by Genistein: 
Modulation of E-Cadherin Expression and Downregulation of β-Catenin Signaling in 
Hormone Refractory PC-3 Prostate Cancer Cells. Nutrition and Cancer, 64,  153-162. 
43. Pinho, S.S., Oliveira, P., Cabral, J., et al. (2012). Loss and Recovery of MGAT3 and 
GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-
Mesenchymal-Epithelial Transitions. PLoS ONE, 7,  e33191. 
44. Xu, Q., Isaji, T., Lu, Y., et al. (2012). Roles of N-Acetylglucosaminyltransferase III in 
Epithelial-to-Mesenchymal Transition Induced by Transforming Growth Factor β1 (TGF-β1) 
in Epithelial Cell Lines. The Journal of Biological Chemistry, 287,  16563-16574. 
45. Tian, H., Miyoshi, E., Kawaguchi, N., et al. (2008). The Implication of N-
Acetylglucosaminyl- transferase V Expression in Gastric Cancer. Pathobiology, 75,  288-
294. 
46. Granovsky, M., Fata, J., Pawling, J., et al. (2000). Suppression of tumor growth and 
metastasis in MGAT5-deficient mice. Nat Med, 6,  306-312. 
47. Guo, H.-B., Lee, I., Kamar, M., et al. (2003). N-Acetylglucosaminyltransferase V 
Expression Levels Regulate Cadherin-associated Homotypic Cell-Cell Adhesion and 
Intracellular Signaling Pathways. Journal of Biological Chemistry, 278,  52412-52424. 
48. Zhao, Y., Nakagawa, T., Itoh, S., et al. (2006). N-Acetylglucosaminyltransferase III 
Antagonizes the Effect of N-Acetylglucosaminyltransferase V on α3β1 Integrin-mediated 
Cell Migration. Journal of Biological Chemistry, 281,  32122-32130. 
49. Zhou, F., Su, J., Fu, L., et al. (2008). Unglycosylation at Asn-633 made extracellular 
domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then 
sequentially degraded by ERAD. Glycoconjugate Journal, 25,  727-740. 
50. Zhao, H., Sun, L., Wang, L., et al. (2008). N-glycosylation at Asn residues 554 and 
566 of E-cadherin affects cell cycle progression through extracellular signal-regulated 
protein kinase signaling pathway. Acta Biochimica et Biophysica Sinica, 40,  140-148. 
51. Langer, M.D., Guo, H., Shashikanth, N., et al. (2012). N-glycosylation alters 
cadherin-mediated intercellular binding kinetics. J Cell Sci, 125,  2478-85. 
52. Guo, H.B., Johnson, H., Randolph, M., et al. (2009). Regulation of homotypic cell-
cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 
domains. J Biol Chem, 284,  34986-97. 
53. Varelas, X., Bouchie, M.P., and Kukuruzinska, M.A. (2014). Protein N-glycosylation 
in oral cancer: Dysregulated cellular networks among DPAGT1, E-cadherin adhesion and 
canonical Wnt signaling. Glycobiology, 24,  579-591. 
54. Nita-Lazar, M., Noonan, V., Rebustini, I., et al. (2009). Overexpression of DPAGT1 
leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. 
Cancer research, 69,  5673-5680. 
References 
147 
 
55. Vester-Christensen, M.B., Halim, A., Joshi, H.J., et al. (2013). Mining the O-
mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proc 
Natl Acad Sci U S A, 110,  21018-23. 
56. Lommel, M., Winterhalter, P.R., Willer, T., et al. (2013). Protein O-mannosylation is 
crucial for E-cadherin–mediated cell adhesion. Proceedings of the National Academy of 
Sciences of the United States of America, 110,  21024-21029. 
57. Winterhalter, P.R., Lommel, M., Ruppert, T., et al. O-glycosylation of the non-
canonical T-cadherin from rabbit skeletal muscle by single mannose residues. FEBS 
Letters, 587,  3715-3721. 
58. Loibl, M. and Strahl, S. (2013). Protein O-mannosylation: what we have learned from 
baker's yeast. Biochim Biophys Acta, 1833,  2438-46. 
59. Loibl, M., Wunderle, L., Hutzler, J., et al. (2014). Protein O-mannosyltransferases 
associate with the translocon to modify translocating polypeptide chains. J Biol Chem, 289,  
8599-611. 
60. Ecker, M., Mrsa, V., Hagen, I., et al. (2003). O-mannosylation precedes and 
potentially controls the N-glycosylation of a yeast cell wall glycoprotein. EMBO Rep, 4,  628-
32. 
 

 149 
 
Chapter VI 
Gastric Cancer: adding glycosylation 
to the equation

Gastric cancer: adding glycosylation to
the equation
Salome´ S. Pinho1,2, Sandra Carvalho1,2, Ricardo Marcos-Pinto2,3, Ana Magalha˜es1,
Carla Oliveira1,4, Jianguo Gu5, Ma´rio Dinis-Ribeiro6,7, Fa´tima Carneiro1,4,8,
Raquel Seruca1,4, and Celso A. Reis1,2,4
1 Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr Roberto Frias s/n, 4200-465 Porto,
Portugal
2 Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira n.8 228, 4050-313
Porto, Portugal
3Department of Gastroenterology, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal
4Medical Faculty, University of Porto, Alameda Prof. Hernaˆ ni Monteiro 4200-319 Porto, Portugal
5Division of Regulatory Glycobiology, Tohoku Pharmaceutical University, Sendai, Miyagi 981-8558, Japan
6Department of Gastroenterology, Portuguese Oncology Institute of Porto, Rua Dr. Anto´ nio Bernardino de Almeida, 4200-072
Porto, Portugal
7Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Medical Faculty, Alameda Prof. Hernaˆ ni
Monteiro 4200-319 Porto, Portugal
8Department of Pathology, Hospital S.Joa˜o, Alameda Prof. Hernaˆ ni Monteiro, 4200-319 Porto, Portugal
Gastric cancer has a high incidence and mortality, so
there is a pressing need to understand the underlying
molecular mechanisms in order to discover novel bio-
markers. Glycosylation alterations are frequent during
gastric carcinogenesis and cancer progression. This re-
view describes the role of glycans from the initial steps
of the carcinogenesis process, in which Helicobacter
pylori adheres to host mucosa glycans and modulates
the glycophenotype, as well as how glycans interfere
with epithelial cell adhesion by modulating epithelial
cadherin functionality in gastric cancer progression. Oth-
er mechanisms regulating gastric cancer malignant be-
havior are discussed, such as increased sialylation
interfering with key signaling pathways and integrin
glycosylation leading to an invasive phenotype. Applica-
tions of these glycosylation alterations in the clinical
management of gastric cancer patients are discussed.
Glycosylation in gastric cancer: understanding its
functional roles
Cancer is a major cause of death worldwide, remaining an
extremely important health problem [1]. Gastric cancer
(GC) is the second leading cause of cancer-related death
worldwide, affecting close to one million people per year [1].
Glycobiology has become a focus of research in cancer
biology with several implications for the clinic. Glycans
are major components of several biomolecules, including
glycoproteins, glycosphingolipids, and proteoglycans
expressed by cells and tissues. Glycans have been shown
to be involved in various pathophysiological steps of tumor
development and progression, regulating tumor cell
proliferation, invasion, metastasis, and angiogenesis
[2,3]. In the process of gastric carcinogenesis, glycans have
been shown to be involved in various steps, such as, cell–
pathogen interactions, cell–cell and cell–matrix interac-
tions, cell differentiation, cancer cell migration, invasion
and metastasis [2,4]. The understanding of glycans’ role in
these steps sets the ground for the development of novel
cancer diagnostic and prognostic biomarkers, as well as
novel pharmaceutical agents that target these molecules.
Thus, deciphering the GC cell ‘glycans code’ will help to
provide cutting-edge knowledge with potential applica-
tions for the improvement of GC clinical management.
This review provides a comprehensive view of the role of
glycans in cancer with a particular focus on GC. We
address the initial steps of the process of gastric carcino-
genesis, in which Helicobacter pylori uses glycans to adhere
and modulates the host gastric mucosa glycophenotype for
chronic infection. We also present how glycans interfere
with basic mechanisms involved in cell–cell adhesion,
modulating the functionality of epithelial cadherin (E-cad-
herin), a key protein involved in the genesis and progres-
sion of gastric carcinoma. Furthermore, we present other
major mechanisms that modulate the malignant behavior
of gastric carcinoma, such as the glycosylation (see Glos-
sary) of integrins and the expression of sialylated glycans,
which interferes with key signaling pathways and leads to
the acquisition of an invasive phenotype. Finally, we dis-
cuss important applications of glycosylation alterations as
biomarkers to improve the clinical management of cancer
patients.
Gastric cancer: epidemiology, clinicopathological
features, and clinical management
GC represents a high burden in terms of incidence and
cancer-related mortality, being the fourth most common
malignancy in the world and the second leading cause of
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cancer death in both sexes worldwide [1,5]. The global
incidence of GC has been declining over the past few
decades, but the total number of cases is expected to rise
as a result of the ageing population [5]. Most cases of GC
are sporadic in nature, but approximately 10% display
familial clustering and only 1–3% of these are predicted
to be hereditary [6] (Figure 1).
Several GC classifications have been proposed over the
past decades. The most commonly used are the World
Health Organization and the Laure´n classifications, the
latter describing two main histological subtypes, intestinal
and diffuse, that display different clinicopathological pro-
files and distinct epidemiological settings [7] (Figure 1).
The intestinal subtype of GC represents nearly 70% of
the cases and predominates in high-risk areas, being more
frequently observed in older male patients [8]. The carci-
nogenesis process leading to the intestinal subtype of GC
is considered to be gradual and stepwise, leading to au-
tonomously growing tumors with glandular structure [8].
The H. pylori infection is a pivotal risk factor for gastric
carcinogenesis, with tumor development occurring only in
a subset of individuals. The progression of the gastric
carcinogenesis pathway has been shown to be related to
the host characteristics, such as host genetic polymor-
phisms of pro-inflammatory interleukins [9,10] and mole-
cules involved in adhesion of the bacteria [11–13], as well
as genetic variations of the bacteria [such as differences in
the H. pylori virulence factors cytotoxin-associated gene A
(cagA) and vacuolating cytotoxin A (vacA)] [9] (Figure 1).
Other risk factors have been described, such as diet [14]
and familial aggregation [15]. Almost half of the world
population is infected with H. pylori, and if occurring, GC
is clinically diagnosed four or more decades later. During
this period, a prolonged precancerous process takes place,
represented by a ‘cascade’ of events with the following
sequential histopathologic stages: chronic active non-atro-
phic gastritis, multifocal atrophic gastritis, intestinal
metaplasia (IM) (precancerous conditions), dysplasia (pre-
cancerous lesion), and carcinoma [16] (Figure 1). The
clinical guidelines for the management of these precan-
cerous conditions and lesions on the stomach recommend a
schedule for endoscopic follow-up of patients with exten-
sive precancerous multifocal conditions [17,18]. Recently,
a new hereditary syndrome has been identified, gastric
adenocarcinoma and proximal polyposis of the stomach
(GAPPS), which is characterized by the autosomal domi-
nant transmission of fundic gland polyposis, including
areas of dysplasia or intestinal-type gastric adenocarcino-
ma restricted to the proximal stomach (Figure 1). Genetic
defects behind this syndrome have not been elucidated yet
[19].
Unlike the intestinal type of GC, the diffuse subtype
(representing nearly 30% of GC cases) tends to occur in
younger individuals, mainly females, and frequently
depicts hereditary forms [20,21]. In contrast to the inci-
dence of the intestinal subtype, which is steadily decreas-
ing in most countries, the incidence of the diffuse subtype
is stable [5]. Diffuse-type GC develops without the inter-
mediate steps of glandular atrophy and IM. It is charac-
terized by poorly cohesive cells, organized in cords or
micro-glands, as well as discohesive cells that may widely
invade the gastric wall, some of which may be of the
signet ring cell type. Diffuse-type GC displays a major
molecular abnormality: defective intercellular adhesion
mainly resulting from E-cadherin dysregulation  [22,23]
(Figure 1). In most cases, this is due to abnormal expres-
sion of E-cadherin [an adhesion molecule encoded by the
human cadherin 1, type 1, E-cadherin (CDH1) gene]
[20,21,23]. Germline alterations (mostly mutations) of
the CDH1 gene are the genetic cause of hereditary diffuse
gastric cancer (HDGC) [24].
In countries without screening programs for early de-
tection of GC, most cases are diagnosed at an advanced
stage. Most patients die during the first year after diagno-
sis, even if submitted to costly and aggressive therapy [25].
The five-year survival rates of GC remain extremely poor
(around 10%) [26]. The diagnosis of GC at advanced disease
stage increases the risk of relapse after surgical treatment.
Consequently, GC remains a huge concern in clinical prac-
tice, and therefore new biomarkers and molecular tools are
urgently needed in order to improve the success of early
diagnosis, prognosis, and therapeutic options for GC
patients and their relatives.
Glossary
Endoplasmic reticulum-associated degradation: is a protein degradation
pathway in the endoplasmic reticulum that has a central clearance function
in the cell. Is a cellular pathway that targets misfolded proteins and mutant
proteins for ubiquitination and subsequent degradation by a protein-degrading
complex called the proteosome.
Familial intestinal gastric cancer (FIGC): an intestinal-type gastric cancer
syndrome with familial aggregation. The criteria of the International Gastric
Cancer Linkage Consortium for FIGC vary accordingly with countries with high
incidence of FIGC or low incidence of FIGC. The germline genetic defect
underlying the disease remains unknown.
Glycosylation: a post- and co-translational modification process in which
carbohydrates (glycans, saccharides, or sugars) are covalently attached to
proteins, lipids, or other organic molecules. It is a tightly regulated process that
occurs in the endoplasmic reticulum and Golgi compartment of all eukaryotic
cells. This process depends on the availability of nucleotide sugar donors and
on the coordinated action of a large number of enzymes (glycosyltransferases
and glycosidases). The majority of mammalian proteins synthesized in the
endoplasmic reticulum undergo glycosylation. There are two main classes of
protein glycosylation: N- and O-glycosylation.
Hereditary diffuse gastric cancer (HDGC): an inherited form of diffuse-type
gastric cancer that represents a rare but incurable autosomal-dominant gastric
cancer syndrome with high penetrance. It is a highly invasive type of tumor
with early onset gastric cancer (diagnosed before 45 years of age).
Approximately 45% of families with HDGC have germline alterations in the
E-cadherin (CDH1) gene. This early gastric cancer is located beneath an intact
mucosal surface, and therefore early detection is extremely difficult. Prophy-
lactic total gastrectomy is usually advised after the age of 20 and before the age
of 40. In 1999, the International Gastric Cancer Linkage Consortium (IGCLC)
proposed specific criteria to define HDGC. Families with aggregation of gastric
cancer and an index case with diffuse IGCLC, but not fulfilling the IGCLC criteria
for HDGC, are termed familial diffuse gastric cancer (FDGC).
Mucins: a family of glycoproteins with a high content of serine, threonine, and
proline residues, and numerous O-linked glycans. Mucins can be membrane-
bound or secreted onto mucosal surfaces. Mucins are high-molecular-weight
and heavily glycosylated proteins constituting an important interface between
many epithelial surfaces of the body and the exterior environment. The main
characteristic of mucins is their ability to form gels.
N-glycosylation: this is characterized by the addition of the glycan chains to an
aspargine residue of the nascent protein in a consensus sequence Asn-X-Ser/
Thr, where X can be any amino acid with the exception of proline. The resulting
N-glycan structures are generally classified into three principal categories: high
mannose, complex, and hybrid types (see Figure 3 in main text).
O-glycosylation: a stepwise process characterized by the covalent linkage of
glycan chains to the hydroxyl group of a serine or threonine. The initial step of
O-glycosylation is controlled by a family of GalNAc transferases that transfer
an initial N-acetylgalactosamine (GalNAc) residue. No consensus sequence
defines an O-linked glycosylation site. The initial GalNAc can be extended,
branched and elongated by several glycosyltransferases.
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Glycosylation in normal gastric mucosa and gastric
carcinogenesis
The gastric mucosa displays a set of mucins that are the
most frequent carriers of O-glycans in higher eukaryotes
[27]. In healthy gastric mucosa, the superficial foveolar
cells express the membrane-associated mucin 1 (MUC1)
and the secreted MUC5AC, which are the major compo-
nents of the gastric mucus layer. The deeper gastric glands
express the secreted MUC6 [28–30]. MUC5AC is accompa-
nied by co-expression of type 1 Lewis a and Lewis b
antigens, whereas MUC6 expression is associated with
the presence of type 2 Lewis x and Lewis y antigens
[30,31] (Figures 2 and 3).
Genetic polymorphisms in glycosyltransferase genes
lead to different expression profiles of gastric mucosa
histo-bood group antigens. For instance, the fucosylated
H-type 1 antigen is only expressed in the foveolar epitheli-
um of secretor individuals and the difucosylated Lewis b
antigen is only expressed in secretor and Lewis-positive
individuals [32]. Secretor individuals constitute 80% of the
Caucasian population and express a functional secretor
fucosyltransferase 2 (FUT2) enzyme; Lewis-positive indi-
viduals represent 90% of the Caucasian population and
express the Lewis FUT3 enzyme [33]. Genetic polymor-
phisms of the genes encoding these enzymes are associated
with different host susceptibilities to infection by H. pylori
[11,34].
H. pylori is a major trigger of gastric carcinogenesis, and
the colonization of the gastric mucosa depends on bacterial
attachment to the gastric mucus layer and epithelial cells.
This binding is mediated by bacterial outer-membrane
proteins, named adhesins, which specifically bind to host
glycosylated receptors (Figure 2). Blood group antigen-
binding adhesin (BabA) binds to the fucosylated blood
group antigens H-type 1 and Lewis b [35,36], which are
present in the MUC5AC mucin of gastric epithelial cells of
healthy secretor individuals. Some H. pylori strains,
named generalists, admit modification of Lewis b with
AB glycan determinants, whereas specialist strains only
recognize the naked form of this epitope [37]. BabA was
also shown to bind Globo H and Globo A, which are blood
group O and A determinants, respectively, on type 4 core
chains [38]. Individuals infected with strains that harbor a
functional BabA adhesin present a higher risk of develop-
ing more severe gastric lesions, including IM and gastric
adenocarcinoma [39].
The gastric glycosylation patterns define the H. pylori
tropism, and bacteria are mainly found at the surface of
mucous cells, where there is co-expression of MUC5AC and
type 1 fucosylated Lewis antigens. By contrast, coloniza-
tion of the deeper gastric glands where MUC6 is expressed
is rare. This distribution is explained by the presence of
unique O-glycan structures with terminal a1,4-linked N-
acetylglucosamine (a1,4GlcNAc) residues in the MUC6
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Figure 1. The two pathways of gastric cancer. There are two main histological subtypes of gastric cancer, the intestinal subtype (70% of cases) and the diffuse subtype (30%
of cases), which display different clinicopathological profiles and occur in distinct epidemiological settings. Sporadic forms account for most cases (90%), whereas
hereditary forms account for only 1–3% of cases. Abbreviations: BabA, blood group antigen-binding adhesin; GAPPS, gastric adenocarcinoma and proximal polyposis of
the stomach; IL, interleukin; SabA, sialic acid-binding adhesin; TNF-a, tumor necrosis factor-a.
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Figure 2. Schematic representation of the glycosylation phenotype in normal gastric mucosa and gastritis (A), and the glycosylation alterations in gastric cancer cells (B). (a)
In normal gastric mucosa, the epithelial cells display normal cell–cell adhesion mediated by epithelial cadherin (E-cadherin) glycosylated with stabilizing glycoforms: the
bisecting N-acetylglucosamine (GlcNAc) N-glycan structures. The cell–extracellular matrix (ECM) interaction is mediated by integrins that are also modified with bisecting
GlcNAc glycan structures. The mucin gel layer covering the gastric mucosa plays an important role in the colonization of Helicobacter pylori. Normal gastric cells express
fucosylated glycans such as Lewis b antigen, which serves as a ligand for H. pylori adhesion and infection, leading to the gastritis process. H. pylori binding is mediated by
bacterial adhesins, such as blood group antigen-binding adhesin (BabA), which specifically binds to Lewis b, and sialic acid-binding adhesin (SabA), which binds to sialyl-
Lewis x antigens expressed during inflammation of the gastric mucosa. H. pylori has been shown to induce an overexpression of b3GnT5, leading to increased biosynthesis
of sialyl-Lewis x. (b) During the gastric carcinogenesis process, the gastric epithelial cells undergo several changes in glycosylation that affect the malignant behavior of
cancer cells. E-cadherin expression induces N-acetylglucosaminyltransferase-III (GnT-III)-mediated glycosylation, which confers advantages over GnT-V-mediated
(Figure legend continued on the bottom of the next page.)
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backbone. Terminal a1,4GlcNAc presents a natural antimi-
crobial activity by inhibiting the synthesis of a-glucosyl
cholesterol, an important constituent of the H. pylori cell
wall, and therefore suppressing bacterial growth [40]. In
addition, a1,4GlcNAc expression was recently shown to
suppress tumor-promoting inflammation. Mice that lack
the enzyme responsible for a1,4GlcNAc biosynthesis
(A4gnt!/! mice) develop gastric adenocarcinoma in the ab-
sence of H. pylori infection, demonstrating that a1,4GlcNAc
loss is sufficient for cancer initiation in this model [41].
glycosylation. The modification of E-cadherin and integrins with bisecting GlcNAc structures is associated with suppression of tumor cell invasion. On the contrary, the
modification of E-cadherin with b1,6GlcNAc branched structures promotes dysfunction of E-cadherin-mediated cell–cell adhesion, leading to an invasive phenotype. This
malignant phenotype is also due to an increased modification of integrins with the branched N-glycan structures that leads to an increased interaction with the ECM. The
overexpression of sialylated glycan structures, such as sialyl-Lewis x and sialyl-Tn, has also been shown to contribute to the aggressive phenotype of gastric tumor cells.
Changes in the expression of sialyltransferases and an induction of sialyl-Lewis x overexpression in gastric cancer cells alters the activation of signaling pathways, leading
to an invasive phenotype. Abbreviations: EPLIN, epithelial protein lost in neoplasm; b3GnT5, b3-N-acetylglucosaminyltransferase-5.
Terminal oligosaccharide structures/Lewis an!gens
Simple-mucin-type carbohydrate an!gens
N-glycans
Symbolic representa!ons of monosaccharide
H-type 1
R
R
Tn
Ser/Thr
High mannose
Asn Asn Asn
Asn Asn
Hybrid Complex
Bisec!ng Branched
Ser/Thr
STn
R R R
R R R
3 3 32 3 34 4 4β β β β
α α α α α α
2
4 4β β β β
α
α
α2 α2 α2
α6 α6
β4
β2
α3 α6
α6
β2
β4
β2 β2 β2 β2 β6
α3 α6
β4
β4
β4 β4
β4
α6α3
β β
β4
β4
α6
β4
β2
β4
β4
β β
α3
α3
α6
α6
α2 α3
α3
β4
β4
β
α6
α6
α
α α α α α
2
Galactose (Gal)Key: N-acetylgalactosamine (GalNAc) Fucose (Fuc)
Sialic acid (Neu5Ac)N-acetylglucosamine (GlcNAc)Mannose (Man)
3
2 6
2 4 3 3 34
Lewis a Lewis b Sialyl Lewis a
H-type 2 Lewis x Lewis y Sialyl Lewis x
TRENDS in Molecular Medicine 
Figure 3. Summary of important glycan structures expressed in gastric tissues. Schematic representation of the most common glycans structures expressed in gastric tissues
either in normal or in pathological conditions. These glycan structures include terminal Lewis and sialylated Lewis structures; simple mucin type glycan structures, such as Tn
and sialyl-Tn; and the N-glycans, particularly the complex types: bisecting N-acetylglucosamine (GlcNAc) and the b1,6GlcNAc branched structures. Abbreviation: R, core
oligosaccharide.
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In healthy conditions, gastric mucosa expresses most-
ly neutral fucosylated glycans, but H. pylori infection and
the associated host inflammatory response can induce a
remodeling of the gastric glycophenotype with de novo
expression of sialylated antigens, including sialyl-Lewis
x and sialyl-Lewis a. H. pylori has been shown to induce
an overexpression of b3-N-acetylglucosaminyltransfer-
ase-5 (b3GnT5), leading to increased biosynthesis of
sialyl-Lewis x [42]. H. pylori binding to inflamed tissue
is mainly mediated by sialic acid-binding adhesin (SabA)
[43].
During gastric carcinogenesis, aberrant cell-surface gly-
cosylation is frequently observed in precancerous condi-
tions, such as IM, which shows major alterations of mucin
expression with marked de novo expression of the intesti-
nal MUC2 mucin [44] and aberrant expression of the
simple mucin-type antigen sialyl-Tn (Figure 3) in goblet
cells [45,46]. Recently, plasminogen with sialyl-Tn was
identified in the serum of patients with gastritis and IM,
suggesting its possible application as a biomarker for non-
invasive clinical screening and diagnosis [47].
In GC, various types of glycosylation alterations have
been described and shown to play key roles in modulating
cancer cell behavior (Figure 2). These molecular mecha-
nisms are discussed in detail in the following sections.
Cellular adhesion in homeostasis and gastric cancer:
E-cadherin as a key molecule
Cellular adhesion determines the polarity of cells, partici-
pating in the spatial and functional tissue organization of
epithelial cells [48,49]. Cell–cell and cell–matrix adhesion
are involved in various processes of tissue morphogenesis
and in the maintenance of mechanical integrity and nor-
mal cell physiology [50]. Integrins and E-cadherin are
fundamental adhesion molecules with key roles in cell–
extracellular matrix (ECM) and cell–cell interactions, re-
spectively, being essential for normal tissue architecture.
Alterations of glycosylation in these key molecules inter-
fere dramatically with their functions and can modulate
physiological and pathological processes.
One of the major regulators of epithelial tissue morpho-
genesis and homeostasis is the cell–cell adhesion molecule
E-cadherin [51,52]. The critical importance of E-cadherin
in normal development is demonstrated by the lethality of
E-cadherin knockout mice at an early stage in embryogen-
esis [53].
In the process of carcinogenesis, alterations in cell–cell
and cell–matrix adhesion have a central role [50,54,55].
The downregulation or inactivation of E-cadherin-mediat-
ed cell–cell adhesion may occur in early steps of cancer
development [55–57]. Specifically, in diffuse-type GC, E-
cadherin dysfunction occurs in intra-epithelial pre-inva-
sive lesions, such as in situ carcinoma and pagetoid spread
of signet ring cells in the setting of HDGC (caused by CDH1
germline mutations) [20,58] (Figure 1). These lesions dis-
play decreased or absent expression of E-cadherin. Similar
pre-invasive lesions of GC have not been identified in the
sporadic setting. In the intestinal subtype of GC, altera-
tions in E-cadherin expression occur predominantly at
later stages of cancer progression (Figure 1). These altera-
tions in E-cadherin expression have been associated with
poor clinical outcome of GC patients [23,59].
Several molecular mechanisms explain the abnormal E-
cadherin expression in GC at the genetic and epigenetic
level (Box 1), and also at the post-translational level
through glycosylation.
The mature E-cadherin protein contains a single trans-
membrane domain, a cytoplasmic domain, and an extracel-
lular domain, which comprises five repeated subdomains
(EC1–EC5) [60]. The extracellular domain mediates the
Ca2+-dependent homophilic/homotypic cell–cell adhesion.
The E-cadherin ectodomain has four potential N-glycosyla-
tion sites: two in EC4 (Asn554 and Asn566) and two in EC5
(Asn618 and Asn633). These N-glycan sites were found to be
crucial for E-cadherin folding, expression, and biological
functions [61,62]. Cell–cell adhesion is further accomplished
through the molecular interaction between the E-cadherin
cytoplasmic domain and catenins (b-catenin, g-catenin,
p120 catenin, and a-catenin), which couple cadherin
to the actin cytoskeleton [60]. The interaction with p120
Box 1. Genetic/epigenetic regulation of E-cadherin expression in gastric cancer
Loss or abnormal expression of the epithelial cadherin (E-cadherin)
gene [cadherin 1, type 1, E-cadherin (CDH1)] and protein in neoplastic
cells generally causes them to turn into the invasive components of
several human cancers, including gastric cancer (GC) [60]. Hereditary
diffuse gastric cancer (HDGC) is the archetypical example of E-
cadherin loss significance and is caused by heterozygous germline
CDH1 point mutations in about 40% and large deletions in !4% of all
families with this syndrome [24,136]. In the sporadic context, a recent
comprehensive analysis showed that CDH1 somatic structural altera-
tions were found in !10% of all GC cases: 10.9% within the sporadic
setting and 9.7% among familial cases [23]. Importantly, the worst
patient survival rate among all GCs analyzed was seen in patients with
tumors carrying CDH1 structural alterations belonging to familial
intestinal gastric cancer (FIGC) families [23].
In all GCs, epigenetic silencing through CDH1 promoter hyper-
methylation has been described, with frequencies varying from 50%
to 83% in diffuse tumors and from 6.25% to 50% in intestinal tumors
[137,138]. Recently, a large GC study revealed CDH1 somatic
hypermethylation in 20.7% of GC cases: 18.4% of the cases within
the sporadic setting and 26.4% within the familial setting. Particularly
among HDGC patients carrying germline CDH1 mutations, the most
frequent somatic event affecting the CDH1 gene is promoter
methylation that leads to complete somatic inactivation of the CDH1
gene [either as a single event (!50%) or concomitantly with loss of
heterozygosity at the CDH1 locus (!19%)] [139,140]. Primary HDGC
tumors that lack germline CDH1 mutations show exclusively CDH1
promoter hypermethylation in 50% of the cases. Among patients with
FIGC, 17.0% of tumors showed hypermethylation [23].
MicroRNAs (miRNAs) have also emerged as a new layer of CDH1
gene regulation [141]. Members of the miR-200 family of miRNAs
have been implicated in the regulation of E-cadherin expression
through direct targeting of the E-cadherin transcriptional repressors
zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2. Inhibition of
endogenous miR-200 expression levels led to a relief of ZEB1 and
ZEB2 repression, a reduction of E-cadherin mRNA expression levels,
and, consequently, a mesenchymal-like morphology and increased
cell migration [142]. Apart from the miR-200 family, miR-9 and miR-
101 have also been implicated in the network of E-cadherin regulation
[137]. miR-101 has been shown to be downregulated in GC in
comparison with normal gastric mucosas and, at least in 65% of GC
cases, this downregulation was due to deletions and/or microdele-
tions at miR-101 genomic loci.
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catenin has been shown to regulate E-cadherin internaliza-
tion, preventing its endocytosis and promoting its stability
at the cell surface [63]. E-cadherin–catenin complex is the
major component of the adherens junctions (AJs), and its
stability is regulated by E-cadherin glycosylation [64]. Fur-
thermore, the engagement of E-cadherin in homophilic
interactions can act as a mechanosensor, triggering the
activation of signal transduction pathways that are impor-
tant in tissue organization [65,66] and in which glycosyla-
tion modifications play a role.
Glycosylation as a modulator of gastric cancer cellular
behavior
Role of glycosylation as a regulator of E-cadherin-
mediated gastric tumor development and progression
Although epigenetic and structural alterations of E-cad-
herin may be considered instrumental for protein down-
regulation or inactivation (Box 1), cancer cells have been
shown to exhibit additional mechanisms that contribute to
the acquisition of the malignant phenotype.
In GC, E-cadherin immunostaining does not always
indicate the absence of expression (which is compatible
with epigenetic or structural alterations), but frequently
shows a redistribution from the cell membrane into the
cytoplasm (aberrant E-cadherin expression). Around 70%
of all GC cases showing E-cadherin aberrant expression do
not harbor CDH1 structural alterations (mutations, loss of
heterozygosity, or hypermethylation) [23] (Box 1).
Recent evidence has shown that glycosylation can inter-
fere with E-cadherin functions in normal and pathological
conditions. E-cadherin N-glycosylation seems to be essen-
tial for its correct folding and transport to the cell surface
[62]. Elimination of N-glycans at Asn633 was demonstrated
to affect E-cadherin expression, targeting it for endoplasmic
reticulum-associated degradation [62]. The regulation of the
recycling and trafficking pathways of E-cadherin has been
demonstrated to be controlled by glycosylation [67,68]. Cy-
toplasmic O-glycosylation of E-cadherin (O-GlcNAc) was
shown to block its cell surface transport, precluding binding
to p120 catenin, which results in reduced intercellular
adhesion [69,70]. N-glycosylation of E-cadherin has also
been reported to affect E-cadherin-mediated signaling path-
ways, particularly the activation of the extracellular-regu-
lated kinase pathway [71] (which has also been described for
neural cadherin [72]), suggesting that glycosylation may
influence the mechanotransduction role of E-cadherin.
Moreover, the E-cadherin N-glycans have been shown to
affect E-cadherin’s intercellular adhesive functions [73] by
interfering with the molecular assembly and maturity of the
AJ, and consequently the assembly of tight junctions
[61,74–76].
During malignant transformation, E-cadherin displays
substantial alterations of its glycans [77] (Figure 2). E-
cadherin controls its own glycosylation by promoting ex-
pression of N-acetylglucosaminyltransferase-III (GnT-III),
which confers a stabilizing E-cadherin glycosylation at the
cell membrane, increasing cell–cell adhesion [78,79]
(Figure 2). This beneficial glycosylation of E-cadherin with
bisecting GlcNAc N-glycans, catalyzed by GnT-III, is asso-
ciated with a delayed turnover of E-cadherin at the cell
surface and an inhibition of E-cadherin endocytosis [64,80].
E-cadherin modified with bisecting GlcNAc N-glycans con-
tributes to the increased recruitment of catenins and in-
creased AJ stability. This glycosylation type of E-cadherin
promotes increased intercellular adhesion and a downregu-
lation of intracellular signaling pathways involved in cell
motility [81], supporting its contribution to tumor suppres-
sion (Figure 2). In addition, this E-cadherin N-glycoform
also contributes an epithelial phenotype that prevents the
epithelial-to-mesenchymal transition (EMT) process
[82,83]. The modification of E-cadherin with bisecting N-
glycoforms was found to have an important role in the
suppression of human gastric carcinoma progression [64].
Conversely, when E-cadherin is glycosylated by GnT-V,
there are major effects on the dysregulation of its functions
in a GC context. GnT-V is known to be upregulated in gastric
carcinoma [84], leading to biosynthesis of the b1,6GlcNAc
branched N-glycans and contributing to cancer cell invasion
and metastases [85,86]. GnT-V overexpression in a GC cell
line model induces significant alterations on E-cadherin
cellular expression, with a delocalization from the cell mem-
brane into the cytoplasm (aberrant E-cadherin expression)
[64]. Concomitantly with this, GC cells acquire a fibroblas-
toid/mesenchymal appearance compatible with an EMT
phenotype induced by GnT-V [87]. In addition, GnT-V-
mediated glycosylation on E-cadherin has been shown to
interfere with the molecular assembly and stability of AJ.
The b1,6GlcNAc branched N-glycans on E-cadherin lead to
an impairment of b-catenin and p120 catenin recruitment,
disturbing the stability of AJs, which affects the cell–cell
adhesion capability of gastric tumor cells [64] (Figure 2).
Moreover, b1,6GlcNAc branched N-glycans on cadherins
can also affect the tyrosine phosphorylation of catenins
associated with increased cell migration and invasion
[88,89]. GC cell line models overexpressing GnT-V showed
an increased metastatic capability when injected in athymic
nude mice [90]. In the clinical setting, gastric carcinoma cells
(diffuse type) exhibiting an aberrant E-cadherin expression
without E-cadherin epigenetic or structural alterations
showed an increased modification with b1,6GlcNAc
branched structures [64].
In summary, other than epigenetic and structural
alterations, modification of the glycosylation of E-cadherin
can remarkably disturb its normal function by promoting
tumor cell development and progression, constituting a
potential biomarker for clinical applications.
Integrins and gastric cancer: role of glycan modifications
in integrin-mediated cell spreading and migration
Integrins are the main link between a cell and the ECM,
playing essential roles in cancer invasion and metastases.
They consist of a- and b-subunits. Each subunit has a large
extracellular region, a single transmembrane domain and
a short cytoplasmic tail (except for b4 integrin). The most
general feature of integrins is that their interaction with
their ligand can activate intracellular signaling pathways
and cytoskeletal formation (outside-in signaling). Another
important feature of integrins is inside-out signaling, in
which intracellular signals received by integrins or other
receptors in turn activate their extracellular domain and
contribute to the assembly of the ECM [91,92]. Therefore
glycosylation modifications of integrins play major roles in
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the interaction between the cell and the ECM by interfer-
ing with biological functions, including cell spreading,
migration, and signal transduction.
Integrins are glycoproteins and major carriers of N-gly-
cans. a5b1 integrin, which is one of the best-characterized
integrins, is modulated with N-glycans that are required for
ab heterodimer formation and integrin–matrix interactions
[93,94]. Indeed, the integrin cannot bind to its substrate or
be normally transported to the cell surface in the presence of
the N-glycosylation inhibitor tunicamycin and deglycosyla-
tion mutants [95–97]. Additionally, alterations on N-glycans
of a5b1 integrin could significantly contribute to tumor
formation, invasion, and metastases. Cells transformed
with the oncogenic Ras gene showed an enhanced cell
spreading on fibronectin (FN) owing to an increase of
b1,6GlcNAc branched glycans in a5b1 integrins [98]. Simi-
larly, the characterization of carbohydrate moieties of a3b1
integrin from non-metastatic and metastatic human mela-
noma cell lines showed that b1,6GlcNAc branched struc-
tures were highly expressed on a3b1 integrin from
metastatic cells compared with a3b1 integrin from non-
metastatic cells [99]. In a GC context, overexpression of
GnT-V leads to severe peritoneal dissemination in athymic
mice and increased cellular migration owing to the in-
creased expression of matriptase [90]; as well as due to
alterations on E-cadherin-mediated cell–cell adhesion [64]
(as discussed above), but also through the specific modifica-
tion of a3b1 integrin with b1,6GlcNAc-branched N-glycans,
which promotes increased cell migration [89] (Figure 2).
In contrast to GnT-V, the overexpression of GnT-III in
GC cells inhibited a3b1 integrin-mediated cell migration
by directly counteracting the effect of GnT-V-mediated
glycosylation on a3b1 integrin [89] (Figure 2). As a result,
GnT-III inhibits GnT-V-induced cell migration in GC cells.
Two mechanisms have been proposed for the inhibition of
cell motility and invasion in GC cells on overexpression of
GnT-III: an enhancement in E-cadherin-mediated cell–cell
adhesion [64] (as discussed above) and the downregulation
of integrin-mediated cell–ECM adhesion [89]. These
results indicate that GnT-III counteracts GnT-V and
strongly suggest that remodeling of glycosyltransferase-
modified N-glycan structures either positively or negative-
ly modulates cell adhesion and migration in a GC context
[64,73,100,101].
Consistently, overexpression of GnT-III resulted in an
inhibition of a5b1 integrin-mediated cell spreading and
migration, and the phosphorylation of the focal adhesion
kinase [102]. The affinity of the binding of integrin a5b1 to
FN was significantly reduced as a result of the introduction
of a bisecting GlcNAc to a specific N-glycosylation site on
the a5 subunit [103].
Overall these observations suggest that glycosylation
has a critical role in GC through modulation of key patho-
physiological steps in gastric tumor genesis and progres-
sion, such as cell–cell and cell–ECM interactions.
Sialylated glycans and gastric cancer: modulating tumor
cell signaling and behavior
GC cells frequently display high levels of terminal sialy-
lated glycans such as sialyl-Lewis x, which has been asso-
ciated with venous invasion and poor disease prognosis
[104] (Figure 2). Recently, the overexpression of sialyl-
Lewis x in cell lines transfected with ST3 b-galactoside
a-2,3-sialyltransferase 4 (ST3GAL4) was shown to in-
crease the cells invasive potential both in vitro and in vivo
[105]. This alteration of cell behavior was shown to be
mediated by the activation of c-Met receptor tyrosine
kinase and its downstream targets, such as focal adhesion
kinase and Src proteins, as well as the cell division control
protein 42 (Cdc42), Rac1 and RhoA GTPases [105]. These
results demonstrate that the expression of sialyl-Lewis x in
membrane-associated and secreted glycoconjugates of GC
cells can cause major alterations in receptor tyrosine
kinases and intracellular signaling pathways controlling
epithelial cell invasion behavior, and therefore they play a
key role in the aggressiveness of GC cells.
Another sialylated glycan frequently expressed in GC is
the sialyl-Tn antigen [106] (Figure 2), which is recognized
as an indicator of poor prognosis [107,108]. ST6GalNAc-I is
the major enzyme controlling the expression of sialyl-Tn
antigen in GC [109,110]. Sialyl-Tn expression in GC cells
has been shown to induce major morphological and cell
behavior alterations, including decreased cell–cell aggre-
gation, altered ECM adhesion, and increased migration
and invasion in vitro [111]. These data indicate that the
sialyl-Tn antigen is able to modulate a malignant pheno-
type, inducing a more aggressive cell behavior.
Overall the alterations of expression of terminal sialy-
lated antigens underlie key molecular events associated
with gastric tumor cell–cell and cell–matrix interactions,
signaling activation, migration, invasion, and metastases.
Glycosylation as a tool for the clinical management of
cancer patients
One of the major concerns of cancer clinical management
(and GC in particular) is to improve the early diagnosis and
the successful rate of the therapeutic strategies. New
approaches for cancer early diagnosis and treatment,
and new biomarkers for risk stratification are urgently
needed, and glycans can be a source for such applications
(Box 2).
Currently, most of the traditional cancer serological
markers, such as CEA and CA19-9 (for GC), CA125 (for
ovarian cancer), and CA15-3 (for breast cancer), are based on
detection of glycoconjugates (glycoproteins and glycolipids)
shed from the tumor cells into the bloodstream [112–114].
Box 2. Outstanding questions
! Could specific glycosylation alterations be a source of novel
biomarkers for improving the clinical practice in oncology? Are
they sensitive and specific for the cancer condition?
! Could the specific detection of glycoforms on key proteins in
serum and/or tissues contribute to the early diagnosis and
determination of prognosis of cancer patients? Can we easily
detect the glycomarkers during the routine screening of patients,
such as in gastric biopsies and/or in blood samples?
! How can we use tumor-associated glycans to improve cancer
therapy? Can we specifically modify glycan biosynthesis in cancer
cells? Can we modulate the activity of glycosyltranferases and the
biosynthesis of tumor-associated glycans to control aggressive
cancer cell behavior? Can we use proteins bearing tumor-
associated glycoforms as a target for immunotherapy ap-
proaches?
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However, the reduced specificity and sensitivity of these
serological assays for early detection of cancer is driving a
search for novel biomarkers. In fact, the detection of specific
glycoforms of a certain protein could contribute to the
establishment of a biomarker with higher specificity for
early detection of cancer or for diagnosis at a precancerous
stage [115–117]. For example, fucosylated a-fetoprotein (L3
fraction) was approved by the US Food and Drug Adminis-
tration as a marker for early detection of hepatocellular
carcinoma (HCC); it appears in serum at the stage of liver
cirrhosis just before the onset of HCC, being therefore
considered the best approved marker in patients with
HCC [118,119]. Recently, altered O-glycosylation (sialyl-
Tn antigen) has been detected in circulating serum plas-
minogen in patients with IM and gastric carcinoma [47].
Such alterations detected in early stages of the carcinogen-
esis process might have valuable applications in the early
diagnosis setting. In addition, recent reports have proposed
fucosylated haptoglobin as a novel biomarker for pancreatic
and colon cancer [120,121].
In line with this, the specific modification of E-cadherin
or integrins with the deleterious b1,6GlcNAc branched
structure might also be considered a potential biomarker
for selecting at-risk patients for clinical surveillance. It is
tempting to suggest the assessment of the pattern of E-
cadherin/integrin glycosylation in a gastric biopsy sample
as a biomarker for the early diagnosis and prognosis of
GC. Furthermore, in combination with the current diag-
nostic procedures, the clinical search of specific glyco-
forms in key proteins, both in tissues and/or in serum,
is of utmost importance to improve early diagnosis,
determination of prognosis, and risk stratification of can-
cer patients (Figure 4). Several studies are now being
conducted in order to assess aberrant glycoforms of spe-
cific proteins as candidate glyco-markers for improving
clinical practice in oncology. In addition, the terminal
carbohydrate determinants sialyl-Lewis x and Sda (a
blood group carbohydrate antigen) on specific proteins
may constitute interesting markers in the clinical setting,
particularly as biomarkers for cancer cell biological be-
havior [122].
Glycosylation modifications are also good targets for
cancer therapy. In the case of GC, targeting deleterious
glycosylation pathways, such as synthesis of the
b1,6GlcNAc branched N-glycans or terminal sialylation
with sialyl-Lewis x, appears to be a promising approach
with potential treatment applications. Inhibition of the
biosynthesis of specific glycan structures can be achieved
using synthetic compounds, and these are attractive tools
for modulation of cancer cell behavior [123,124]. Swain-
sonine, an inhibitor of the Golgi protein a-mannosidase
II, which blocks the synthesis of complex type N-glycans,
has been demonstrated to have antitumor properties in
vitro [125], in vivo [126], and in patients with advanced
malignancies [127]. However, its efficacy in the clinical
setting has been shown to be limited [128]. Additional
specific compounds targeting specific glycosyltrans-
ferases expressed in specific cells might constitute a
source of important tools for modulating cancer cell be-
havior contributing to cancer therapy.
Furthermore, anticancer vaccines targeting tumor-as-
sociated carbohydrate antigens provide another appealing
option for cancer treatment; these have major advantages,
as they can be designed to incorporate only those elements
required for a desired immune response [129–131]. Vari-
ous studies have shown that passive immunotherapy using
antibodies directed to glycoform-specific targets, such as
MUC1 mucin, expressed in tumor cells can be effective in
inducing an antibody-dependent cell-mediated cytotoxicity
[132]. Moreover, various active immunotherapy studies
targeting glycoproteins expressed in tumor cells have been
tested and are under clinical evaluation [133].
TRENDS in Molecular Medicine 
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Figure 4. Glycans as potential biomarkers in the clinical setting. The alteration of cellular polarity and topology of cancer cells can lead to the shedding of glycoconjugates
bearing important tumor-associated glycoforms into the bloodstream. These might constitute valuable molecular markers that can be detected in serological assays and
used to improve the early diagnosis, prognosis, risk stratification, and surveillance of cancer patients.
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In the GC setting, we can envision the design of glyco-
peptides based on proteins expressed by gastric carcinoma
cells, such as MUC1, E-cadherin, or integrins specifically
modified with cancer-associated glycans, as attractive com-
pounds that are able to induce a classical major histocom-
patibility complex-mediated immune response [129]. Such
glycopeptides could be a promising anticancer vaccine for
GC treatment. The identification of the specific sites of
glycosylation and cancer-associated glycoforms of key pro-
teins expressed by GC remains of utmost importance and
will aid in the effective design of synthetic glycopeptides for
anticancer vaccine development.
Concluding remarks and future perspectives
The characterization of glycosylation in a given cell or tissue
context is crucial for the understanding of its role in physio-
logic and pathologic conditions. In gastric tissues, glycans
mediate the adhesion and infection of H. pylori as well as
gastric carcinogenesis, and the alterations of O-linked and
N-linked glycans modulate key mechanisms of GC progres-
sion, such as cancer cell invasion and metastasis.
Our comprehension of cancer cell biology will be im-
proved through understanding the molecular mechanisms
that control glycosylation alterations in these disease
states — such as determining the glycosyltransferases
involved in such changes — and through the constant
technological improvement of the analysis of glycan struc-
ture in key proteins. Such progress will provide markers
for improving the early diagnosis, prognosis, risk stratifi-
cation, and surveillance of cancer, as well as the develop-
ment of novel therapeutic strategies that will ultimately
benefit cancer patients [114,134,135].
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Supplementary Figures of Chapter II 
 
Figure S1: Effects of exogenous E-cadherin expression on the phosphoproteome profile. 
Figure S2: Effects of stimulation of Mock-transfected cells with insulin and IGF-I on the 
phosphorylation of tyrosine kinase receptors and downstream proteins. 
Figure S3: Effects of stimulation of Mock-transfected cells with insulin and IGF-I on cell 
invasion. 
Figure S4: Subcellular localization of E-cadherin and β-catenin of Mock-transfected cells 
stimulated with insulin and IGF-I. 
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Figure S1 
 
 
 
Figure S1. Effects of exogenous E-cadherin expression on the phosphoproteome 
profile. Total cell lysates from MDA-MB-435+mock and MDA-MB-435+E-cad were 
obtained and analyzed by Phospho-RTK array using 300 µg of proteins. The phosphor-RTK 
coordinates are shown on the top of figure illustrating the localization of the spots containing 
immobilized antibodies on the nitrocellulose membrane. The bar graphs show the relative 
densities of black dots. The most pronounced changes are observed in IR (coordinates B17 
and B18) and IGF-IR (coordinates B19 and B20). 
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Figure S2 
 
 
Figure S2. Effects of stimulation of Mock-transfected cells with insulin and IGF-I on 
the phosphorylation of tyrosine kinase receptors and downstream proteins. (A, B) 
Total cell lysates from MDA-MB-435+mock cells and MDA-MB-435+mock stimulated (24h) 
with insulin or IGF-1 were obtained and analyzed by Western-blot for phospho-IR(Tyr1150-
51)/phospho-IGF-IR(Tyr1135-36), IR, IGFR, Akt, phospho-Akt (Ser 473), ERK 1/2, 
phospho-ERK 1/2, β-catenin and E-cadherin. Increased phosphorylation levels of IR, IGF-
IR, ERK 1/2 and Akt were observed after stimulation with insulin or IGF-I. Tubulin was used 
as a loading control.
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Figure S3 
 
 
 
Figure S3. Effects of stimulation of Mock-transfected cells with insulin and IGF-I on 
cell invasion. (A) Representative images of cell invasion through Matrigel using 8 mm pore 
of a polycarbonate membrane. Nuclei were stained with DAPI. No significant differences 
were observed on cellular invasion upon insulin and IGF-I stimulation of mock-transfected 
cells. (B) The bar graph shows the amount of cells/field. Effects of stimulation with insulin 
and IGF-I on the fibronectin protein and mRNA expression levels, respectively. (C) and (D) 
A slight increase of fibronectin protein expression levels were observed after stimulation 
with insulin or IGF-I, however, no significant changes were observed at the mRNA 
transcription levels after stimulation of MDA-MB-435+E-mock cells with insulin and IGF-I 
.Effects of overexpression of MGAT5 on the IR expression levels of MKN45 cell line. (E) 
Total cell lysates from MKN45+mock and MKN45+MGAT5 were obtained and analyzed by 
Western blot for IR. An increased expression of IR were observed after overexpression of 
MGAT5. Tubulin was used as a loading control.
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Figure S4 
 
 
Figure S4. Subcellular localization of E-cadherin and β-catenin of Mock-transfected 
cells stimulated with insulin and IGF-I. Cell monolayers from MDA-MB-435+mock 
stimulated (24h) with insulin or IGF-1 were fixed and stained for E-cadherin, β-catenin and 
nucleus (DAPI). No significant differences were observed on the β-catenin subcellular 
localization after insulin or IGF-I stimulation. The representative images were obtained by 
fluorescence microscopy. Bar = 10 µm.
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Supplementary Figure 1: Evaluation of the branched N-glycosylation profile of E-cadherin 
mediated by GnT-V in different cell lines from different cellular origins.  
Supplementary Figure 2: Relative abundance of the released N-glycans carried by E-
cadherin and its respective mutants M123 and M234. 
Supplementary Figure 3: Evaluation of the N-glycosylation profile of E- cadherin M1, M2, 
M3, and M4 in AGS cells. 
Supplementary Figure 4: Evaluation of the impact of site-specific occupancy of Asn-554 
(site 1) with complex type N-glycans on E-cadherin biological functions. 
Supplementary Figure 5: Evaluation of the calcium binding effect on E-cadherin N-glycan 
mutant expression. 
Supplementary Figure 6: Analysis of N-glycosylation profile mediated by GnT-V after 
MGAT5 knockdown. 
 
Supplementary Table 1: List of released N-glycans detected on E-cadherin WT and the 
respective mutants namely M123 and M234. 
Supplementary Table 2: List of released N-glycans detected on E-cadherin WT and the 
respective mutants M123 and M234. 
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Supplementary Figure 1 
 
Supplementary Figure 1. Evaluation of the branched N-glycosylation profile of E-
cadherin mediated by GnT-V in different cell lines from different cellular origins. The 
pattern of branched glycosylation of E-cadherin comparing normal epithelial cells (MDCK), 
breast (BT20), colon (HT29) and gastric cancer (AGS) cells varies in a cell and tissue 
specific manner. 
 
Supplementary Figure 2 
 
Supplementary Figure 2. Relative abundance of the released N-glycans carried by E-
cadherin and its respective mutants M123 and M234. Overview on the N-glycan 
distribution of E-cadherin WT (blue bars), M123 (brown bars) and M234 (green bars). The 
structure ID numbers associated with the respective structures is found in Supplementary 
Table 1 and the respective relative intensities in Supplementary Table 2. The data clearly 
shows that despite the fact that the overall amount of the high mannose type structures 
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remains unaltered, E-cadherin WT and M123 contain increased amounts of complex type 
di- and triantennary structures, which were not detectable in M234. Furthermore, M234 also 
showed an increased level of Man9 type structure, but reduced levels of processed high 
mannose type structures. 
 
Supplementary Figure 3 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Evaluation of the N-glycosylation profile of E- cadherin M1, 
M2, M3, and M4 in AGS cells. E-cadherin M2 and M3 were sensitive to Endo H 
(arrowhead) and PNGase F (arrow) being modified with high mannose, hybrid, and 
complex-type N-glycans. E-cadherin M4 was predominantly PNGase F sensitive (arrow) 
while E-cadherin M1 was predominantly Endo H-sensitive (arrowhead). 
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Supplementary Figure 4 
 
 
Supplementary Figure 4. Evaluation of the impact of site-specific occupancy of Asn-
554 (site 1) with complex type N-glycans on E-cadherin biological functions (A) 
Immunofluorescence analysis of E-cadherin M2, M3, M123, and M23 N-glycan mutants 
displaying a membrane pattern of E-cadherin expression (arrowhead), and E-cadherin M4 
exhibiting an aberrant pattern of E-cadherin expression as evidenced by a clear cytoplasmic 
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staining (arrow). (B) Evaluation of cis-dimer formation of E-cadherin WT, M1, M234, and 
M4. (B1) Bar graphs. Amounts of E-cadherin cis-dimer were determined from the ratio of 
densities of E-cadherin cis-dimer/ E-cadherin monomer (without BS3), and normalization to 
E-cadherin WT. Results are described as mean ±standard deviation of two independent 
experiments. (C) Evaluation of the cell-cell aggregation capacity of E-cadherin WT, M1, 
M123, M4, and M234. (D) E-cadherin M4 mutant (with site 1 available) displays a decreased 
interaction between E-cadherin and β-catenin, as was observed for M234 mutant. (D1) Bar 
graphs. Amounts of association were determined from the ratios of densities of β- catenin 
after normalization to E-cadherin.  
 
Supplementary Figure 5 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5. Evaluation of the calcium binding effect on E-cadherin 
expression among the different N-glycosylation forms. Mutagenesis of different N-
glycosylation sites of E-cadherin did not interfere with the calcium binding property. After 
24h of calcium chelation (with EGTA), the expression of E-cadherin was completely 
recovered in all E-cadherin N-glycosylation forms, supporting that the calcium binding 
property is independent of E-cadherin glycosylation.
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Supplementary Figure 6 
 
 
 
Supplementary Figure 6. Analysis of branched N-glycosylation profile of AGS cells 
after MGAT5 knockdown. Lectin blot analysis of GnT-V product on total cell lysate from 
AGS Mock cells before (NS) and after MGAT5 knockdown (siRNA). A decreased L-PHA 
reactivity after MGAT5 knockdown was observed.
ID theor. [M-H]- Core Hex HexNAc Fuc NeuAc NeuGc Structure Category Comments
1 1235,44 1 2 0 0 0 0 Oligomannose MS/MS
2 1397,49 1 3 0 0 0 0 Oligomannose MS/MS
3 1559,55 1 4 0 0 0 0 Oligomannose MS/MS
4 1559,55 1 4 0 0 0 0 Oligomannose MS/MS
5 1721,60 1 5 0 0 0 0 Oligomannose MS/MS
6 1883,65 1 6 0 0 0 0 Oligomannose MS/MS
7 1463,55 1 0 2 1 0 0 Complex neutral MS/MS
Supplementary Table 1- List of released N-glycans detected on E-cadherin WT and the respective mutants 
namely M123 and M234.
8 1479,55 1 1 2 0 0 0 Complex neutral no MS/MS
9 1600,59 1 3 1 0 0 0 Hybrid MS/MS
10 1625,61 1 1 2 1 0 0 Complex neutral MS/MS
11 1625,61 1 1 2 1 0 0 Complex neutral MS/MS
12 1641,60 1 2 2 0 0 0 Complex neutral MS/MS
13 1666,63 1 0 3 1 0 0 no MS/MS
14 1666,63 1 0 3 1 0 0 no MS/MS
15 1746,63 1 3 1 1 0 0 Hybrid MS/MS
{
{
16 1787,66 1 2 2 1 0 0 Complex neutral MS/MS
17 1990,74 1 2 3 1 0 0 MS/MS
18 1828,69 1 1 3 1 0 0 no MS/MS
19 1891,67 1 3 1 0 1 0 Hybrid MS/MS
20 1932,70 1 2 2 0 1 0 Complex sialylated MS/MS
21 2094,75 1 2 2 1 0 1 Complex sialylated no MS/MS
22 2427,89 1 2 3 2 1 0 Complex sialylated no MS/MS
23 2223,79 1 2 2 0 2 0 Complex sialylated MS/MS
{
{
24 2223,79 1 2 2 0 2 0 Complex sialylated MS/MS
25 2223,79 1 2 2 0 2 0 Complex sialylated MS/MS
26 2588,92 1 3 3 0 2 0 Complex sialylated no MS/MS
27 2588,92 1 3 3 0 2 0 Complex sialylated no MS/MS
28 2880,02 1 3 3 0 3 0 Complex sialylated no MS/MS
29 2880,02 1 3 3 0 3 0 Complex sialylated MS/MS
30 2880,02 1 3 3 0 3 0 Complex sialylated no MS/MS
31 2880,02 1 3 3 0 3 0 Complex sialylated MS/MS
+
+
+
+
+
+
32 3171,11 1 3 3 0 4 0 Complex sialylated no MS/MS
33 3171,11 1 3 3 0 4 0 Complex sialylated no MS/MS
23
4
6 8
not defined
Fucose N-Acetylneuraminic acid
Mannose Galactose
Legend
N-Acetylglucosamine N-Glycolylneuraminic acid
+
+

Structure 
ID
Wild 
type M123 M234 Wild type M123 M234 1,01 911,34 162,1 203,08 146,06 291,1 307,09
rt rt rt m/z m/z m/z average  m/z z [M-H]- core hex HexNAc  Fuc NeuAc NeuGc m/z theor ΔM 
1 32,0 31,9 32,1 1235,50 1235,49 1235,56 1235,52 1 1235,52 1 2 0 0 0 0 1235,44 -0,075
2 24,2 24,4 24,2 1397,59 1397,65 1397,48 1397,57 1 1397,57 1 3 0 0 0 0 1397,49 -0,079
2 24,2 24,2 24,2 698,26 698,28 698,28 698,27 2 1397,55 1 3 0 0 0 0 1397,49 -0,060
3 23,0 23,3 23,2 1559,66 1559,53 1559,51 1559,57 1 1559,57 1 4 0 0 0 0 1559,55 -0,019
4 24,2 24,4 24,4 1559,49 1559,45 1559,51 1559,48 1 1559,48 1 4 0 0 0 0 1559,55 0,064
3 23,0 23,1 23,3 779,29 779,30 779,32 779,30 2 1559,61 1 4 0 0 0 0 1559,55 -0,067
4 24,2 24,2 24,2 779,29 779,31 779,27 779,29 2 1559,59 1 4 0 0 0 0 1559,55 -0,040
5 23,2 23,3 23,2 860,32 860,31 860,34 860,32 2 1721,65 1 5 0 0 0 0 1721,60 -0,054
6 23,6 23,7 23,7 941,37 941,35 941,32 941,35 2 1883,70 1 6 0 0 0 0 1883,65 -0,048
7 31,0 31,1 31,1 731,30 731,30 731,31 731,30 2 1463,61 1 0 2 1 0 0 1463,55 -0,062
8 27,2 739,30 739,30 2 1479,61 1 1 2 0 0 0 1479,55 -0,060
9 27,5 27,5 27,6 799,80 799,80 799,75 799,78 2 1600,57 1 3 1 0 0 0 1600,57 0,000
10 33,3 33,4 33,4 812,34 812,32 812,34 812,33 2 1625,67 1 1 2 1 0 0 1625,61 -0,069
11 34,0 34,0 34,0 812,31 812,31 812,33 812,32 2 1625,64 1 1 2 1 0 0 1625,61 -0,035
12 29,7 29,6 29,7 820,30 820,34 820,32 820,32 2 1641,65 1 2 2 0 0 0 1641,60 -0,047
13 21,9 21,8 21,9 832,81 832,82 832,83 832,82 2 1666,65 1 0 3 1 0 0 1666,63 -0,016
14 29,0 832,84 832,84 2 1666,69 1 0 3 1 0 0 1666,63 -0,056
15 24,9 24,9 872,81 872,82 872,82 2 1746,64 1 3 1 1 0 0 1746,63 -0,006
16 36,2 36,0 36,2 893,36 893,32 893,37 893,35 2 1787,71 1 2 2 1 0 0 1787,66 -0,049
17 25,7 25,7 25,7 994,85 994,83 994,79 994,82 2 1990,65 1 2 3 1 0 0 1990,74 0,083
18 24,4 24,4 24,4 913,83 913,87 913,82 913,84 2 1828,69 1 1 3 1 0 0 1828,69 -0,003
19 28,9 29,0 29,3 945,39 945,32 945,40 945,37 2 1891,75 1 3 1 0 1 0 1891,67 -0,078
20 30,8 31,4 31,2 965,87 965,84 965,77 965,83 2 1932,66 1 2 2 0 1 0 1932,70 0,035
21 36,3 36,6 36,7 1046,84 1046,83 1046,85 1046,84 2 2094,69 1 2 2 1 0 1 2094,75 0,061
22 25,9 1213,42 1213,42 2 2427,85 1 2 3 2 1 0 2427,89 0,043
23 27,0 27,5 27,3 1111,40 1111,39 1111,46 1111,42 2 2223,84 1 2 2 0 2 0 2223,79 -0,050
24 32,6 33,2 33,5 1111,42 1111,38 1111,39 1111,40 2 2223,80 1 2 2 0 2 0 2223,79 -0,010
25 41,7 42,6 42,8 1111,38 1111,42 1111,4 1111,40 2 2223,81 1 2 2 0 2 0 2223,79 -0,016
26 36,5 1293,95 1293,95 2 2588,91 1 3 3 0 2 0 2588,92 0,016
27 43,2 1293,90 1293,90 2 2588,81 1 3 3 0 2 0 2588,92 0,116
Mono sialylated 
Di- and tri-sialylated
Supplementary Table 2- List of released N-glycans detected on E-cadherin WT and the respective mutants M123 and M234.
High Mannose
Complex neutral/Hybrid
28 27,5 27,6 1439,55 1439,49 1439,52 2 2880,05 1 3 3 0 3 0 2880,02 -0,029
29 35,5 35,7 1439,51 1439,49 1439,50 2 2880,01 1 3 3 0 3 0 2880,02 0,011
30 44,5 44,4 1439,55 1439,53 1439,54 2 2880,09 1 3 3 0 3 0 2880,02 -0,069
31 52,2 1439,56 1439,56 2 2880,12 1 3 3 0 3 0 2880,02 -0,099
28 27,5 959,34 959,34 3 2880,04 1 3 3 0 3 0 2880,02 -0,017
29 35,7 35,7 959,28 959,37 959,33 3 2879,99 1 3 3 0 3 0 2880,02 0,028
31 52,0 959,36 959,36 3 2880,10 1 3 3 0 3 0 2880,02 -0,077
32 35,7 1056,32 1056,32 3 3170,98 1 3 3 0 4 0 3171,11 0,139
33 54,5 1056,35 1056,35 3 3171,07 1 3 3 0 4 0 3171,11 0,049
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Supplementary Figure 3: Evaluation of PNGase F efficiency through mobility shift of E-
cadherin band.  
Supplementary Figure 4: Evaluation of mRNA transcripts of POMT2 and MGAT5 in 
different backgrounds 
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Supplementary Figure 1 
 
 
 
Supplementary Figure 1. Profile of O-mannosyl glycans on stomach tissue lysate. To 
evaluate the expression of O-mannosyl glycans, we performed to digestion of total tissue 
lysate with PNGase F to remove N-glycans, followed by lectin blotting using Con A lectin 
(which binds to α-mannose residues from O-Man and N-glycoproteins). As expected, 
PNGase F treatment resulted in a decrease in the reactivity to Con A lectin. Regarding the 
expression of O-mannosyl glycans (detected by treatment with PNGase F + Con A lectin 
blotting), diffuse gastric carcinoma displayed a decreased O-mannosylation profile.
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Supplementary Figure 2 
 
 
 
Supplementary Figure 2. Evaluation of O-mannosyl glycans profile, and particularly 
on E-cadherin in MKN28 and Kato III cells. (A) O-mannosyl glycans profile. α-linked 
mannose residues present in the core N-oligosaccharide were removed by PNGase F 
digestion and Con A- mannose-binding lectin blotting was performed to evaluate the 
expression of O-mannosyl glycans from O-mannosylated proteins. The reactivity to Con A 
lectin decreased after removal of N-glycans. Note that both represented lectin blots 
corresponded to the same exposure time. (B) POMT1 mRNA expression. No significant 
differences were verified in the transcript levels of POMT1 in MKN28 and Kato III cells. 
Results are described as mean ± s.d of three independent biological replicates. (C) O-
mannosylation of E-cadherin in MKN28 and Kato III cell lines. E-cadherin 
immunoprecipitated from MKN28 cells exhibited a positive reactivity to Con A lectin (with 
and without PNGase F treatment). Regarding Kato III cells, E-cadherin immunoprecipitated 
showed a significant lower reactivity to Con A lectin after removal of N-glycans. Note that 
both represented lectin blots corresponded to the same exposure time.
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Supplementary Figure 3 
 
 
 
Supplementary Figure 3. Evaluation of PNGase F efficiency through mobility shift of 
E-cadherin band. E-cadherin immunoprecipitated after (A) POMT2 knockdown in MKN28 
or (B) POMT2 overexpression in Kato III cells was treated with PNGase F enzyme to release 
the N-glycans, and the mobility shift resulting this treatment was compared with E-cadherin 
N-glycan naked (E-cadherin M1234). 
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Supplementary Figure 4 
 
 
 
Supplementary Figure 4. Evaluation of mRNA transcripts of POMT2 and MGAT5 in four 
different backgrounds: (A1) MKN28 versus Kato III cells; after modulation of POMT2 
expression either by (B1) knockdown or by (C1) overexpression, and (D1) after 
overexpression of MGAT5 in MKN45 cell line. The relative POMT2 and MGAT5 mRNA 
expression of MKN28 + siPOMT2, Kato III + POMT2 and MKN45 + T5 cells are expressed 
as the fold increase, compared with non-silencing cells or mock cells, respectively, which 
was taken as 1. The data presented is referred to three independent biological replicates. 
